Mitch Report
Antony Kaspi & Mark Ziemann
date generated: 2020-07-13
Background
Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch
Input profiles
Here is the first few lines of the input profile.
## x
## A2M 1.45975674
## A3GALT2 0.08222001
## A4GALT 1.70760621
## AAAS -0.83461264
## AACS -2.73557983
## AAED1 0.02403748Here are some metrics about the input data profile:
| Profile metrics | |
|---|---|
| num_genesets | 2400 |
| num_genes_in_profile | 14009 |
| duplicated_genes_present | 0 |
| num_profile_genes_in_sets | 7928 |
| num_profile_genes_not_in_sets | 6081 |
Here is a plot of the input profiles. Note the dynamic ranges. 
Here is the contour plot of the profile including all detected genes.
Input genesets
Here are some metrics about the gene sets used: GMT file of genesets: ReactomePathways.gmt
| Gene sets metrics | |
|---|---|
| num_genesets | 2400 |
| num_genesets_excluded | 1046 |
| num_genesets_included | 1354 |
Differential pathway expression
Interactive enrichment scatterplot
Significance is calculated by -log10(p-value). All points shown are FDR<0.05.
Results table
Top N= 50 gene sets
| set | setSize | pANOVA | s.dist | p.adjustANOVA |
|---|---|---|---|---|
| Classical antibody-mediated complement activation | 11 | 6.00e-07 | 0.869 | 2.08e-05 |
| Initial triggering of complement | 22 | 7.11e-08 | 0.664 | 3.01e-06 |
| Creation of C4 and C2 activators | 15 | 9.43e-06 | 0.661 | 2.24e-04 |
| Mucopolysaccharidoses | 11 | 1.81e-04 | 0.652 | 2.51e-03 |
| Digestion | 14 | 2.59e-05 | -0.649 | 5.24e-04 |
| Trafficking and processing of endosomal TLR | 11 | 1.93e-04 | 0.649 | 2.61e-03 |
| FCGR activation | 17 | 5.39e-06 | 0.637 | 1.35e-04 |
| HDMs demethylate histones | 21 | 1.18e-06 | -0.613 | 3.63e-05 |
| Digestion and absorption | 15 | 4.09e-05 | -0.612 | 7.59e-04 |
| SRP-dependent cotranslational protein targeting to membrane | 77 | 1.67e-18 | 0.578 | 1.13e-15 |
| Cholesterol biosynthesis | 23 | 5.33e-06 | -0.548 | 1.35e-04 |
| Viral mRNA Translation | 56 | 2.10e-12 | 0.543 | 3.55e-10 |
| Peptide chain elongation | 56 | 3.56e-12 | 0.537 | 4.82e-10 |
| G beta:gamma signalling through BTK | 14 | 5.24e-04 | 0.535 | 5.76e-03 |
| Selenocysteine synthesis | 59 | 3.32e-12 | 0.524 | 4.82e-10 |
| Prostacyclin signalling through prostacyclin receptor | 15 | 5.96e-04 | 0.512 | 6.31e-03 |
| GABA synthesis, release, reuptake and degradation | 15 | 6.21e-04 | -0.510 | 6.47e-03 |
| Eukaryotic Translation Termination | 59 | 1.46e-11 | 0.508 | 1.65e-09 |
| Eukaryotic Translation Elongation | 60 | 2.70e-11 | 0.497 | 2.44e-09 |
| rRNA processing in the mitochondrion | 17 | 4.06e-04 | -0.495 | 4.75e-03 |
| Activation of gene expression by SREBF (SREBP) | 41 | 5.33e-08 | -0.491 | 2.33e-06 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | 20 | 1.45e-04 | -0.491 | 2.14e-03 |
| Regulation of IFNA signaling | 12 | 3.38e-03 | 0.489 | 2.27e-02 |
| Signal regulatory protein family interactions | 13 | 2.63e-03 | 0.482 | 1.90e-02 |
| Formation of a pool of free 40S subunits | 66 | 1.45e-11 | 0.481 | 1.65e-09 |
| Mitotic Telophase/Cytokinesis | 12 | 4.66e-03 | -0.472 | 2.91e-02 |
| Signaling by FGFR4 in disease | 11 | 6.92e-03 | -0.470 | 3.89e-02 |
| Na+/Cl- dependent neurotransmitter transporters | 14 | 2.34e-03 | -0.470 | 1.75e-02 |
| Glucagon-type ligand receptors | 20 | 2.89e-04 | 0.468 | 3.70e-03 |
| ADP signalling through P2Y purinoceptor 12 | 17 | 9.00e-04 | 0.465 | 8.61e-03 |
| G beta:gamma signalling through CDC42 | 16 | 1.37e-03 | 0.462 | 1.16e-02 |
| tRNA processing in the mitochondrion | 16 | 1.39e-03 | -0.462 | 1.17e-02 |
| G beta:gamma signalling through PLC beta | 16 | 1.55e-03 | 0.457 | 1.26e-02 |
| Signaling by FGFR3 fusions in cancer | 10 | 1.24e-02 | -0.457 | 6.06e-02 |
| ADP signalling through P2Y purinoceptor 1 | 21 | 3.12e-04 | 0.454 | 3.81e-03 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | 23 | 1.77e-04 | -0.452 | 2.49e-03 |
| Diseases associated with glycosylation precursor biosynthesis | 18 | 9.68e-04 | 0.449 | 9.01e-03 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 61 | 1.75e-09 | 0.446 | 1.08e-07 |
| Processing of Intronless Pre-mRNAs | 17 | 1.49e-03 | -0.445 | 1.23e-02 |
| Transport of Ribonucleoproteins into the Host Nucleus | 27 | 8.18e-05 | -0.438 | 1.30e-03 |
| IRAK4 deficiency (TLR2/4) | 11 | 1.26e-02 | 0.435 | 6.14e-02 |
| Establishment of Sister Chromatid Cohesion | 10 | 1.80e-02 | -0.432 | 7.65e-02 |
| Citric acid cycle (TCA cycle) | 22 | 4.86e-04 | -0.430 | 5.43e-03 |
| L13a-mediated translational silencing of Ceruloplasmin expression | 74 | 1.70e-10 | 0.429 | 1.35e-08 |
| MyD88 deficiency (TLR2/4) | 10 | 1.90e-02 | 0.428 | 7.90e-02 |
| Interferon alpha/beta signaling | 45 | 8.32e-07 | 0.425 | 2.68e-05 |
| Export of Viral Ribonucleoproteins from Nucleus | 28 | 1.04e-04 | -0.424 | 1.61e-03 |
| Regulation of Complement cascade | 36 | 1.13e-05 | 0.423 | 2.64e-04 |
| Thromboxane signalling through TP receptor | 20 | 1.09e-03 | 0.422 | 9.98e-03 |
| Presynaptic function of Kainate receptors | 17 | 2.78e-03 | 0.419 | 1.93e-02 |
Results (complete table)
Click HERE to show results for all gene sets
| set | setSize | pANOVA | s.dist | p.adjustANOVA |
|---|---|---|---|---|
| Classical antibody-mediated complement activation | 11 | 6.00e-07 | 8.69e-01 | 2.08e-05 |
| Initial triggering of complement | 22 | 7.11e-08 | 6.64e-01 | 3.01e-06 |
| Creation of C4 and C2 activators | 15 | 9.43e-06 | 6.61e-01 | 2.24e-04 |
| Mucopolysaccharidoses | 11 | 1.81e-04 | 6.52e-01 | 2.51e-03 |
| Digestion | 14 | 2.59e-05 | -6.49e-01 | 5.24e-04 |
| Trafficking and processing of endosomal TLR | 11 | 1.93e-04 | 6.49e-01 | 2.61e-03 |
| FCGR activation | 17 | 5.39e-06 | 6.37e-01 | 1.35e-04 |
| HDMs demethylate histones | 21 | 1.18e-06 | -6.13e-01 | 3.63e-05 |
| Digestion and absorption | 15 | 4.09e-05 | -6.12e-01 | 7.59e-04 |
| SRP-dependent cotranslational protein targeting to membrane | 77 | 1.67e-18 | 5.78e-01 | 1.13e-15 |
| Cholesterol biosynthesis | 23 | 5.33e-06 | -5.48e-01 | 1.35e-04 |
| Viral mRNA Translation | 56 | 2.10e-12 | 5.43e-01 | 3.55e-10 |
| Peptide chain elongation | 56 | 3.56e-12 | 5.37e-01 | 4.82e-10 |
| G beta:gamma signalling through BTK | 14 | 5.24e-04 | 5.35e-01 | 5.76e-03 |
| Selenocysteine synthesis | 59 | 3.32e-12 | 5.24e-01 | 4.82e-10 |
| Prostacyclin signalling through prostacyclin receptor | 15 | 5.96e-04 | 5.12e-01 | 6.31e-03 |
| GABA synthesis, release, reuptake and degradation | 15 | 6.21e-04 | -5.10e-01 | 6.47e-03 |
| Eukaryotic Translation Termination | 59 | 1.46e-11 | 5.08e-01 | 1.65e-09 |
| Eukaryotic Translation Elongation | 60 | 2.70e-11 | 4.97e-01 | 2.44e-09 |
| rRNA processing in the mitochondrion | 17 | 4.06e-04 | -4.95e-01 | 4.75e-03 |
| Activation of gene expression by SREBF (SREBP) | 41 | 5.33e-08 | -4.91e-01 | 2.33e-06 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | 20 | 1.45e-04 | -4.91e-01 | 2.14e-03 |
| Regulation of IFNA signaling | 12 | 3.38e-03 | 4.89e-01 | 2.27e-02 |
| Signal regulatory protein family interactions | 13 | 2.63e-03 | 4.82e-01 | 1.90e-02 |
| Formation of a pool of free 40S subunits | 66 | 1.45e-11 | 4.81e-01 | 1.65e-09 |
| Mitotic Telophase/Cytokinesis | 12 | 4.66e-03 | -4.72e-01 | 2.91e-02 |
| Signaling by FGFR4 in disease | 11 | 6.92e-03 | -4.70e-01 | 3.89e-02 |
| Na+/Cl- dependent neurotransmitter transporters | 14 | 2.34e-03 | -4.70e-01 | 1.75e-02 |
| Glucagon-type ligand receptors | 20 | 2.89e-04 | 4.68e-01 | 3.70e-03 |
| ADP signalling through P2Y purinoceptor 12 | 17 | 9.00e-04 | 4.65e-01 | 8.61e-03 |
| G beta:gamma signalling through CDC42 | 16 | 1.37e-03 | 4.62e-01 | 1.16e-02 |
| tRNA processing in the mitochondrion | 16 | 1.39e-03 | -4.62e-01 | 1.17e-02 |
| G beta:gamma signalling through PLC beta | 16 | 1.55e-03 | 4.57e-01 | 1.26e-02 |
| Signaling by FGFR3 fusions in cancer | 10 | 1.24e-02 | -4.57e-01 | 6.06e-02 |
| ADP signalling through P2Y purinoceptor 1 | 21 | 3.12e-04 | 4.54e-01 | 3.81e-03 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | 23 | 1.77e-04 | -4.52e-01 | 2.49e-03 |
| Diseases associated with glycosylation precursor biosynthesis | 18 | 9.68e-04 | 4.49e-01 | 9.01e-03 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 61 | 1.75e-09 | 4.46e-01 | 1.08e-07 |
| Processing of Intronless Pre-mRNAs | 17 | 1.49e-03 | -4.45e-01 | 1.23e-02 |
| Transport of Ribonucleoproteins into the Host Nucleus | 27 | 8.18e-05 | -4.38e-01 | 1.30e-03 |
| IRAK4 deficiency (TLR2/4) | 11 | 1.26e-02 | 4.35e-01 | 6.14e-02 |
| Establishment of Sister Chromatid Cohesion | 10 | 1.80e-02 | -4.32e-01 | 7.65e-02 |
| Citric acid cycle (TCA cycle) | 22 | 4.86e-04 | -4.30e-01 | 5.43e-03 |
| L13a-mediated translational silencing of Ceruloplasmin expression | 74 | 1.70e-10 | 4.29e-01 | 1.35e-08 |
| MyD88 deficiency (TLR2/4) | 10 | 1.90e-02 | 4.28e-01 | 7.90e-02 |
| Interferon alpha/beta signaling | 45 | 8.32e-07 | 4.25e-01 | 2.68e-05 |
| Export of Viral Ribonucleoproteins from Nucleus | 28 | 1.04e-04 | -4.24e-01 | 1.61e-03 |
| Regulation of Complement cascade | 36 | 1.13e-05 | 4.23e-01 | 2.64e-04 |
| Thromboxane signalling through TP receptor | 20 | 1.09e-03 | 4.22e-01 | 9.98e-03 |
| Presynaptic function of Kainate receptors | 17 | 2.78e-03 | 4.19e-01 | 1.93e-02 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | 38 | 7.86e-06 | -4.19e-01 | 1.94e-04 |
| G-protein activation | 19 | 1.59e-03 | 4.18e-01 | 1.29e-02 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | 25 | 3.00e-04 | -4.18e-01 | 3.71e-03 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | 25 | 3.00e-04 | -4.18e-01 | 3.71e-03 |
| Folding of actin by CCT/TriC | 10 | 2.23e-02 | -4.17e-01 | 8.72e-02 |
| Selenoamino acid metabolism | 72 | 9.85e-10 | 4.17e-01 | 6.96e-08 |
| Deadenylation of mRNA | 24 | 4.21e-04 | -4.16e-01 | 4.88e-03 |
| FOXO-mediated transcription of cell cycle genes | 16 | 4.00e-03 | -4.16e-01 | 2.59e-02 |
| Pyruvate metabolism and Citric Acid (TCA) cycle | 50 | 3.81e-07 | -4.15e-01 | 1.40e-05 |
| Interleukin-10 signaling | 37 | 1.28e-05 | 4.15e-01 | 2.79e-04 |
| Misspliced GSK3beta mutants stabilize beta-catenin | 14 | 7.37e-03 | -4.14e-01 | 3.96e-02 |
| S33 mutants of beta-catenin aren't phosphorylated | 14 | 7.37e-03 | -4.14e-01 | 3.96e-02 |
| S37 mutants of beta-catenin aren't phosphorylated | 14 | 7.37e-03 | -4.14e-01 | 3.96e-02 |
| S45 mutants of beta-catenin aren't phosphorylated | 14 | 7.37e-03 | -4.14e-01 | 3.96e-02 |
| T41 mutants of beta-catenin aren't phosphorylated | 14 | 7.37e-03 | -4.14e-01 | 3.96e-02 |
| phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex | 14 | 7.37e-03 | -4.14e-01 | 3.96e-02 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | 76 | 5.10e-10 | 4.13e-01 | 3.84e-08 |
| Transport of Mature mRNA Derived from an Intronless Transcript | 37 | 1.46e-05 | -4.12e-01 | 3.09e-04 |
| Formation of the ternary complex, and subsequently, the 43S complex | 39 | 9.31e-06 | 4.10e-01 | 2.24e-04 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | 20 | 1.50e-03 | -4.10e-01 | 1.23e-02 |
| NS1 Mediated Effects on Host Pathways | 33 | 4.70e-05 | -4.09e-01 | 8.48e-04 |
| Presynaptic depolarization and calcium channel opening | 12 | 1.54e-02 | -4.04e-01 | 7.01e-02 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | 66 | 1.52e-08 | 4.03e-01 | 7.35e-07 |
| NEP/NS2 Interacts with the Cellular Export Machinery | 27 | 2.93e-04 | -4.03e-01 | 3.70e-03 |
| Transport of the SLBP Dependant Mature mRNA | 31 | 1.09e-04 | -4.02e-01 | 1.67e-03 |
| Pyruvate metabolism | 26 | 4.07e-04 | -4.01e-01 | 4.75e-03 |
| Nuclear import of Rev protein | 28 | 2.67e-04 | -3.98e-01 | 3.47e-03 |
| PKMTs methylate histone lysines | 37 | 3.07e-05 | -3.96e-01 | 6.02e-04 |
| Heme degradation | 11 | 2.41e-02 | 3.93e-01 | 9.20e-02 |
| Transport of the SLBP independent Mature mRNA | 30 | 2.02e-04 | -3.92e-01 | 2.70e-03 |
| Plasma lipoprotein assembly | 13 | 1.44e-02 | 3.92e-01 | 6.72e-02 |
| Antimicrobial peptides | 26 | 5.79e-04 | 3.90e-01 | 6.18e-03 |
| Cap-dependent Translation Initiation | 82 | 1.08e-09 | 3.90e-01 | 6.96e-08 |
| Eukaryotic Translation Initiation | 82 | 1.08e-09 | 3.90e-01 | 6.96e-08 |
| Formation of the beta-catenin:TCF transactivating complex | 31 | 1.80e-04 | -3.89e-01 | 2.51e-03 |
| Condensation of Prophase Chromosomes | 13 | 1.59e-02 | -3.86e-01 | 7.10e-02 |
| Interferon gamma signaling | 65 | 7.74e-08 | 3.85e-01 | 3.18e-06 |
| AMER1 mutants destabilize the destruction complex | 13 | 1.63e-02 | -3.85e-01 | 7.10e-02 |
| APC truncation mutants have impaired AXIN binding | 13 | 1.63e-02 | -3.85e-01 | 7.10e-02 |
| AXIN missense mutants destabilize the destruction complex | 13 | 1.63e-02 | -3.85e-01 | 7.10e-02 |
| AXIN mutants destabilize the destruction complex, activating WNT signaling | 13 | 1.63e-02 | -3.85e-01 | 7.10e-02 |
| Truncations of AMER1 destabilize the destruction complex | 13 | 1.63e-02 | -3.85e-01 | 7.10e-02 |
| truncated APC mutants destabilize the destruction complex | 13 | 1.63e-02 | -3.85e-01 | 7.10e-02 |
| Interactions of Rev with host cellular proteins | 31 | 2.19e-04 | -3.84e-01 | 2.91e-03 |
| Common Pathway of Fibrin Clot Formation | 15 | 1.01e-02 | 3.84e-01 | 5.15e-02 |
| RORA activates gene expression | 17 | 6.29e-03 | -3.83e-01 | 3.63e-02 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | 54 | 1.18e-06 | -3.82e-01 | 3.63e-05 |
| Glucuronidation | 10 | 3.71e-02 | 3.81e-01 | 1.21e-01 |
| Scavenging by Class A Receptors | 14 | 1.41e-02 | 3.79e-01 | 6.61e-02 |
| Rev-mediated nuclear export of HIV RNA | 30 | 3.79e-04 | -3.75e-01 | 4.50e-03 |
| Dissolution of Fibrin Clot | 11 | 3.17e-02 | 3.74e-01 | 1.11e-01 |
| TP53 Regulates Transcription of Cell Cycle Genes | 47 | 1.18e-05 | -3.69e-01 | 2.67e-04 |
| Regulation of TLR by endogenous ligand | 12 | 2.68e-02 | 3.69e-01 | 9.85e-02 |
| G0 and Early G1 | 25 | 1.46e-03 | -3.68e-01 | 1.22e-02 |
| Complement cascade | 43 | 3.17e-05 | 3.67e-01 | 6.13e-04 |
| Acetylcholine Neurotransmitter Release Cycle | 10 | 4.56e-02 | -3.65e-01 | 1.43e-01 |
| Regulation of pyruvate dehydrogenase (PDH) complex | 15 | 1.45e-02 | -3.64e-01 | 6.74e-02 |
| Signal amplification | 28 | 8.57e-04 | 3.64e-01 | 8.41e-03 |
| Constitutive Signaling by EGFRvIII | 15 | 1.51e-02 | -3.63e-01 | 6.89e-02 |
| Signaling by EGFRvIII in Cancer | 15 | 1.51e-02 | -3.63e-01 | 6.89e-02 |
| FOXO-mediated transcription of cell death genes | 15 | 1.55e-02 | -3.61e-01 | 7.01e-02 |
| Vpr-mediated nuclear import of PICs | 29 | 8.10e-04 | -3.59e-01 | 8.12e-03 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | 12 | 3.30e-02 | 3.55e-01 | 1.13e-01 |
| SUMOylation of SUMOylation proteins | 29 | 9.63e-04 | -3.54e-01 | 9.01e-03 |
| Striated Muscle Contraction | 31 | 6.89e-04 | -3.52e-01 | 7.01e-03 |
| Cell recruitment (pro-inflammatory response) | 22 | 4.30e-03 | 3.52e-01 | 2.74e-02 |
| Purinergic signaling in leishmaniasis infection | 22 | 4.30e-03 | 3.52e-01 | 2.74e-02 |
| Diseases of carbohydrate metabolism | 28 | 1.30e-03 | 3.51e-01 | 1.12e-02 |
| SUMOylation of ubiquitinylation proteins | 33 | 4.89e-04 | -3.51e-01 | 5.43e-03 |
| Regulation of TP53 Activity through Methylation | 14 | 2.38e-02 | -3.49e-01 | 9.15e-02 |
| Interactions of Vpr with host cellular proteins | 31 | 8.20e-04 | -3.47e-01 | 8.16e-03 |
| Translation initiation complex formation | 45 | 6.11e-05 | 3.45e-01 | 1.06e-03 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | 11 | 4.78e-02 | -3.45e-01 | 1.48e-01 |
| Signaling by FGFR3 in disease | 15 | 2.14e-02 | -3.43e-01 | 8.53e-02 |
| Signaling by FGFR3 point mutants in cancer | 15 | 2.14e-02 | -3.43e-01 | 8.53e-02 |
| Receptor-type tyrosine-protein phosphatases | 13 | 3.25e-02 | 3.43e-01 | 1.12e-01 |
| DNA Damage/Telomere Stress Induced Senescence | 27 | 2.18e-03 | -3.41e-01 | 1.67e-02 |
| Regulation of MECP2 expression and activity | 29 | 1.51e-03 | -3.41e-01 | 1.24e-02 |
| Activation of G protein gated Potassium channels | 22 | 5.78e-03 | 3.40e-01 | 3.40e-02 |
| G protein gated Potassium channels | 22 | 5.78e-03 | 3.40e-01 | 3.40e-02 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | 22 | 5.78e-03 | 3.40e-01 | 3.40e-02 |
| Cytosolic iron-sulfur cluster assembly | 11 | 5.12e-02 | -3.40e-01 | 1.55e-01 |
| Activation of the pre-replicative complex | 32 | 9.03e-04 | -3.39e-01 | 8.61e-03 |
| Condensation of Prometaphase Chromosomes | 11 | 5.23e-02 | -3.38e-01 | 1.56e-01 |
| Gluconeogenesis | 26 | 2.86e-03 | -3.38e-01 | 1.98e-02 |
| Dermatan sulfate biosynthesis | 10 | 6.60e-02 | 3.36e-01 | 1.84e-01 |
| Regulation of FOXO transcriptional activity by acetylation | 10 | 6.65e-02 | -3.35e-01 | 1.85e-01 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 78 | 3.42e-07 | 3.34e-01 | 1.29e-05 |
| Heme biosynthesis | 13 | 3.73e-02 | -3.34e-01 | 1.21e-01 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | 23 | 5.66e-03 | -3.33e-01 | 3.39e-02 |
| Regulation of TP53 Degradation | 32 | 1.12e-03 | -3.33e-01 | 1.01e-02 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 46 | 9.56e-05 | 3.33e-01 | 1.49e-03 |
| Regulation of beta-cell development | 26 | 3.35e-03 | -3.32e-01 | 2.26e-02 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | 17 | 1.83e-02 | -3.31e-01 | 7.69e-02 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | 17 | 1.83e-02 | -3.31e-01 | 7.69e-02 |
| Formation of Fibrin Clot (Clotting Cascade) | 28 | 2.59e-03 | 3.29e-01 | 1.88e-02 |
| Inwardly rectifying K+ channels | 25 | 4.43e-03 | 3.29e-01 | 2.80e-02 |
| G1/S-Specific Transcription | 27 | 3.41e-03 | -3.26e-01 | 2.27e-02 |
| SUMOylation of DNA replication proteins | 40 | 3.67e-04 | -3.26e-01 | 4.40e-03 |
| Signal attenuation | 10 | 7.53e-02 | -3.25e-01 | 2.02e-01 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | 17 | 2.10e-02 | 3.23e-01 | 8.46e-02 |
| Ribosomal scanning and start codon recognition | 46 | 1.52e-04 | 3.23e-01 | 2.21e-03 |
| Activation of kainate receptors upon glutamate binding | 25 | 5.35e-03 | 3.22e-01 | 3.25e-02 |
| Activation of SMO | 14 | 3.78e-02 | 3.21e-01 | 1.23e-01 |
| Signaling by ERBB2 ECD mutants | 15 | 3.18e-02 | -3.20e-01 | 1.11e-01 |
| Signaling by WNT in cancer | 31 | 2.16e-03 | -3.18e-01 | 1.67e-02 |
| Collagen degradation | 30 | 2.57e-03 | 3.18e-01 | 1.87e-02 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | 14 | 3.94e-02 | 3.18e-01 | 1.27e-01 |
| Amino acid transport across the plasma membrane | 29 | 3.09e-03 | -3.18e-01 | 2.11e-02 |
| Constitutive Signaling by AKT1 E17K in Cancer | 25 | 6.19e-03 | -3.16e-01 | 3.60e-02 |
| Postmitotic nuclear pore complex (NPC) reformation | 25 | 6.28e-03 | -3.16e-01 | 3.63e-02 |
| Attenuation phase | 22 | 1.06e-02 | -3.15e-01 | 5.32e-02 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | 40 | 5.73e-04 | -3.15e-01 | 6.16e-03 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | 36 | 1.11e-03 | -3.14e-01 | 1.01e-02 |
| Biosynthesis of specialized proresolving mediators (SPMs) | 14 | 4.23e-02 | 3.13e-01 | 1.35e-01 |
| Protein methylation | 11 | 7.23e-02 | 3.13e-01 | 1.97e-01 |
| Glycolysis | 60 | 2.84e-05 | -3.13e-01 | 5.65e-04 |
| Beta-catenin phosphorylation cascade | 16 | 3.05e-02 | -3.13e-01 | 1.09e-01 |
| Glucose metabolism | 76 | 2.60e-06 | -3.12e-01 | 7.50e-05 |
| Nuclear Pore Complex (NPC) Disassembly | 31 | 2.72e-03 | -3.11e-01 | 1.90e-02 |
| Resolution of Sister Chromatid Cohesion | 99 | 9.16e-08 | -3.11e-01 | 3.59e-06 |
| Polo-like kinase mediated events | 16 | 3.19e-02 | -3.10e-01 | 1.12e-01 |
| FOXO-mediated transcription | 57 | 5.50e-05 | -3.09e-01 | 9.80e-04 |
| Platelet Adhesion to exposed collagen | 13 | 5.40e-02 | 3.09e-01 | 1.59e-01 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | 87 | 6.59e-07 | -3.09e-01 | 2.18e-05 |
| Amplification of signal from the kinetochores | 87 | 6.59e-07 | -3.09e-01 | 2.18e-05 |
| Eicosanoid ligand-binding receptors | 12 | 6.44e-02 | 3.08e-01 | 1.81e-01 |
| Constitutive Signaling by Overexpressed ERBB2 | 10 | 9.27e-02 | -3.07e-01 | 2.31e-01 |
| Regulation of expression of SLITs and ROBOs | 126 | 2.81e-09 | 3.07e-01 | 1.59e-07 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | 18 | 2.44e-02 | -3.07e-01 | 9.25e-02 |
| Erythropoietin activates RAS | 13 | 5.63e-02 | -3.06e-01 | 1.64e-01 |
| Translation | 231 | 1.90e-15 | 3.04e-01 | 5.15e-13 |
| Triglyceride catabolism | 17 | 3.01e-02 | -3.04e-01 | 1.08e-01 |
| G beta:gamma signalling through PI3Kgamma | 21 | 1.60e-02 | 3.04e-01 | 7.10e-02 |
| Regulation of localization of FOXO transcription factors | 11 | 8.13e-02 | -3.04e-01 | 2.12e-01 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | 11 | 8.35e-02 | -3.01e-01 | 2.15e-01 |
| Antigen processing-Cross presentation | 84 | 2.00e-06 | 3.00e-01 | 6.01e-05 |
| Regulation of TP53 Expression and Degradation | 33 | 3.08e-03 | -2.98e-01 | 2.11e-02 |
| SUMOylation of transcription cofactors | 39 | 1.30e-03 | -2.98e-01 | 1.12e-02 |
| Thrombin signalling through proteinase activated receptors (PARs) | 28 | 6.56e-03 | 2.97e-01 | 3.72e-02 |
| Budding and maturation of HIV virion | 23 | 1.37e-02 | 2.97e-01 | 6.55e-02 |
| Disorders of developmental biology | 11 | 9.09e-02 | -2.94e-01 | 2.28e-01 |
| Loss of function of MECP2 in Rett syndrome | 11 | 9.09e-02 | -2.94e-01 | 2.28e-01 |
| Pervasive developmental disorders | 11 | 9.09e-02 | -2.94e-01 | 2.28e-01 |
| Synthesis, secretion, and deacylation of Ghrelin | 14 | 5.67e-02 | 2.94e-01 | 1.64e-01 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | 13 | 6.63e-02 | -2.94e-01 | 1.84e-01 |
| Downstream signaling of activated FGFR3 | 18 | 3.15e-02 | -2.93e-01 | 1.11e-01 |
| Class B/2 (Secretin family receptors) | 57 | 1.34e-04 | 2.93e-01 | 2.01e-03 |
| Metabolism of steroid hormones | 24 | 1.34e-02 | 2.92e-01 | 6.47e-02 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | 26 | 1.01e-02 | 2.91e-01 | 5.15e-02 |
| Scavenging of heme from plasma | 10 | 1.11e-01 | 2.91e-01 | 2.59e-01 |
| Signaling by Erythropoietin | 24 | 1.36e-02 | -2.91e-01 | 6.53e-02 |
| Pregnenolone biosynthesis | 10 | 1.11e-01 | 2.91e-01 | 2.60e-01 |
| Cellular response to heat stress | 87 | 2.93e-06 | -2.90e-01 | 8.25e-05 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | 36 | 2.67e-03 | -2.89e-01 | 1.90e-02 |
| Plasma lipoprotein clearance | 28 | 8.09e-03 | 2.89e-01 | 4.23e-02 |
| Transcription of E2F targets under negative control by DREAM complex | 18 | 3.42e-02 | -2.88e-01 | 1.15e-01 |
| Downstream signaling of activated FGFR4 | 18 | 3.48e-02 | -2.87e-01 | 1.17e-01 |
| SUMO E3 ligases SUMOylate target proteins | 144 | 2.99e-09 | -2.87e-01 | 1.62e-07 |
| Circadian Clock | 63 | 8.37e-05 | -2.87e-01 | 1.32e-03 |
| Regulation of TP53 Activity through Acetylation | 29 | 7.69e-03 | -2.86e-01 | 4.10e-02 |
| Transcriptional activation of mitochondrial biogenesis | 50 | 4.81e-04 | -2.86e-01 | 5.43e-03 |
| Dectin-2 family | 15 | 5.64e-02 | 2.85e-01 | 1.64e-01 |
| VEGFR2 mediated cell proliferation | 19 | 3.23e-02 | -2.84e-01 | 1.12e-01 |
| Triglyceride metabolism | 25 | 1.44e-02 | -2.83e-01 | 6.72e-02 |
| HSF1 activation | 24 | 1.66e-02 | -2.83e-01 | 7.20e-02 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | 81 | 1.20e-05 | 2.82e-01 | 2.67e-04 |
| Nonsense-Mediated Decay (NMD) | 81 | 1.20e-05 | 2.82e-01 | 2.67e-04 |
| EML4 and NUDC in mitotic spindle formation | 91 | 3.58e-06 | -2.81e-01 | 9.89e-05 |
| TNFs bind their physiological receptors | 26 | 1.31e-02 | 2.81e-01 | 6.37e-02 |
| SUMOylation | 150 | 3.21e-09 | -2.80e-01 | 1.67e-07 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | 25 | 1.58e-02 | -2.79e-01 | 7.10e-02 |
| Miscellaneous transport and binding events | 20 | 3.09e-02 | -2.79e-01 | 1.10e-01 |
| PI-3K cascade:FGFR1 | 11 | 1.11e-01 | -2.78e-01 | 2.59e-01 |
| Surfactant metabolism | 16 | 5.46e-02 | 2.78e-01 | 1.61e-01 |
| HSF1-dependent transactivation | 32 | 6.62e-03 | -2.77e-01 | 3.73e-02 |
| ER-Phagosome pathway | 69 | 6.87e-05 | 2.77e-01 | 1.14e-03 |
| Binding and Uptake of Ligands by Scavenger Receptors | 34 | 5.27e-03 | 2.77e-01 | 3.23e-02 |
| InlB-mediated entry of Listeria monocytogenes into host cell | 13 | 8.43e-02 | -2.77e-01 | 2.16e-01 |
| SHC-mediated cascade:FGFR1 | 11 | 1.13e-01 | -2.76e-01 | 2.63e-01 |
| CS/DS degradation | 13 | 8.52e-02 | 2.76e-01 | 2.17e-01 |
| Transcriptional regulation by small RNAs | 42 | 2.04e-03 | -2.75e-01 | 1.60e-02 |
| ROS and RNS production in phagocytes | 30 | 9.12e-03 | 2.75e-01 | 4.73e-02 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | 16 | 5.75e-02 | 2.74e-01 | 1.65e-01 |
| Processive synthesis on the C-strand of the telomere | 19 | 3.90e-02 | -2.74e-01 | 1.26e-01 |
| Regulation of HSF1-mediated heat shock response | 70 | 7.65e-05 | -2.74e-01 | 1.23e-03 |
| Activation of Matrix Metalloproteinases | 25 | 1.81e-02 | 2.73e-01 | 7.65e-02 |
| Hyaluronan uptake and degradation | 12 | 1.02e-01 | 2.73e-01 | 2.48e-01 |
| Repression of WNT target genes | 12 | 1.02e-01 | -2.72e-01 | 2.49e-01 |
| Cytosolic sulfonation of small molecules | 17 | 5.21e-02 | 2.72e-01 | 1.56e-01 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | 17 | 5.27e-02 | -2.71e-01 | 1.57e-01 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | 17 | 5.27e-02 | -2.71e-01 | 1.57e-01 |
| Regulation of IFNG signaling | 14 | 8.05e-02 | 2.70e-01 | 2.11e-01 |
| Mitochondrial translation initiation | 85 | 1.77e-05 | 2.70e-01 | 3.63e-04 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | 18 | 4.95e-02 | -2.67e-01 | 1.52e-01 |
| Chemokine receptors bind chemokines | 43 | 2.42e-03 | 2.67e-01 | 1.79e-02 |
| Chondroitin sulfate biosynthesis | 17 | 5.66e-02 | 2.67e-01 | 1.64e-01 |
| NOTCH2 intracellular domain regulates transcription | 11 | 1.26e-01 | -2.67e-01 | 2.87e-01 |
| P2Y receptors | 10 | 1.45e-01 | 2.66e-01 | 3.14e-01 |
| Processing of Capped Intronless Pre-mRNA | 26 | 1.90e-02 | -2.66e-01 | 7.90e-02 |
| Intrinsic Pathway of Fibrin Clot Formation | 17 | 5.78e-02 | 2.66e-01 | 1.65e-01 |
| Neutrophil degranulation | 398 | 1.49e-19 | 2.65e-01 | 2.02e-16 |
| CLEC7A (Dectin-1) induces NFAT activation | 10 | 1.49e-01 | -2.64e-01 | 3.18e-01 |
| Mitochondrial biogenesis | 69 | 1.60e-04 | -2.63e-01 | 2.30e-03 |
| Activation of ATR in response to replication stress | 37 | 5.82e-03 | -2.62e-01 | 3.41e-02 |
| FRS-mediated FGFR1 signaling | 13 | 1.02e-01 | -2.62e-01 | 2.48e-01 |
| Mitotic Spindle Checkpoint | 104 | 4.05e-06 | -2.62e-01 | 1.07e-04 |
| Oncogene Induced Senescence | 30 | 1.31e-02 | -2.62e-01 | 6.37e-02 |
| HS-GAG degradation | 19 | 4.86e-02 | 2.61e-01 | 1.50e-01 |
| Glucagon signaling in metabolic regulation | 26 | 2.13e-02 | 2.61e-01 | 8.53e-02 |
| SUMOylation of RNA binding proteins | 41 | 3.86e-03 | -2.61e-01 | 2.51e-02 |
| Glyoxylate metabolism and glycine degradation | 26 | 2.16e-02 | -2.60e-01 | 8.57e-02 |
| Fertilization | 11 | 1.36e-01 | 2.60e-01 | 3.00e-01 |
| Mitotic Prometaphase | 179 | 2.31e-09 | -2.59e-01 | 1.36e-07 |
| Ovarian tumor domain proteases | 35 | 7.95e-03 | -2.59e-01 | 4.17e-02 |
| Defective CFTR causes cystic fibrosis | 53 | 1.13e-03 | 2.59e-01 | 1.01e-02 |
| Regulation of TP53 Activity through Phosphorylation | 86 | 3.68e-05 | -2.58e-01 | 7.02e-04 |
| Cross-presentation of soluble exogenous antigens (endosomes) | 46 | 2.53e-03 | 2.57e-01 | 1.85e-02 |
| Metabolism of Angiotensinogen to Angiotensins | 13 | 1.08e-01 | 2.57e-01 | 2.55e-01 |
| Effects of PIP2 hydrolysis | 24 | 3.02e-02 | -2.56e-01 | 1.08e-01 |
| Collagen biosynthesis and modifying enzymes | 56 | 9.62e-04 | 2.55e-01 | 9.01e-03 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | 28 | 1.96e-02 | -2.55e-01 | 8.12e-02 |
| HCMV Early Events | 54 | 1.27e-03 | -2.54e-01 | 1.10e-02 |
| WNT ligand biogenesis and trafficking | 20 | 4.98e-02 | 2.53e-01 | 1.52e-01 |
| TRP channels | 17 | 7.09e-02 | 2.53e-01 | 1.93e-01 |
| Phase 2 - plateau phase | 20 | 5.08e-02 | -2.52e-01 | 1.54e-01 |
| Mitochondrial translation termination | 85 | 5.86e-05 | 2.52e-01 | 1.03e-03 |
| Telomere Extension By Telomerase | 22 | 4.08e-02 | -2.52e-01 | 1.31e-01 |
| Resolution of D-Loop Structures | 32 | 1.39e-02 | -2.51e-01 | 6.61e-02 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 15 | 9.28e-02 | -2.51e-01 | 2.31e-01 |
| SUMOylation of chromatin organization proteins | 49 | 2.41e-03 | -2.51e-01 | 1.79e-02 |
| G-protein beta:gamma signalling | 28 | 2.19e-02 | 2.50e-01 | 8.64e-02 |
| Mitochondrial translation elongation | 85 | 6.80e-05 | 2.50e-01 | 1.14e-03 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | 12 | 1.34e-01 | -2.50e-01 | 2.99e-01 |
| Deactivation of the beta-catenin transactivating complex | 35 | 1.08e-02 | -2.49e-01 | 5.43e-02 |
| Formation of tubulin folding intermediates by CCT/TriC | 21 | 4.84e-02 | -2.49e-01 | 1.49e-01 |
| Diseases associated with N-glycosylation of proteins | 16 | 8.51e-02 | 2.49e-01 | 2.17e-01 |
| Removal of the Flap Intermediate from the C-strand | 17 | 7.80e-02 | -2.47e-01 | 2.07e-01 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | 15 | 9.91e-02 | -2.46e-01 | 2.44e-01 |
| Telomere C-strand (Lagging Strand) Synthesis | 33 | 1.50e-02 | -2.45e-01 | 6.89e-02 |
| Glycosphingolipid metabolism | 34 | 1.40e-02 | 2.44e-01 | 6.61e-02 |
| SUMOylation of DNA damage response and repair proteins | 66 | 6.31e-04 | -2.43e-01 | 6.47e-03 |
| EPHB-mediated forward signaling | 34 | 1.41e-02 | 2.43e-01 | 6.61e-02 |
| Extension of Telomeres | 49 | 3.23e-03 | -2.43e-01 | 2.20e-02 |
| Reversible hydration of carbon dioxide | 10 | 1.84e-01 | -2.43e-01 | 3.62e-01 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | 26 | 3.41e-02 | -2.40e-01 | 1.15e-01 |
| Downstream signaling of activated FGFR2 | 20 | 6.36e-02 | -2.40e-01 | 1.79e-01 |
| Unwinding of DNA | 12 | 1.51e-01 | -2.40e-01 | 3.19e-01 |
| Nuclear Envelope Breakdown | 48 | 4.12e-03 | -2.39e-01 | 2.66e-02 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | 13 | 1.35e-01 | 2.39e-01 | 2.99e-01 |
| Detoxification of Reactive Oxygen Species | 30 | 2.35e-02 | 2.39e-01 | 9.10e-02 |
| Regulation of TP53 Activity | 148 | 5.75e-07 | -2.38e-01 | 2.05e-05 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | 31 | 2.18e-02 | -2.38e-01 | 8.62e-02 |
| Peptide ligand-binding receptors | 95 | 6.35e-05 | 2.38e-01 | 1.09e-03 |
| Ubiquitin-dependent degradation of Cyclin D | 46 | 5.41e-03 | 2.37e-01 | 3.26e-02 |
| TNFR1-induced NFkappaB signaling pathway | 24 | 4.46e-02 | -2.37e-01 | 1.41e-01 |
| Plasma lipoprotein assembly, remodeling, and clearance | 58 | 1.84e-03 | 2.37e-01 | 1.46e-02 |
| RHO GTPases Activate Formins | 113 | 1.61e-05 | -2.35e-01 | 3.35e-04 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | 10 | 1.98e-01 | -2.35e-01 | 3.82e-01 |
| Chromatin modifying enzymes | 189 | 2.96e-08 | -2.34e-01 | 1.34e-06 |
| Chromatin organization | 189 | 2.96e-08 | -2.34e-01 | 1.34e-06 |
| Chondroitin sulfate/dermatan sulfate metabolism | 44 | 7.23e-03 | 2.34e-01 | 3.96e-02 |
| Regulation of PTEN mRNA translation | 11 | 1.79e-01 | -2.34e-01 | 3.58e-01 |
| Nucleobase catabolism | 30 | 2.66e-02 | 2.34e-01 | 9.82e-02 |
| MET activates RAS signaling | 10 | 2.01e-01 | -2.33e-01 | 3.84e-01 |
| EPH-ephrin mediated repulsion of cells | 44 | 7.58e-03 | 2.33e-01 | 4.05e-02 |
| PI-3K cascade:FGFR3 | 11 | 1.84e-01 | -2.32e-01 | 3.61e-01 |
| Biosynthesis of DHA-derived SPMs | 12 | 1.65e-01 | 2.31e-01 | 3.41e-01 |
| Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP) | 10 | 2.05e-01 | 2.31e-01 | 3.87e-01 |
| SLC transporter disorders | 75 | 5.43e-04 | -2.31e-01 | 5.93e-03 |
| Transport of Mature Transcript to Cytoplasm | 75 | 5.49e-04 | -2.31e-01 | 5.95e-03 |
| Activation of GABAB receptors | 34 | 2.01e-02 | 2.30e-01 | 8.20e-02 |
| GABA B receptor activation | 34 | 2.01e-02 | 2.30e-01 | 8.20e-02 |
| Processive synthesis on the lagging strand | 15 | 1.23e-01 | -2.30e-01 | 2.82e-01 |
| Depolymerisation of the Nuclear Lamina | 15 | 1.23e-01 | -2.30e-01 | 2.82e-01 |
| SHC-mediated cascade:FGFR3 | 11 | 1.87e-01 | -2.30e-01 | 3.67e-01 |
| FCGR3A-mediated IL10 synthesis | 41 | 1.14e-02 | 2.28e-01 | 5.68e-02 |
| E2F mediated regulation of DNA replication | 21 | 7.20e-02 | -2.27e-01 | 1.96e-01 |
| Mitochondrial translation | 91 | 1.87e-04 | 2.27e-01 | 2.56e-03 |
| Synthesis of very long-chain fatty acyl-CoAs | 15 | 1.29e-01 | -2.26e-01 | 2.92e-01 |
| mRNA decay by 5' to 3' exoribonuclease | 15 | 1.30e-01 | -2.26e-01 | 2.93e-01 |
| p130Cas linkage to MAPK signaling for integrins | 12 | 1.76e-01 | 2.26e-01 | 3.54e-01 |
| Hedgehog ligand biogenesis | 54 | 4.14e-03 | 2.26e-01 | 2.66e-02 |
| CDC6 association with the ORC:origin complex | 11 | 1.97e-01 | -2.25e-01 | 3.79e-01 |
| IRS-mediated signalling | 35 | 2.18e-02 | -2.24e-01 | 8.62e-02 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | 13 | 1.62e-01 | 2.24e-01 | 3.37e-01 |
| Interleukin-27 signaling | 10 | 2.22e-01 | 2.23e-01 | 4.04e-01 |
| FRS-mediated FGFR3 signaling | 13 | 1.64e-01 | -2.23e-01 | 3.40e-01 |
| Removal of the Flap Intermediate | 14 | 1.49e-01 | -2.23e-01 | 3.18e-01 |
| PI-3K cascade:FGFR4 | 11 | 2.01e-01 | -2.23e-01 | 3.84e-01 |
| Homologous DNA Pairing and Strand Exchange | 41 | 1.37e-02 | -2.23e-01 | 6.55e-02 |
| Activation of the AP-1 family of transcription factors | 10 | 2.24e-01 | -2.22e-01 | 4.07e-01 |
| Viral Messenger RNA Synthesis | 38 | 1.78e-02 | -2.22e-01 | 7.63e-02 |
| Hh mutants that don't undergo autocatalytic processing are degraded by ERAD | 48 | 7.82e-03 | 2.22e-01 | 4.14e-02 |
| SHC-mediated cascade:FGFR4 | 11 | 2.05e-01 | -2.21e-01 | 3.87e-01 |
| ABC transporter disorders | 62 | 2.70e-03 | 2.20e-01 | 1.90e-02 |
| Gap junction trafficking | 14 | 1.56e-01 | 2.19e-01 | 3.27e-01 |
| MET activates RAP1 and RAC1 | 11 | 2.09e-01 | 2.19e-01 | 3.89e-01 |
| Signaling by cytosolic FGFR1 fusion mutants | 18 | 1.09e-01 | -2.19e-01 | 2.56e-01 |
| Downstream signaling of activated FGFR1 | 21 | 8.31e-02 | -2.19e-01 | 2.15e-01 |
| DNA strand elongation | 32 | 3.26e-02 | -2.18e-01 | 1.12e-01 |
| Class I peroxisomal membrane protein import | 19 | 1.02e-01 | 2.17e-01 | 2.48e-01 |
| AURKA Activation by TPX2 | 71 | 1.62e-03 | -2.17e-01 | 1.30e-02 |
| Signaling by FGFR1 in disease | 31 | 3.72e-02 | -2.16e-01 | 1.21e-01 |
| Regulation of PLK1 Activity at G2/M Transition | 84 | 6.27e-04 | -2.16e-01 | 6.47e-03 |
| Meiotic synapsis | 29 | 4.44e-02 | -2.16e-01 | 1.40e-01 |
| FRS-mediated FGFR4 signaling | 13 | 1.79e-01 | -2.15e-01 | 3.58e-01 |
| Tie2 Signaling | 17 | 1.25e-01 | -2.15e-01 | 2.85e-01 |
| Recruitment of NuMA to mitotic centrosomes | 79 | 9.71e-04 | -2.15e-01 | 9.01e-03 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | 14 | 1.65e-01 | -2.14e-01 | 3.41e-01 |
| Prolonged ERK activation events | 13 | 1.82e-01 | -2.14e-01 | 3.60e-01 |
| Synthesis of PA | 28 | 5.03e-02 | -2.14e-01 | 1.53e-01 |
| MET receptor recycling | 10 | 2.42e-01 | -2.14e-01 | 4.30e-01 |
| HDR through Homologous Recombination (HRR) | 63 | 3.49e-03 | -2.13e-01 | 2.30e-02 |
| Platelet degranulation | 107 | 1.46e-04 | 2.13e-01 | 2.14e-03 |
| Insulin receptor signalling cascade | 41 | 1.85e-02 | -2.13e-01 | 7.74e-02 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | 25 | 6.62e-02 | -2.12e-01 | 1.84e-01 |
| Translesion synthesis by REV1 | 14 | 1.70e-01 | -2.12e-01 | 3.49e-01 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | 12 | 2.04e-01 | -2.12e-01 | 3.86e-01 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | 12 | 2.04e-01 | -2.12e-01 | 3.86e-01 |
| HDR through Single Strand Annealing (SSA) | 36 | 2.80e-02 | -2.12e-01 | 1.02e-01 |
| activated TAK1 mediates p38 MAPK activation | 18 | 1.20e-01 | -2.12e-01 | 2.77e-01 |
| Deadenylation-dependent mRNA decay | 54 | 7.24e-03 | -2.11e-01 | 3.96e-02 |
| RAF activation | 34 | 3.32e-02 | -2.11e-01 | 1.13e-01 |
| Notch-HLH transcription pathway | 25 | 6.84e-02 | -2.11e-01 | 1.88e-01 |
| Loss of Nlp from mitotic centrosomes | 68 | 2.70e-03 | -2.11e-01 | 1.90e-02 |
| Loss of proteins required for interphase microtubule organization from the centrosome | 68 | 2.70e-03 | -2.11e-01 | 1.90e-02 |
| Hh mutants abrogate ligand secretion | 50 | 1.01e-02 | 2.10e-01 | 5.15e-02 |
| Centrosome maturation | 80 | 1.15e-03 | -2.10e-01 | 1.02e-02 |
| Recruitment of mitotic centrosome proteins and complexes | 80 | 1.15e-03 | -2.10e-01 | 1.02e-02 |
| Negative regulation of MAPK pathway | 41 | 2.00e-02 | -2.10e-01 | 8.20e-02 |
| TICAM1, RIP1-mediated IKK complex recruitment | 16 | 1.46e-01 | -2.10e-01 | 3.16e-01 |
| Negative regulation of NOTCH4 signaling | 48 | 1.22e-02 | 2.09e-01 | 6.02e-02 |
| Norepinephrine Neurotransmitter Release Cycle | 12 | 2.10e-01 | -2.09e-01 | 3.89e-01 |
| Response of EIF2AK1 (HRI) to heme deficiency | 14 | 1.76e-01 | -2.09e-01 | 3.54e-01 |
| RUNX2 regulates osteoblast differentiation | 22 | 9.02e-02 | 2.09e-01 | 2.27e-01 |
| Translesion Synthesis by POLH | 16 | 1.49e-01 | -2.08e-01 | 3.18e-01 |
| Vasopressin regulates renal water homeostasis via Aquaporins | 34 | 3.56e-02 | 2.08e-01 | 1.18e-01 |
| Uptake and actions of bacterial toxins | 28 | 5.65e-02 | -2.08e-01 | 1.64e-01 |
| RHO GTPases activate KTN1 | 11 | 2.33e-01 | 2.08e-01 | 4.18e-01 |
| Synthesis of substrates in N-glycan biosythesis | 55 | 7.80e-03 | 2.08e-01 | 4.14e-02 |
| Vif-mediated degradation of APOBEC3G | 45 | 1.61e-02 | 2.08e-01 | 7.10e-02 |
| Transport of inorganic cations/anions and amino acids/oligopeptides | 77 | 1.68e-03 | -2.07e-01 | 1.35e-02 |
| Transcriptional Regulation by MECP2 | 50 | 1.13e-02 | -2.07e-01 | 5.67e-02 |
| PD-1 signaling | 16 | 1.52e-01 | -2.07e-01 | 3.22e-01 |
| Laminin interactions | 23 | 8.62e-02 | -2.07e-01 | 2.19e-01 |
| Signaling by EGFR | 45 | 1.66e-02 | -2.07e-01 | 7.20e-02 |
| Influenza Viral RNA Transcription and Replication | 97 | 4.56e-04 | 2.06e-01 | 5.23e-03 |
| FCGR3A-mediated phagocytosis | 62 | 5.06e-03 | 2.06e-01 | 3.11e-02 |
| Leishmania phagocytosis | 62 | 5.06e-03 | 2.06e-01 | 3.11e-02 |
| Parasite infection | 62 | 5.06e-03 | 2.06e-01 | 3.11e-02 |
| Synthesis of glycosylphosphatidylinositol (GPI) | 18 | 1.31e-01 | 2.06e-01 | 2.94e-01 |
| Synaptic adhesion-like molecules | 17 | 1.42e-01 | 2.06e-01 | 3.11e-01 |
| Negative regulators of DDX58/IFIH1 signaling | 30 | 5.15e-02 | -2.05e-01 | 1.56e-01 |
| Signaling by ROBO receptors | 168 | 4.50e-06 | 2.05e-01 | 1.17e-04 |
| Lagging Strand Synthesis | 20 | 1.12e-01 | -2.05e-01 | 2.61e-01 |
| Glutamate Neurotransmitter Release Cycle | 18 | 1.33e-01 | -2.05e-01 | 2.97e-01 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | 69 | 3.31e-03 | 2.05e-01 | 2.24e-02 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | 44 | 1.89e-02 | 2.05e-01 | 7.90e-02 |
| Downstream signal transduction | 29 | 5.70e-02 | -2.04e-01 | 1.64e-01 |
| Bile acid and bile salt metabolism | 25 | 7.77e-02 | 2.04e-01 | 2.06e-01 |
| Nucleotide-like (purinergic) receptors | 13 | 2.04e-01 | 2.04e-01 | 3.86e-01 |
| Kinesins | 37 | 3.24e-02 | -2.03e-01 | 1.12e-01 |
| Synthesis of PIPs at the early endosome membrane | 16 | 1.60e-01 | -2.03e-01 | 3.34e-01 |
| Oxidative Stress Induced Senescence | 61 | 6.11e-03 | -2.03e-01 | 3.56e-02 |
| Signaling by NTRK3 (TRKC) | 17 | 1.48e-01 | -2.03e-01 | 3.17e-01 |
| Carnitine metabolism | 12 | 2.24e-01 | -2.03e-01 | 4.07e-01 |
| Other interleukin signaling | 21 | 1.08e-01 | 2.03e-01 | 2.55e-01 |
| Activated NTRK2 signals through FRS2 and FRS3 | 10 | 2.68e-01 | -2.02e-01 | 4.56e-01 |
| DAG and IP3 signaling | 38 | 3.12e-02 | -2.02e-01 | 1.11e-01 |
| Metabolism of polyamines | 52 | 1.19e-02 | 2.02e-01 | 5.91e-02 |
| Cyclin A/B1/B2 associated events during G2/M transition | 23 | 9.53e-02 | -2.01e-01 | 2.36e-01 |
| Deubiquitination | 240 | 9.27e-08 | -2.01e-01 | 3.59e-06 |
| Apoptotic execution phase | 43 | 2.29e-02 | -2.01e-01 | 8.90e-02 |
| Presynaptic phase of homologous DNA pairing and strand exchange | 38 | 3.26e-02 | -2.00e-01 | 1.12e-01 |
| Suppression of phagosomal maturation | 11 | 2.50e-01 | -2.00e-01 | 4.36e-01 |
| Translesion synthesis by POLK | 15 | 1.79e-01 | -2.00e-01 | 3.58e-01 |
| Maturation of nucleoprotein | 10 | 2.73e-01 | 2.00e-01 | 4.62e-01 |
| Cargo concentration in the ER | 26 | 7.73e-02 | 2.00e-01 | 2.06e-01 |
| RNA Polymerase III Chain Elongation | 18 | 1.42e-01 | 2.00e-01 | 3.11e-01 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | 27 | 7.28e-02 | -2.00e-01 | 1.97e-01 |
| Trafficking of AMPA receptors | 27 | 7.28e-02 | -2.00e-01 | 1.97e-01 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) | 34 | 4.45e-02 | -1.99e-01 | 1.40e-01 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | 12 | 2.35e-01 | 1.98e-01 | 4.21e-01 |
| Plasma lipoprotein remodeling | 23 | 1.01e-01 | 1.98e-01 | 2.47e-01 |
| Gene Silencing by RNA | 62 | 7.17e-03 | -1.98e-01 | 3.96e-02 |
| Recognition of DNA damage by PCNA-containing replication complex | 28 | 7.05e-02 | -1.98e-01 | 1.93e-01 |
| DNA Damage Bypass | 44 | 2.35e-02 | -1.98e-01 | 9.10e-02 |
| Gap junction trafficking and regulation | 16 | 1.72e-01 | 1.97e-01 | 3.51e-01 |
| Signaling by Leptin | 11 | 2.59e-01 | -1.96e-01 | 4.48e-01 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | 40 | 3.21e-02 | -1.96e-01 | 1.12e-01 |
| Heparan sulfate/heparin (HS-GAG) metabolism | 42 | 2.83e-02 | 1.96e-01 | 1.03e-01 |
| Regulation of Apoptosis | 47 | 2.09e-02 | 1.95e-01 | 8.46e-02 |
| CD28 dependent PI3K/Akt signaling | 21 | 1.23e-01 | -1.94e-01 | 2.82e-01 |
| Apoptotic cleavage of cellular proteins | 35 | 4.69e-02 | -1.94e-01 | 1.46e-01 |
| The canonical retinoid cycle in rods (twilight vision) | 14 | 2.09e-01 | -1.94e-01 | 3.89e-01 |
| Signaling by PDGFRA extracellular domain mutants | 12 | 2.45e-01 | -1.94e-01 | 4.32e-01 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | 12 | 2.45e-01 | -1.94e-01 | 4.32e-01 |
| Interleukin-4 and Interleukin-13 signaling | 100 | 8.46e-04 | 1.93e-01 | 8.37e-03 |
| Homology Directed Repair | 97 | 1.02e-03 | -1.93e-01 | 9.41e-03 |
| Regulation of FZD by ubiquitination | 16 | 1.81e-01 | -1.93e-01 | 3.60e-01 |
| Polymerase switching on the C-strand of the telomere | 25 | 9.52e-02 | -1.93e-01 | 2.36e-01 |
| Smooth Muscle Contraction | 34 | 5.18e-02 | 1.93e-01 | 1.56e-01 |
| Endogenous sterols | 21 | 1.27e-01 | 1.93e-01 | 2.88e-01 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | 66 | 7.00e-03 | -1.92e-01 | 3.91e-02 |
| Synthesis of PC | 25 | 9.68e-02 | -1.92e-01 | 2.39e-01 |
| Arachidonic acid metabolism | 40 | 3.59e-02 | 1.92e-01 | 1.19e-01 |
| Hyaluronan metabolism | 15 | 1.99e-01 | 1.91e-01 | 3.83e-01 |
| Mitotic Prophase | 77 | 3.75e-03 | -1.91e-01 | 2.45e-02 |
| Telomere C-strand synthesis initiation | 12 | 2.54e-01 | -1.90e-01 | 4.40e-01 |
| Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | 46 | 2.65e-02 | 1.89e-01 | 9.79e-02 |
| p53-Independent DNA Damage Response | 46 | 2.65e-02 | 1.89e-01 | 9.79e-02 |
| p53-Independent G1/S DNA damage checkpoint | 46 | 2.65e-02 | 1.89e-01 | 9.79e-02 |
| Signaling by EGFR in Cancer | 20 | 1.43e-01 | -1.89e-01 | 3.12e-01 |
| GABA receptor activation | 41 | 3.68e-02 | 1.89e-01 | 1.21e-01 |
| N-glycan antennae elongation in the medial/trans-Golgi | 21 | 1.35e-01 | 1.89e-01 | 2.99e-01 |
| Energy dependent regulation of mTOR by LKB1-AMPK | 28 | 8.45e-02 | -1.88e-01 | 2.16e-01 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | 22 | 1.26e-01 | -1.88e-01 | 2.87e-01 |
| Neurodegenerative Diseases | 22 | 1.26e-01 | -1.88e-01 | 2.87e-01 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | 91 | 1.95e-03 | -1.88e-01 | 1.54e-02 |
| DNA Double-Strand Break Repair | 124 | 3.25e-04 | -1.87e-01 | 3.93e-03 |
| Metabolism of non-coding RNA | 48 | 2.50e-02 | -1.87e-01 | 9.39e-02 |
| snRNP Assembly | 48 | 2.50e-02 | -1.87e-01 | 9.39e-02 |
| Adrenaline,noradrenaline inhibits insulin secretion | 23 | 1.21e-01 | 1.87e-01 | 2.78e-01 |
| Retrograde neurotrophin signalling | 13 | 2.43e-01 | 1.87e-01 | 4.31e-01 |
| RET signaling | 35 | 5.61e-02 | -1.87e-01 | 1.64e-01 |
| Lysine catabolism | 11 | 2.85e-01 | -1.86e-01 | 4.77e-01 |
| NOTCH1 Intracellular Domain Regulates Transcription | 44 | 3.26e-02 | -1.86e-01 | 1.12e-01 |
| Autodegradation of the E3 ubiquitin ligase COP1 | 46 | 2.92e-02 | 1.86e-01 | 1.05e-01 |
| Insulin processing | 22 | 1.31e-01 | -1.86e-01 | 2.95e-01 |
| SUMOylation of transcription factors | 15 | 2.14e-01 | -1.86e-01 | 3.94e-01 |
| AKT phosphorylates targets in the cytosol | 14 | 2.29e-01 | -1.86e-01 | 4.14e-01 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | 49 | 2.52e-02 | 1.85e-01 | 9.46e-02 |
| Transferrin endocytosis and recycling | 26 | 1.03e-01 | 1.85e-01 | 2.49e-01 |
| PI3K Cascade | 31 | 7.57e-02 | -1.84e-01 | 2.02e-01 |
| Ub-specific processing proteases | 166 | 4.33e-05 | -1.84e-01 | 7.92e-04 |
| Synthesis of PIPs at the Golgi membrane | 15 | 2.18e-01 | -1.84e-01 | 3.98e-01 |
| Response of Mtb to phagocytosis | 21 | 1.45e-01 | -1.84e-01 | 3.14e-01 |
| Response to elevated platelet cytosolic Ca2+ | 112 | 8.03e-04 | 1.84e-01 | 8.12e-03 |
| Transcriptional Regulation by TP53 | 335 | 8.94e-09 | -1.83e-01 | 4.48e-07 |
| Listeria monocytogenes entry into host cells | 18 | 1.78e-01 | -1.83e-01 | 3.57e-01 |
| LDL clearance | 16 | 2.05e-01 | 1.83e-01 | 3.87e-01 |
| Termination of translesion DNA synthesis | 29 | 8.84e-02 | -1.83e-01 | 2.23e-01 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | 35 | 6.13e-02 | -1.83e-01 | 1.74e-01 |
| Interleukin-12 family signaling | 51 | 2.43e-02 | 1.82e-01 | 9.24e-02 |
| Nuclear signaling by ERBB4 | 27 | 1.01e-01 | 1.82e-01 | 2.48e-01 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | 11 | 2.95e-01 | 1.82e-01 | 4.90e-01 |
| Interleukin-7 signaling | 22 | 1.39e-01 | -1.82e-01 | 3.06e-01 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | 11 | 2.97e-01 | -1.82e-01 | 4.91e-01 |
| Nephrin family interactions | 19 | 1.71e-01 | -1.81e-01 | 3.51e-01 |
| Collagen formation | 76 | 6.48e-03 | 1.81e-01 | 3.70e-02 |
| Processing of DNA double-strand break ends | 58 | 1.79e-02 | -1.80e-01 | 7.63e-02 |
| Regulation of ornithine decarboxylase (ODC) | 46 | 3.51e-02 | 1.80e-01 | 1.18e-01 |
| Apoptotic factor-mediated response | 13 | 2.64e-01 | 1.79e-01 | 4.52e-01 |
| RNA Polymerase III Transcription Termination | 23 | 1.38e-01 | 1.79e-01 | 3.04e-01 |
| Rap1 signalling | 15 | 2.31e-01 | -1.79e-01 | 4.16e-01 |
| Amine ligand-binding receptors | 18 | 1.90e-01 | -1.79e-01 | 3.69e-01 |
| TBC/RABGAPs | 42 | 4.53e-02 | -1.79e-01 | 1.42e-01 |
| Cell Cycle, Mitotic | 466 | 5.76e-11 | -1.78e-01 | 4.87e-09 |
| Syndecan interactions | 19 | 1.80e-01 | 1.78e-01 | 3.59e-01 |
| Protein ubiquitination | 56 | 2.15e-02 | -1.78e-01 | 8.54e-02 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | 26 | 1.18e-01 | -1.77e-01 | 2.73e-01 |
| Asymmetric localization of PCP proteins | 58 | 1.98e-02 | 1.77e-01 | 8.19e-02 |
| Cleavage of the damaged purine | 11 | 3.10e-01 | -1.77e-01 | 5.04e-01 |
| Depurination | 11 | 3.10e-01 | -1.77e-01 | 5.04e-01 |
| Recognition and association of DNA glycosylase with site containing an affected purine | 11 | 3.10e-01 | -1.77e-01 | 5.04e-01 |
| Regulation of lipid metabolism by PPARalpha | 111 | 1.33e-03 | -1.77e-01 | 1.13e-02 |
| IGF1R signaling cascade | 39 | 5.72e-02 | -1.76e-01 | 1.64e-01 |
| Glutamate and glutamine metabolism | 12 | 2.91e-01 | 1.76e-01 | 4.85e-01 |
| Cellular Senescence | 121 | 9.01e-04 | -1.75e-01 | 8.61e-03 |
| GPCR ligand binding | 237 | 3.83e-06 | 1.75e-01 | 1.04e-04 |
| Innate Immune System | 819 | 4.65e-17 | 1.74e-01 | 2.10e-14 |
| Transcriptional regulation of pluripotent stem cells | 20 | 1.77e-01 | 1.74e-01 | 3.56e-01 |
| Beta-oxidation of very long chain fatty acids | 10 | 3.40e-01 | 1.74e-01 | 5.38e-01 |
| Biotin transport and metabolism | 11 | 3.18e-01 | -1.74e-01 | 5.13e-01 |
| Signaling by TGF-beta Receptor Complex | 68 | 1.33e-02 | -1.74e-01 | 6.41e-02 |
| Iron uptake and transport | 50 | 3.36e-02 | 1.74e-01 | 1.14e-01 |
| Interferon Signaling | 147 | 2.91e-04 | 1.73e-01 | 3.70e-03 |
| IRS-related events triggered by IGF1R | 38 | 6.48e-02 | -1.73e-01 | 1.81e-01 |
| Vpu mediated degradation of CD4 | 46 | 4.28e-02 | 1.73e-01 | 1.36e-01 |
| BMAL1:CLOCK,NPAS2 activates circadian gene expression | 24 | 1.43e-01 | -1.73e-01 | 3.12e-01 |
| Signaling by FGFR4 | 30 | 1.03e-01 | -1.72e-01 | 2.49e-01 |
| Meiosis | 52 | 3.24e-02 | -1.72e-01 | 1.12e-01 |
| TRAF6 mediated IRF7 activation | 15 | 2.50e-01 | -1.71e-01 | 4.36e-01 |
| mRNA 3'-end processing | 52 | 3.26e-02 | -1.71e-01 | 1.12e-01 |
| RAB geranylgeranylation | 55 | 2.82e-02 | 1.71e-01 | 1.02e-01 |
| Leading Strand Synthesis | 14 | 2.68e-01 | -1.71e-01 | 4.56e-01 |
| Polymerase switching | 14 | 2.68e-01 | -1.71e-01 | 4.56e-01 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | 65 | 1.76e-02 | 1.70e-01 | 7.55e-02 |
| PPARA activates gene expression | 109 | 2.28e-03 | -1.69e-01 | 1.72e-02 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | 23 | 1.61e-01 | -1.69e-01 | 3.36e-01 |
| Anti-inflammatory response favouring Leishmania parasite infection | 111 | 2.22e-03 | 1.68e-01 | 1.68e-02 |
| Leishmania parasite growth and survival | 111 | 2.22e-03 | 1.68e-01 | 1.68e-02 |
| Leishmania infection | 189 | 6.93e-05 | 1.68e-01 | 1.14e-03 |
| Metabolism of nitric oxide: NOS3 activation and regulation | 15 | 2.60e-01 | 1.68e-01 | 4.48e-01 |
| Interleukin-2 signaling | 11 | 3.35e-01 | -1.68e-01 | 5.31e-01 |
| NRIF signals cell death from the nucleus | 14 | 2.78e-01 | 1.68e-01 | 4.68e-01 |
| G2/M DNA damage checkpoint | 59 | 2.62e-02 | -1.67e-01 | 9.77e-02 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | 36 | 8.27e-02 | -1.67e-01 | 2.15e-01 |
| Diseases of mitotic cell cycle | 36 | 8.27e-02 | -1.67e-01 | 2.15e-01 |
| Late endosomal microautophagy | 26 | 1.40e-01 | 1.67e-01 | 3.07e-01 |
| Sphingolipid metabolism | 68 | 1.80e-02 | 1.66e-01 | 7.65e-02 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | 26 | 1.43e-01 | -1.66e-01 | 3.12e-01 |
| CD28 dependent Vav1 pathway | 12 | 3.21e-01 | 1.66e-01 | 5.16e-01 |
| Glycosaminoglycan metabolism | 99 | 4.47e-03 | 1.66e-01 | 2.81e-02 |
| Post-translational protein phosphorylation | 74 | 1.40e-02 | 1.65e-01 | 6.61e-02 |
| Signaling by KIT in disease | 20 | 2.01e-01 | -1.65e-01 | 3.84e-01 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | 20 | 2.01e-01 | -1.65e-01 | 3.84e-01 |
| Post NMDA receptor activation events | 54 | 3.59e-02 | -1.65e-01 | 1.19e-01 |
| Cell Cycle | 586 | 1.58e-11 | -1.64e-01 | 1.65e-09 |
| Telomere Maintenance | 63 | 2.53e-02 | -1.63e-01 | 9.46e-02 |
| Cell Cycle Checkpoints | 241 | 1.37e-05 | -1.63e-01 | 2.95e-04 |
| Collagen chain trimerization | 37 | 8.68e-02 | 1.63e-01 | 2.20e-01 |
| Signaling by Retinoic Acid | 33 | 1.06e-01 | -1.63e-01 | 2.51e-01 |
| CaMK IV-mediated phosphorylation of CREB | 10 | 3.74e-01 | -1.62e-01 | 5.73e-01 |
| Gastrin-CREB signalling pathway via PKC and MAPK | 16 | 2.61e-01 | -1.62e-01 | 4.50e-01 |
| eNOS activation | 11 | 3.52e-01 | 1.62e-01 | 5.51e-01 |
| Chromosome Maintenance | 86 | 9.65e-03 | -1.62e-01 | 4.98e-02 |
| Estrogen-dependent gene expression | 82 | 1.15e-02 | -1.62e-01 | 5.72e-02 |
| ISG15 antiviral mechanism | 62 | 2.80e-02 | -1.61e-01 | 1.02e-01 |
| TNFR2 non-canonical NF-kB pathway | 91 | 7.89e-03 | 1.61e-01 | 4.16e-02 |
| FRS-mediated FGFR2 signaling | 15 | 2.80e-01 | -1.61e-01 | 4.70e-01 |
| Transport of vitamins, nucleosides, and related molecules | 33 | 1.10e-01 | 1.61e-01 | 2.57e-01 |
| Diseases of programmed cell death | 23 | 1.83e-01 | -1.60e-01 | 3.61e-01 |
| MECP2 regulates neuronal receptors and channels | 13 | 3.17e-01 | -1.60e-01 | 5.13e-01 |
| Lewis blood group biosynthesis | 13 | 3.18e-01 | 1.60e-01 | 5.13e-01 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | 14 | 3.01e-01 | -1.60e-01 | 4.97e-01 |
| Role of phospholipids in phagocytosis | 28 | 1.45e-01 | 1.59e-01 | 3.14e-01 |
| PI-3K cascade:FGFR2 | 13 | 3.21e-01 | -1.59e-01 | 5.16e-01 |
| Factors involved in megakaryocyte development and platelet production | 107 | 4.62e-03 | -1.59e-01 | 2.90e-02 |
| Purine catabolism | 16 | 2.73e-01 | 1.58e-01 | 4.62e-01 |
| Transcriptional regulation of white adipocyte differentiation | 80 | 1.46e-02 | -1.58e-01 | 6.75e-02 |
| SHC-mediated cascade:FGFR2 | 13 | 3.26e-01 | -1.57e-01 | 5.21e-01 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | 55 | 4.42e-02 | -1.57e-01 | 1.40e-01 |
| Cell-extracellular matrix interactions | 16 | 2.77e-01 | 1.57e-01 | 4.68e-01 |
| Ion homeostasis | 42 | 7.96e-02 | -1.56e-01 | 2.09e-01 |
| Processing of Capped Intron-Containing Pre-mRNA | 221 | 7.10e-05 | -1.55e-01 | 1.16e-03 |
| Processing of SMDT1 | 15 | 2.98e-01 | 1.55e-01 | 4.92e-01 |
| Regulation of TNFR1 signaling | 27 | 1.63e-01 | -1.55e-01 | 3.39e-01 |
| Glycogen breakdown (glycogenolysis) | 14 | 3.15e-01 | -1.55e-01 | 5.12e-01 |
| Aquaporin-mediated transport | 37 | 1.03e-01 | 1.55e-01 | 2.49e-01 |
| SUMOylation of intracellular receptors | 26 | 1.73e-01 | -1.54e-01 | 3.52e-01 |
| Integration of energy metabolism | 94 | 9.75e-03 | -1.54e-01 | 5.02e-02 |
| TNF signaling | 37 | 1.04e-01 | -1.54e-01 | 2.49e-01 |
| Negative regulation of MET activity | 19 | 2.45e-01 | -1.54e-01 | 4.32e-01 |
| Class A/1 (Rhodopsin-like receptors) | 173 | 4.88e-04 | 1.54e-01 | 5.43e-03 |
| Interleukin-35 Signalling | 12 | 3.56e-01 | 1.54e-01 | 5.56e-01 |
| Assembly of active LPL and LIPC lipase complexes | 17 | 2.74e-01 | 1.53e-01 | 4.63e-01 |
| GLI3 is processed to GLI3R by the proteasome | 52 | 5.61e-02 | 1.53e-01 | 1.64e-01 |
| Caspase activation via Death Receptors in the presence of ligand | 16 | 2.89e-01 | 1.53e-01 | 4.83e-01 |
| Regulation of actin dynamics for phagocytic cup formation | 64 | 3.46e-02 | 1.53e-01 | 1.16e-01 |
| Interleukin-12 signaling | 43 | 8.32e-02 | 1.53e-01 | 2.15e-01 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | 48 | 6.74e-02 | 1.53e-01 | 1.87e-01 |
| Translesion synthesis by POLI | 15 | 3.06e-01 | -1.53e-01 | 5.03e-01 |
| Cyclin D associated events in G1 | 43 | 8.38e-02 | -1.52e-01 | 2.15e-01 |
| G1 Phase | 43 | 8.38e-02 | -1.52e-01 | 2.15e-01 |
| M Phase | 327 | 2.36e-06 | -1.52e-01 | 6.94e-05 |
| Hedgehog 'on' state | 75 | 2.27e-02 | 1.52e-01 | 8.85e-02 |
| HDACs deacetylate histones | 30 | 1.49e-01 | -1.52e-01 | 3.18e-01 |
| Deposition of new CENPA-containing nucleosomes at the centromere | 25 | 1.88e-01 | -1.52e-01 | 3.67e-01 |
| Nucleosome assembly | 25 | 1.88e-01 | -1.52e-01 | 3.67e-01 |
| Incretin synthesis, secretion, and inactivation | 14 | 3.25e-01 | 1.52e-01 | 5.21e-01 |
| EPH-Ephrin signaling | 86 | 1.53e-02 | 1.51e-01 | 6.97e-02 |
| Regulated proteolysis of p75NTR | 11 | 3.84e-01 | 1.51e-01 | 5.79e-01 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | 57 | 4.81e-02 | 1.51e-01 | 1.49e-01 |
| Degradation of GLI1 by the proteasome | 53 | 5.67e-02 | 1.51e-01 | 1.64e-01 |
| Signaling by PDGFR in disease | 20 | 2.42e-01 | -1.51e-01 | 4.29e-01 |
| Synthesis of PE | 11 | 3.86e-01 | -1.51e-01 | 5.79e-01 |
| ABC-family proteins mediated transport | 86 | 1.57e-02 | 1.51e-01 | 7.09e-02 |
| Major pathway of rRNA processing in the nucleolus and cytosol | 141 | 2.11e-03 | 1.50e-01 | 1.64e-02 |
| TAK1 activates NFkB by phosphorylation and activation of IKKs complex | 24 | 2.03e-01 | -1.50e-01 | 3.86e-01 |
| TP53 Regulates Transcription of Death Receptors and Ligands | 12 | 3.69e-01 | -1.50e-01 | 5.68e-01 |
| Asparagine N-linked glycosylation | 257 | 3.81e-05 | 1.50e-01 | 7.17e-04 |
| Pentose phosphate pathway | 13 | 3.50e-01 | 1.50e-01 | 5.50e-01 |
| N-Glycan antennae elongation | 13 | 3.51e-01 | 1.49e-01 | 5.50e-01 |
| Defects in vitamin and cofactor metabolism | 20 | 2.47e-01 | -1.49e-01 | 4.35e-01 |
| RNA polymerase II transcribes snRNA genes | 71 | 2.99e-02 | -1.49e-01 | 1.07e-01 |
| RNA Polymerase I Transcription Termination | 30 | 1.60e-01 | 1.48e-01 | 3.34e-01 |
| MTOR signalling | 39 | 1.09e-01 | -1.48e-01 | 2.56e-01 |
| CaM pathway | 32 | 1.47e-01 | -1.48e-01 | 3.16e-01 |
| Calmodulin induced events | 32 | 1.47e-01 | -1.48e-01 | 3.16e-01 |
| Branched-chain amino acid catabolism | 21 | 2.41e-01 | -1.48e-01 | 4.29e-01 |
| TP53 Regulates Transcription of DNA Repair Genes | 57 | 5.40e-02 | -1.48e-01 | 1.59e-01 |
| TRAF3-dependent IRF activation pathway | 13 | 3.57e-01 | -1.47e-01 | 5.56e-01 |
| MAP kinase activation | 60 | 4.89e-02 | -1.47e-01 | 1.50e-01 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 84 | 2.06e-02 | 1.46e-01 | 8.36e-02 |
| RUNX3 regulates NOTCH signaling | 14 | 3.43e-01 | -1.46e-01 | 5.42e-01 |
| Activation of RAC1 | 12 | 3.81e-01 | -1.46e-01 | 5.78e-01 |
| Meiotic recombination | 25 | 2.06e-01 | -1.46e-01 | 3.87e-01 |
| HIV elongation arrest and recovery | 28 | 1.82e-01 | -1.46e-01 | 3.60e-01 |
| Pausing and recovery of HIV elongation | 28 | 1.82e-01 | -1.46e-01 | 3.60e-01 |
| Insulin receptor recycling | 21 | 2.48e-01 | 1.46e-01 | 4.35e-01 |
| ATF4 activates genes in response to endoplasmic reticulum stress | 24 | 2.17e-01 | -1.45e-01 | 3.98e-01 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | 28 | 1.83e-01 | -1.45e-01 | 3.61e-01 |
| Diseases of glycosylation | 118 | 6.54e-03 | 1.45e-01 | 3.72e-02 |
| The NLRP3 inflammasome | 14 | 3.47e-01 | 1.45e-01 | 5.47e-01 |
| Signaling by FGFR3 | 31 | 1.64e-01 | -1.44e-01 | 3.40e-01 |
| SCF-beta-TrCP mediated degradation of Emi1 | 49 | 8.09e-02 | 1.44e-01 | 2.12e-01 |
| Early Phase of HIV Life Cycle | 13 | 3.68e-01 | -1.44e-01 | 5.67e-01 |
| Degradation of GLI2 by the proteasome | 52 | 7.28e-02 | 1.44e-01 | 1.97e-01 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | 11 | 4.09e-01 | 1.44e-01 | 6.05e-01 |
| Anchoring of the basal body to the plasma membrane | 92 | 1.73e-02 | -1.44e-01 | 7.45e-02 |
| Autodegradation of Cdh1 by Cdh1:APC/C | 58 | 5.91e-02 | 1.43e-01 | 1.69e-01 |
| Gene expression (Transcription) | 1117 | 1.73e-15 | -1.43e-01 | 5.15e-13 |
| Phosphorylation of CD3 and TCR zeta chains | 15 | 3.40e-01 | -1.42e-01 | 5.38e-01 |
| rRNA modification in the nucleus and cytosol | 53 | 7.32e-02 | -1.42e-01 | 1.97e-01 |
| APC/C:Cdc20 mediated degradation of Securin | 62 | 5.31e-02 | 1.42e-01 | 1.57e-01 |
| MASTL Facilitates Mitotic Progression | 10 | 4.37e-01 | -1.42e-01 | 6.26e-01 |
| DNA Double Strand Break Response | 38 | 1.31e-01 | -1.42e-01 | 2.94e-01 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | 24 | 2.33e-01 | -1.41e-01 | 4.18e-01 |
| Acyl chain remodelling of PI | 12 | 4.00e-01 | 1.40e-01 | 5.95e-01 |
| Influenza Infection | 113 | 1.02e-02 | 1.40e-01 | 5.15e-02 |
| Fcgamma receptor (FCGR) dependent phagocytosis | 87 | 2.41e-02 | 1.40e-01 | 9.20e-02 |
| HATs acetylate histones | 75 | 3.62e-02 | -1.40e-01 | 1.19e-01 |
| DAP12 interactions | 32 | 1.71e-01 | 1.40e-01 | 3.50e-01 |
| RNA Polymerase II Transcription | 998 | 1.57e-13 | -1.40e-01 | 3.04e-11 |
| Interleukin-17 signaling | 65 | 5.17e-02 | -1.40e-01 | 1.56e-01 |
| HS-GAG biosynthesis | 23 | 2.50e-01 | 1.39e-01 | 4.36e-01 |
| Generation of second messenger molecules | 27 | 2.13e-01 | -1.38e-01 | 3.94e-01 |
| PCNA-Dependent Long Patch Base Excision Repair | 21 | 2.73e-01 | -1.38e-01 | 4.62e-01 |
| Signaling by ERBB2 KD Mutants | 22 | 2.62e-01 | -1.38e-01 | 4.50e-01 |
| TICAM1-dependent activation of IRF3/IRF7 | 10 | 4.52e-01 | -1.37e-01 | 6.42e-01 |
| PRC2 methylates histones and DNA | 14 | 3.74e-01 | -1.37e-01 | 5.73e-01 |
| Serotonin Neurotransmitter Release Cycle | 13 | 3.91e-01 | -1.37e-01 | 5.85e-01 |
| Translocation of ZAP-70 to Immunological synapse | 12 | 4.13e-01 | -1.37e-01 | 6.10e-01 |
| Signaling by MET | 64 | 6.03e-02 | -1.36e-01 | 1.71e-01 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | 11 | 4.36e-01 | 1.36e-01 | 6.26e-01 |
| RNA Polymerase II Transcription Termination | 61 | 6.75e-02 | -1.35e-01 | 1.87e-01 |
| RHO GTPases Activate WASPs and WAVEs | 35 | 1.66e-01 | 1.35e-01 | 3.42e-01 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | 37 | 1.55e-01 | -1.35e-01 | 3.27e-01 |
| Glycogen storage diseases | 11 | 4.38e-01 | 1.35e-01 | 6.28e-01 |
| Cardiac conduction | 94 | 2.39e-02 | -1.35e-01 | 9.15e-02 |
| Signaling by ERBB2 in Cancer | 23 | 2.63e-01 | -1.35e-01 | 4.51e-01 |
| mRNA Splicing - Major Pathway | 167 | 2.70e-03 | -1.35e-01 | 1.90e-02 |
| Separation of Sister Chromatids | 158 | 3.54e-03 | -1.35e-01 | 2.32e-02 |
| NIK-->noncanonical NF-kB signaling | 52 | 9.39e-02 | 1.34e-01 | 2.34e-01 |
| Generic Transcription Pathway | 883 | 2.18e-11 | -1.34e-01 | 2.11e-09 |
| Regulation of signaling by CBL | 18 | 3.25e-01 | -1.34e-01 | 5.21e-01 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | 17 | 3.40e-01 | -1.34e-01 | 5.38e-01 |
| Stabilization of p53 | 50 | 1.02e-01 | 1.34e-01 | 2.48e-01 |
| Synthesis of bile acids and bile salts | 22 | 2.78e-01 | 1.34e-01 | 4.68e-01 |
| Ras activation upon Ca2+ influx through NMDA receptor | 18 | 3.27e-01 | -1.33e-01 | 5.23e-01 |
| Frs2-mediated activation | 11 | 4.44e-01 | -1.33e-01 | 6.33e-01 |
| Signaling by FGFR1 | 37 | 1.61e-01 | -1.33e-01 | 3.36e-01 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | 31 | 2.00e-01 | 1.33e-01 | 3.84e-01 |
| Signaling by NOTCH4 | 75 | 4.69e-02 | 1.33e-01 | 1.46e-01 |
| Fanconi Anemia Pathway | 32 | 1.94e-01 | -1.33e-01 | 3.75e-01 |
| EPHA-mediated growth cone collapse | 14 | 3.90e-01 | 1.33e-01 | 5.84e-01 |
| EGFR downregulation | 26 | 2.43e-01 | -1.32e-01 | 4.30e-01 |
| The citric acid (TCA) cycle and respiratory electron transport | 149 | 5.40e-03 | -1.32e-01 | 3.26e-02 |
| mRNA decay by 3' to 5' exoribonuclease | 15 | 3.76e-01 | 1.32e-01 | 5.74e-01 |
| Platelet activation, signaling and aggregation | 228 | 6.08e-04 | 1.32e-01 | 6.38e-03 |
| Metabolism of amino acids and derivatives | 266 | 2.23e-04 | 1.32e-01 | 2.93e-03 |
| Downregulation of TGF-beta receptor signaling | 24 | 2.65e-01 | -1.31e-01 | 4.53e-01 |
| Transcriptional Regulation by E2F6 | 33 | 1.93e-01 | -1.31e-01 | 3.74e-01 |
| Nuclear Envelope (NE) Reassembly | 65 | 7.02e-02 | -1.30e-01 | 1.93e-01 |
| Pre-NOTCH Transcription and Translation | 32 | 2.04e-01 | -1.30e-01 | 3.86e-01 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | 13 | 4.20e-01 | -1.29e-01 | 6.14e-01 |
| RIPK1-mediated regulated necrosis | 15 | 3.86e-01 | 1.29e-01 | 5.79e-01 |
| Regulated Necrosis | 15 | 3.86e-01 | 1.29e-01 | 5.79e-01 |
| rRNA processing in the nucleus and cytosol | 150 | 6.43e-03 | 1.29e-01 | 3.69e-02 |
| ADORA2B mediated anti-inflammatory cytokines production | 74 | 5.51e-02 | 1.29e-01 | 1.62e-01 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | 53 | 1.05e-01 | -1.29e-01 | 2.49e-01 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | 53 | 1.05e-01 | -1.29e-01 | 2.49e-01 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | 53 | 1.05e-01 | -1.29e-01 | 2.49e-01 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | 53 | 1.05e-01 | -1.29e-01 | 2.49e-01 |
| Signaling by NOTCH1 in Cancer | 53 | 1.05e-01 | -1.29e-01 | 2.49e-01 |
| CDT1 association with the CDC6:ORC:origin complex | 53 | 1.05e-01 | 1.29e-01 | 2.49e-01 |
| TGF-beta receptor signaling activates SMADs | 29 | 2.31e-01 | -1.29e-01 | 4.16e-01 |
| Killing mechanisms | 11 | 4.61e-01 | 1.28e-01 | 6.47e-01 |
| WNT5:FZD7-mediated leishmania damping | 11 | 4.61e-01 | 1.28e-01 | 6.47e-01 |
| Trafficking of GluR2-containing AMPA receptors | 13 | 4.26e-01 | -1.28e-01 | 6.18e-01 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | 54 | 1.05e-01 | 1.28e-01 | 2.49e-01 |
| Intraflagellar transport | 38 | 1.75e-01 | 1.27e-01 | 3.53e-01 |
| Positive epigenetic regulation of rRNA expression | 45 | 1.40e-01 | -1.27e-01 | 3.07e-01 |
| RNA Polymerase I Promoter Escape | 30 | 2.29e-01 | 1.27e-01 | 4.14e-01 |
| Cytochrome c-mediated apoptotic response | 10 | 4.89e-01 | 1.26e-01 | 6.75e-01 |
| CRMPs in Sema3A signaling | 15 | 3.98e-01 | 1.26e-01 | 5.92e-01 |
| Dectin-1 mediated noncanonical NF-kB signaling | 54 | 1.09e-01 | 1.26e-01 | 2.56e-01 |
| Prefoldin mediated transfer of substrate to CCT/TriC | 26 | 2.67e-01 | -1.26e-01 | 4.56e-01 |
| FGFR1 mutant receptor activation | 24 | 2.87e-01 | -1.26e-01 | 4.80e-01 |
| tRNA processing in the nucleus | 51 | 1.21e-01 | -1.26e-01 | 2.78e-01 |
| Interleukin-20 family signaling | 16 | 3.86e-01 | 1.25e-01 | 5.79e-01 |
| PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases | 14 | 4.18e-01 | -1.25e-01 | 6.14e-01 |
| FCERI mediated Ca+2 mobilization | 29 | 2.45e-01 | -1.25e-01 | 4.32e-01 |
| Fatty acyl-CoA biosynthesis | 25 | 2.82e-01 | -1.24e-01 | 4.73e-01 |
| Toll Like Receptor 3 (TLR3) Cascade | 87 | 4.56e-02 | -1.24e-01 | 1.43e-01 |
| CD209 (DC-SIGN) signaling | 19 | 3.50e-01 | -1.24e-01 | 5.50e-01 |
| Extracellular matrix organization | 245 | 8.64e-04 | 1.24e-01 | 8.41e-03 |
| RHO GTPases activate CIT | 19 | 3.50e-01 | -1.24e-01 | 5.50e-01 |
| RHO GTPase Effectors | 230 | 1.25e-03 | -1.24e-01 | 1.09e-02 |
| Regulation of RUNX3 expression and activity | 48 | 1.39e-01 | 1.24e-01 | 3.05e-01 |
| Signaling by NOTCH1 | 68 | 7.86e-02 | -1.23e-01 | 2.08e-01 |
| Regulation of RUNX1 Expression and Activity | 17 | 3.79e-01 | -1.23e-01 | 5.77e-01 |
| Mitotic Metaphase and Anaphase | 211 | 2.08e-03 | -1.23e-01 | 1.63e-02 |
| Signal transduction by L1 | 21 | 3.29e-01 | 1.23e-01 | 5.25e-01 |
| Regulation of RUNX2 expression and activity | 66 | 8.41e-02 | 1.23e-01 | 2.16e-01 |
| Diseases of metabolism | 192 | 3.44e-03 | 1.23e-01 | 2.28e-02 |
| RHO GTPases Activate NADPH Oxidases | 22 | 3.19e-01 | 1.23e-01 | 5.15e-01 |
| Interleukin-21 signaling | 10 | 5.05e-01 | -1.22e-01 | 6.89e-01 |
| Platelet homeostasis | 74 | 7.03e-02 | 1.22e-01 | 1.93e-01 |
| Integrin cell surface interactions | 58 | 1.09e-01 | 1.22e-01 | 2.56e-01 |
| Degradation of DVL | 51 | 1.33e-01 | 1.22e-01 | 2.97e-01 |
| Mitotic Anaphase | 210 | 2.52e-03 | -1.21e-01 | 1.85e-02 |
| E3 ubiquitin ligases ubiquitinate target proteins | 39 | 1.90e-01 | -1.21e-01 | 3.69e-01 |
| MHC class II antigen presentation | 95 | 4.19e-02 | 1.21e-01 | 1.34e-01 |
| Interleukin-6 family signaling | 20 | 3.56e-01 | 1.19e-01 | 5.56e-01 |
| Cellular response to hypoxia | 65 | 9.69e-02 | 1.19e-01 | 2.39e-01 |
| Glycerophospholipid biosynthesis | 103 | 3.73e-02 | -1.19e-01 | 1.21e-01 |
| Antiviral mechanism by IFN-stimulated genes | 70 | 8.57e-02 | -1.19e-01 | 2.18e-01 |
| Phase II - Conjugation of compounds | 73 | 7.94e-02 | 1.19e-01 | 2.09e-01 |
| Hedgehog 'off' state | 90 | 5.16e-02 | 1.19e-01 | 1.56e-01 |
| Signaling by FGFR2 in disease | 32 | 2.45e-01 | -1.19e-01 | 4.32e-01 |
| Immune System | 1698 | 3.49e-15 | 1.18e-01 | 7.88e-13 |
| Signaling by Hedgehog | 120 | 2.69e-02 | 1.17e-01 | 9.85e-02 |
| Ca-dependent events | 34 | 2.38e-01 | -1.17e-01 | 4.25e-01 |
| Retrograde transport at the Trans-Golgi-Network | 44 | 1.82e-01 | -1.16e-01 | 3.60e-01 |
| TRAF6 mediated NF-kB activation | 21 | 3.57e-01 | -1.16e-01 | 5.56e-01 |
| Transcriptional regulation by RUNX2 | 109 | 3.72e-02 | 1.16e-01 | 1.21e-01 |
| NOD1/2 Signaling Pathway | 30 | 2.74e-01 | -1.15e-01 | 4.63e-01 |
| Other semaphorin interactions | 19 | 3.84e-01 | 1.15e-01 | 5.79e-01 |
| mRNA Splicing | 175 | 8.77e-03 | -1.15e-01 | 4.57e-02 |
| Interleukin-6 signaling | 10 | 5.30e-01 | 1.15e-01 | 7.06e-01 |
| Sialic acid metabolism | 26 | 3.12e-01 | 1.15e-01 | 5.07e-01 |
| Formation of RNA Pol II elongation complex | 53 | 1.50e-01 | -1.14e-01 | 3.18e-01 |
| RNA Polymerase II Transcription Elongation | 53 | 1.50e-01 | -1.14e-01 | 3.18e-01 |
| Cytochrome P450 - arranged by substrate type | 34 | 2.52e-01 | 1.13e-01 | 4.39e-01 |
| G alpha (z) signalling events | 39 | 2.20e-01 | 1.13e-01 | 4.02e-01 |
| TCF dependent signaling in response to WNT | 151 | 1.67e-02 | -1.13e-01 | 7.23e-02 |
| PIWI-interacting RNA (piRNA) biogenesis | 19 | 3.96e-01 | 1.12e-01 | 5.91e-01 |
| RHO GTPases activate PKNs | 33 | 2.65e-01 | -1.12e-01 | 4.53e-01 |
| PCP/CE pathway | 85 | 7.43e-02 | 1.12e-01 | 2.00e-01 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | 13 | 4.84e-01 | -1.12e-01 | 6.70e-01 |
| Degradation of AXIN | 49 | 1.75e-01 | 1.12e-01 | 3.53e-01 |
| Signaling by Interleukins | 388 | 1.63e-04 | 1.12e-01 | 2.32e-03 |
| Mismatch Repair | 15 | 4.53e-01 | -1.12e-01 | 6.42e-01 |
| SUMOylation of immune response proteins | 11 | 5.20e-01 | -1.12e-01 | 7.03e-01 |
| RUNX2 regulates bone development | 28 | 3.06e-01 | 1.12e-01 | 5.03e-01 |
| Initiation of Nuclear Envelope (NE) Reformation | 19 | 4.00e-01 | -1.12e-01 | 5.95e-01 |
| Cell surface interactions at the vascular wall | 111 | 4.29e-02 | 1.11e-01 | 1.36e-01 |
| Metabolism of steroids | 115 | 4.10e-02 | -1.10e-01 | 1.32e-01 |
| IL-6-type cytokine receptor ligand interactions | 14 | 4.74e-01 | 1.10e-01 | 6.60e-01 |
| Metabolism of nucleotides | 88 | 7.49e-02 | 1.10e-01 | 2.01e-01 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | 39 | 2.36e-01 | -1.10e-01 | 4.21e-01 |
| Signalling to ERKs | 31 | 2.91e-01 | -1.10e-01 | 4.85e-01 |
| Muscle contraction | 153 | 2.01e-02 | -1.09e-01 | 8.20e-02 |
| DNA Repair | 268 | 2.19e-03 | -1.09e-01 | 1.67e-02 |
| Regulation of PTEN gene transcription | 58 | 1.51e-01 | -1.09e-01 | 3.20e-01 |
| Sema3A PAK dependent Axon repulsion | 16 | 4.52e-01 | 1.09e-01 | 6.42e-01 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | 11 | 5.33e-01 | -1.09e-01 | 7.06e-01 |
| alpha-linolenic acid (ALA) metabolism | 11 | 5.33e-01 | -1.09e-01 | 7.06e-01 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | 66 | 1.33e-01 | 1.07e-01 | 2.97e-01 |
| Sema4D in semaphorin signaling | 24 | 3.66e-01 | 1.07e-01 | 5.64e-01 |
| RMTs methylate histone arginines | 29 | 3.22e-01 | -1.06e-01 | 5.17e-01 |
| Methylation | 11 | 5.43e-01 | -1.06e-01 | 7.12e-01 |
| MyD88-independent TLR4 cascade | 91 | 8.20e-02 | -1.06e-01 | 2.13e-01 |
| TRIF(TICAM1)-mediated TLR4 signaling | 91 | 8.20e-02 | -1.06e-01 | 2.13e-01 |
| Pre-NOTCH Expression and Processing | 47 | 2.14e-01 | -1.05e-01 | 3.94e-01 |
| Costimulation by the CD28 family | 61 | 1.57e-01 | -1.05e-01 | 3.29e-01 |
| Recycling pathway of L1 | 27 | 3.46e-01 | -1.05e-01 | 5.46e-01 |
| Blood group systems biosynthesis | 16 | 4.71e-01 | 1.04e-01 | 6.56e-01 |
| Dual Incision in GG-NER | 39 | 2.61e-01 | -1.04e-01 | 4.49e-01 |
| Mitotic G1 phase and G1/S transition | 138 | 3.54e-02 | -1.04e-01 | 1.18e-01 |
| Organelle biogenesis and maintenance | 242 | 5.71e-03 | -1.03e-01 | 3.40e-02 |
| G alpha (s) signalling events | 98 | 7.77e-02 | 1.03e-01 | 2.06e-01 |
| Degradation of the extracellular matrix | 86 | 9.88e-02 | 1.03e-01 | 2.44e-01 |
| Receptor Mediated Mitophagy | 11 | 5.54e-01 | -1.03e-01 | 7.19e-01 |
| Interleukin-1 family signaling | 120 | 5.17e-02 | 1.03e-01 | 1.56e-01 |
| Pausing and recovery of Tat-mediated HIV elongation | 26 | 3.64e-01 | -1.03e-01 | 5.63e-01 |
| Tat-mediated HIV elongation arrest and recovery | 26 | 3.64e-01 | -1.03e-01 | 5.63e-01 |
| Translation of structural proteins | 26 | 3.66e-01 | 1.03e-01 | 5.64e-01 |
| Nuclear Receptor transcription pathway | 44 | 2.41e-01 | -1.02e-01 | 4.29e-01 |
| Mitochondrial iron-sulfur cluster biogenesis | 12 | 5.44e-01 | -1.01e-01 | 7.12e-01 |
| ERBB2 Regulates Cell Motility | 13 | 5.27e-01 | 1.01e-01 | 7.05e-01 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | 50 | 2.16e-01 | -1.01e-01 | 3.98e-01 |
| PLC beta mediated events | 47 | 2.31e-01 | -1.01e-01 | 4.16e-01 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | 14 | 5.13e-01 | -1.01e-01 | 6.96e-01 |
| Signaling by Rho GTPases | 353 | 1.20e-03 | -1.01e-01 | 1.06e-02 |
| ERKs are inactivated | 13 | 5.29e-01 | 1.01e-01 | 7.06e-01 |
| B-WICH complex positively regulates rRNA expression | 32 | 3.25e-01 | -1.00e-01 | 5.21e-01 |
| Mitotic G2-G2/M phases | 176 | 2.22e-02 | -1.00e-01 | 8.70e-02 |
| Activation of NMDA receptors and postsynaptic events | 62 | 1.73e-01 | -1.00e-01 | 3.53e-01 |
| PERK regulates gene expression | 28 | 3.60e-01 | -1.00e-01 | 5.59e-01 |
| DSCAM interactions | 10 | 5.84e-01 | 9.99e-02 | 7.39e-01 |
| Sulfur amino acid metabolism | 23 | 4.07e-01 | -9.99e-02 | 6.04e-01 |
| Phospholipid metabolism | 181 | 2.10e-02 | -9.97e-02 | 8.46e-02 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | 20 | 4.41e-01 | -9.96e-02 | 6.30e-01 |
| Diseases associated with the TLR signaling cascade | 22 | 4.20e-01 | 9.93e-02 | 6.14e-01 |
| Diseases of Immune System | 22 | 4.20e-01 | 9.93e-02 | 6.14e-01 |
| G2/M Transition | 174 | 2.49e-02 | -9.88e-02 | 9.39e-02 |
| Mitochondrial tRNA aminoacylation | 18 | 4.69e-01 | 9.87e-02 | 6.54e-01 |
| Signaling by FGFR in disease | 52 | 2.19e-01 | -9.86e-02 | 4.00e-01 |
| SCF(Skp2)-mediated degradation of p27/p21 | 53 | 2.17e-01 | 9.82e-02 | 3.98e-01 |
| Formation of the cornified envelope | 23 | 4.16e-01 | -9.81e-02 | 6.13e-01 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | 67 | 1.66e-01 | 9.80e-02 | 3.41e-01 |
| Signaling by FGFR2 | 56 | 2.06e-01 | -9.79e-02 | 3.87e-01 |
| Transport to the Golgi and subsequent modification | 152 | 3.95e-02 | 9.69e-02 | 1.27e-01 |
| ER Quality Control Compartment (ERQC) | 18 | 4.77e-01 | 9.69e-02 | 6.63e-01 |
| TP53 Regulates Metabolic Genes | 82 | 1.30e-01 | -9.68e-02 | 2.93e-01 |
| Signaling by TGFB family members | 90 | 1.14e-01 | -9.66e-02 | 2.63e-01 |
| ERBB2 Activates PTK6 Signaling | 11 | 5.80e-01 | 9.65e-02 | 7.38e-01 |
| APC-Cdc20 mediated degradation of Nek2A | 24 | 4.14e-01 | -9.64e-02 | 6.11e-01 |
| Reproduction | 63 | 1.87e-01 | -9.62e-02 | 3.67e-01 |
| Semaphorin interactions | 63 | 1.89e-01 | 9.57e-02 | 3.69e-01 |
| MAPK targets/ Nuclear events mediated by MAP kinases | 31 | 3.58e-01 | -9.55e-02 | 5.56e-01 |
| IKK complex recruitment mediated by RIP1 | 20 | 4.61e-01 | -9.52e-02 | 6.47e-01 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | 16 | 5.11e-01 | 9.49e-02 | 6.95e-01 |
| ESR-mediated signaling | 143 | 5.30e-02 | -9.39e-02 | 1.57e-01 |
| Caspase activation via extrinsic apoptotic signalling pathway | 25 | 4.19e-01 | 9.33e-02 | 6.14e-01 |
| Potassium Channels | 66 | 1.91e-01 | 9.31e-02 | 3.71e-01 |
| tRNA processing | 106 | 9.91e-02 | -9.28e-02 | 2.44e-01 |
| G alpha (12/13) signalling events | 73 | 1.72e-01 | 9.25e-02 | 3.51e-01 |
| PECAM1 interactions | 11 | 5.98e-01 | 9.18e-02 | 7.49e-01 |
| VLDLR internalisation and degradation | 11 | 5.99e-01 | 9.15e-02 | 7.50e-01 |
| Keratan sulfate biosynthesis | 21 | 4.69e-01 | -9.13e-02 | 6.54e-01 |
| Regulation of insulin secretion | 64 | 2.09e-01 | -9.09e-02 | 3.89e-01 |
| RNA Polymerase II Pre-transcription Events | 75 | 1.75e-01 | -9.07e-02 | 3.53e-01 |
| Calnexin/calreticulin cycle | 23 | 4.53e-01 | 9.04e-02 | 6.42e-01 |
| Selective autophagy | 53 | 2.56e-01 | -9.03e-02 | 4.42e-01 |
| Signaling by ERBB2 | 45 | 2.96e-01 | -9.02e-02 | 4.90e-01 |
| Nonhomologous End-Joining (NHEJ) | 33 | 3.71e-01 | -9.00e-02 | 5.70e-01 |
| HIV Life Cycle | 132 | 7.51e-02 | -8.99e-02 | 2.01e-01 |
| Epigenetic regulation of gene expression | 84 | 1.55e-01 | -8.98e-02 | 3.27e-01 |
| MyD88 cascade initiated on plasma membrane | 77 | 1.74e-01 | -8.97e-02 | 3.53e-01 |
| Toll Like Receptor 10 (TLR10) Cascade | 77 | 1.74e-01 | -8.97e-02 | 3.53e-01 |
| Toll Like Receptor 5 (TLR5) Cascade | 77 | 1.74e-01 | -8.97e-02 | 3.53e-01 |
| CDK-mediated phosphorylation and removal of Cdc6 | 66 | 2.10e-01 | 8.94e-02 | 3.89e-01 |
| G1/S Transition | 121 | 9.25e-02 | -8.87e-02 | 2.31e-01 |
| Degradation of cysteine and homocysteine | 13 | 5.80e-01 | -8.87e-02 | 7.38e-01 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | 68 | 2.07e-01 | 8.86e-02 | 3.87e-01 |
| Synthesis of IP2, IP, and Ins in the cytosol | 13 | 5.81e-01 | 8.85e-02 | 7.38e-01 |
| Nicotinamide salvaging | 14 | 5.67e-01 | 8.84e-02 | 7.27e-01 |
| GP1b-IX-V activation signalling | 10 | 6.29e-01 | -8.83e-02 | 7.78e-01 |
| Regulation of innate immune responses to cytosolic DNA | 11 | 6.14e-01 | 8.79e-02 | 7.64e-01 |
| Sphingolipid de novo biosynthesis | 34 | 3.77e-01 | 8.76e-02 | 5.75e-01 |
| S Phase | 154 | 6.20e-02 | -8.73e-02 | 1.76e-01 |
| Prolactin receptor signaling | 14 | 5.72e-01 | -8.73e-02 | 7.32e-01 |
| Signaling by NTRK2 (TRKB) | 23 | 4.69e-01 | -8.73e-02 | 6.54e-01 |
| Formation of HIV elongation complex in the absence of HIV Tat | 40 | 3.40e-01 | -8.72e-02 | 5.38e-01 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | 69 | 2.12e-01 | 8.70e-02 | 3.92e-01 |
| Signaling by ERBB2 TMD/JMD mutants | 19 | 5.12e-01 | -8.69e-02 | 6.95e-01 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | 14 | 5.75e-01 | -8.65e-02 | 7.34e-01 |
| Formation of TC-NER Pre-Incision Complex | 50 | 2.91e-01 | 8.63e-02 | 4.85e-01 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | 34 | 3.84e-01 | 8.62e-02 | 5.79e-01 |
| Assembly Of The HIV Virion | 13 | 5.91e-01 | 8.62e-02 | 7.44e-01 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | 17 | 5.39e-01 | -8.61e-02 | 7.09e-01 |
| Interleukin-1 signaling | 92 | 1.56e-01 | 8.57e-02 | 3.27e-01 |
| Neurotransmitter release cycle | 35 | 3.81e-01 | -8.57e-02 | 5.78e-01 |
| Chaperone Mediated Autophagy | 17 | 5.41e-01 | -8.56e-02 | 7.11e-01 |
| Transcription of the HIV genome | 64 | 2.38e-01 | -8.53e-02 | 4.25e-01 |
| trans-Golgi Network Vesicle Budding | 67 | 2.28e-01 | 8.53e-02 | 4.13e-01 |
| GPVI-mediated activation cascade | 32 | 4.07e-01 | 8.46e-02 | 6.04e-01 |
| IRE1alpha activates chaperones | 49 | 3.08e-01 | 8.43e-02 | 5.03e-01 |
| Signaling by NOTCH2 | 29 | 4.33e-01 | -8.42e-02 | 6.26e-01 |
| G-protein mediated events | 48 | 3.16e-01 | -8.37e-02 | 5.13e-01 |
| SARS-CoV-1 Infection | 41 | 3.57e-01 | 8.32e-02 | 5.56e-01 |
| Amyloid fiber formation | 38 | 3.75e-01 | 8.31e-02 | 5.74e-01 |
| CD28 co-stimulation | 32 | 4.16e-01 | -8.31e-02 | 6.13e-01 |
| COPI-mediated anterograde transport | 79 | 2.04e-01 | 8.28e-02 | 3.86e-01 |
| NF-kB is activated and signals survival | 11 | 6.35e-01 | -8.26e-02 | 7.82e-01 |
| Negative regulation of FGFR1 signaling | 20 | 5.23e-01 | -8.25e-02 | 7.03e-01 |
| Signaling by FGFR2 IIIa TM | 18 | 5.45e-01 | 8.24e-02 | 7.13e-01 |
| Late Phase of HIV Life Cycle | 120 | 1.23e-01 | -8.16e-02 | 2.82e-01 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | 13 | 6.11e-01 | -8.14e-02 | 7.62e-01 |
| TP53 Regulates Transcription of Cell Death Genes | 38 | 3.86e-01 | -8.13e-02 | 5.79e-01 |
| Transmission across Chemical Synapses | 186 | 5.69e-02 | -8.11e-02 | 1.64e-01 |
| Acetylcholine regulates insulin secretion | 10 | 6.59e-01 | 8.06e-02 | 7.95e-01 |
| WNT5A-dependent internalization of FZD4 | 15 | 5.89e-01 | -8.06e-02 | 7.43e-01 |
| Glycogen synthesis | 12 | 6.30e-01 | 8.03e-02 | 7.78e-01 |
| Glutathione conjugation | 31 | 4.40e-01 | 8.02e-02 | 6.29e-01 |
| CASP8 activity is inhibited | 11 | 6.45e-01 | 8.01e-02 | 7.87e-01 |
| Dimerization of procaspase-8 | 11 | 6.45e-01 | 8.01e-02 | 7.87e-01 |
| Regulation by c-FLIP | 11 | 6.45e-01 | 8.01e-02 | 7.87e-01 |
| Cytokine Signaling in Immune system | 718 | 3.01e-04 | 7.99e-02 | 3.71e-03 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | 70 | 2.52e-01 | 7.93e-02 | 4.38e-01 |
| Role of LAT2/NTAL/LAB on calcium mobilization | 15 | 5.95e-01 | -7.93e-02 | 7.46e-01 |
| Defective B3GALT6 causes EDSP2 and SEMDJL1 | 18 | 5.61e-01 | 7.92e-02 | 7.22e-01 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | 10 | 6.65e-01 | -7.92e-02 | 7.98e-01 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | 13 | 6.22e-01 | -7.90e-02 | 7.72e-01 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | 20 | 5.44e-01 | -7.85e-02 | 7.12e-01 |
| Phosphorylation of the APC/C | 20 | 5.44e-01 | -7.83e-02 | 7.12e-01 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | 21 | 5.35e-01 | -7.83e-02 | 7.06e-01 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | 21 | 5.35e-01 | -7.83e-02 | 7.06e-01 |
| Interleukin receptor SHC signaling | 22 | 5.26e-01 | -7.82e-02 | 7.05e-01 |
| ER to Golgi Anterograde Transport | 126 | 1.33e-01 | 7.77e-02 | 2.97e-01 |
| Netrin-1 signaling | 46 | 3.63e-01 | -7.76e-02 | 5.63e-01 |
| HCMV Infection | 74 | 2.50e-01 | -7.73e-02 | 4.36e-01 |
| NoRC negatively regulates rRNA expression | 45 | 3.70e-01 | 7.73e-02 | 5.68e-01 |
| Synthesis of IP3 and IP4 in the cytosol | 23 | 5.21e-01 | 7.73e-02 | 7.03e-01 |
| Inflammasomes | 19 | 5.61e-01 | 7.71e-02 | 7.22e-01 |
| Post-translational modification: synthesis of GPI-anchored proteins | 63 | 2.91e-01 | 7.69e-02 | 4.85e-01 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | 28 | 4.82e-01 | 7.68e-02 | 6.68e-01 |
| tRNA Aminoacylation | 24 | 5.16e-01 | 7.67e-02 | 6.98e-01 |
| Intracellular signaling by second messengers | 275 | 2.98e-02 | -7.64e-02 | 1.07e-01 |
| Signaling by Insulin receptor | 60 | 3.07e-01 | -7.64e-02 | 5.03e-01 |
| Membrane binding and targetting of GAG proteins | 11 | 6.62e-01 | 7.61e-02 | 7.96e-01 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | 11 | 6.62e-01 | 7.61e-02 | 7.96e-01 |
| Metal ion SLC transporters | 23 | 5.30e-01 | 7.57e-02 | 7.06e-01 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | 61 | 3.07e-01 | -7.57e-02 | 5.03e-01 |
| Metabolism of fat-soluble vitamins | 35 | 4.41e-01 | 7.53e-02 | 6.30e-01 |
| PI Metabolism | 79 | 2.48e-01 | -7.52e-02 | 4.35e-01 |
| Regulation of PTEN stability and activity | 62 | 3.07e-01 | 7.51e-02 | 5.03e-01 |
| COPII-mediated vesicle transport | 62 | 3.09e-01 | 7.47e-02 | 5.04e-01 |
| Free fatty acids regulate insulin secretion | 11 | 6.71e-01 | -7.40e-02 | 8.00e-01 |
| Axon guidance | 456 | 7.13e-03 | 7.40e-02 | 3.96e-02 |
| Base Excision Repair | 45 | 3.97e-01 | -7.31e-02 | 5.91e-01 |
| Synthesis of PIPs at the late endosome membrane | 11 | 6.76e-01 | -7.28e-02 | 8.04e-01 |
| VEGFA-VEGFR2 Pathway | 92 | 2.29e-01 | -7.26e-02 | 4.14e-01 |
| G alpha (i) signalling events | 251 | 4.91e-02 | 7.24e-02 | 1.51e-01 |
| Biological oxidations | 143 | 1.37e-01 | 7.21e-02 | 3.04e-01 |
| Signaling by Nuclear Receptors | 202 | 7.91e-02 | -7.18e-02 | 2.09e-01 |
| Diseases of DNA repair | 10 | 6.95e-01 | 7.16e-02 | 8.18e-01 |
| XBP1(S) activates chaperone genes | 47 | 3.96e-01 | 7.16e-02 | 5.91e-01 |
| Complex I biogenesis | 54 | 3.65e-01 | 7.14e-02 | 5.63e-01 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | 22 | 5.62e-01 | -7.14e-02 | 7.23e-01 |
| Tight junction interactions | 13 | 6.56e-01 | 7.13e-02 | 7.94e-01 |
| SHC1 events in ERBB2 signaling | 20 | 5.81e-01 | -7.13e-02 | 7.38e-01 |
| RHO GTPases Activate ROCKs | 19 | 5.95e-01 | 7.04e-02 | 7.46e-01 |
| IRF3-mediated induction of type I IFN | 10 | 7.00e-01 | -7.04e-02 | 8.21e-01 |
| Protein folding | 88 | 2.55e-01 | 7.03e-02 | 4.42e-01 |
| Aflatoxin activation and detoxification | 10 | 7.03e-01 | 6.96e-02 | 8.24e-01 |
| APC/C:Cdc20 mediated degradation of Cyclin B | 22 | 5.75e-01 | -6.90e-02 | 7.34e-01 |
| SHC1 events in ERBB4 signaling | 12 | 6.79e-01 | -6.90e-02 | 8.07e-01 |
| Mitochondrial calcium ion transport | 20 | 5.93e-01 | 6.90e-02 | 7.45e-01 |
| Regulation of necroptotic cell death | 13 | 6.67e-01 | 6.89e-02 | 7.99e-01 |
| Amino acids regulate mTORC1 | 49 | 4.06e-01 | 6.86e-02 | 6.03e-01 |
| DNA Replication | 120 | 1.96e-01 | -6.84e-02 | 3.78e-01 |
| tRNA modification in the nucleus and cytosol | 38 | 4.67e-01 | 6.83e-02 | 6.53e-01 |
| Hemostasis | 492 | 1.02e-02 | 6.81e-02 | 5.15e-02 |
| Inactivation, recovery and regulation of the phototransduction cascade | 24 | 5.65e-01 | -6.80e-02 | 7.25e-01 |
| The phototransduction cascade | 24 | 5.65e-01 | -6.80e-02 | 7.25e-01 |
| NOTCH4 Intracellular Domain Regulates Transcription | 19 | 6.10e-01 | -6.77e-02 | 7.60e-01 |
| O-glycosylation of TSR domain-containing proteins | 33 | 5.02e-01 | 6.76e-02 | 6.86e-01 |
| Acyl chain remodelling of PS | 17 | 6.30e-01 | 6.74e-02 | 7.78e-01 |
| HIV Transcription Initiation | 45 | 4.35e-01 | 6.73e-02 | 6.26e-01 |
| RNA Polymerase II HIV Promoter Escape | 45 | 4.35e-01 | 6.73e-02 | 6.26e-01 |
| RNA Polymerase II Promoter Escape | 45 | 4.35e-01 | 6.73e-02 | 6.26e-01 |
| RNA Polymerase II Transcription Initiation | 45 | 4.35e-01 | 6.73e-02 | 6.26e-01 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | 45 | 4.35e-01 | 6.73e-02 | 6.26e-01 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | 45 | 4.35e-01 | 6.73e-02 | 6.26e-01 |
| Infectious disease | 601 | 5.34e-03 | 6.71e-02 | 3.25e-02 |
| Rab regulation of trafficking | 118 | 2.09e-01 | -6.70e-02 | 3.89e-01 |
| Oncogenic MAPK signaling | 72 | 3.28e-01 | -6.68e-02 | 5.23e-01 |
| Intra-Golgi traffic | 42 | 4.57e-01 | 6.64e-02 | 6.45e-01 |
| Interleukin-15 signaling | 14 | 6.68e-01 | -6.62e-02 | 8.00e-01 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | 23 | 5.83e-01 | 6.62e-02 | 7.38e-01 |
| RNA Pol II CTD phosphorylation and interaction with CE | 26 | 5.60e-01 | 6.61e-02 | 7.22e-01 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | 26 | 5.60e-01 | 6.61e-02 | 7.22e-01 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | 34 | 5.08e-01 | 6.57e-02 | 6.91e-01 |
| ATF6 (ATF6-alpha) activates chaperone genes | 10 | 7.20e-01 | -6.56e-02 | 8.37e-01 |
| rRNA processing | 167 | 1.47e-01 | 6.52e-02 | 3.16e-01 |
| Retinoid metabolism and transport | 32 | 5.24e-01 | 6.51e-02 | 7.03e-01 |
| Downstream TCR signaling | 83 | 3.07e-01 | -6.49e-02 | 5.03e-01 |
| Voltage gated Potassium channels | 29 | 5.46e-01 | -6.48e-02 | 7.13e-01 |
| Synthesis of PIPs at the plasma membrane | 51 | 4.26e-01 | -6.45e-02 | 6.18e-01 |
| Protein-protein interactions at synapses | 63 | 3.80e-01 | 6.40e-02 | 5.78e-01 |
| G2/M Checkpoints | 126 | 2.16e-01 | -6.39e-02 | 3.97e-01 |
| TNFR1-induced proapoptotic signaling | 13 | 6.90e-01 | -6.39e-02 | 8.17e-01 |
| Defective B3GALTL causes Peters-plus syndrome (PpS) | 32 | 5.32e-01 | 6.38e-02 | 7.06e-01 |
| GAB1 signalosome | 14 | 6.80e-01 | 6.36e-02 | 8.08e-01 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | 18 | 6.42e-01 | 6.33e-02 | 7.86e-01 |
| SLC-mediated transmembrane transport | 179 | 1.45e-01 | -6.33e-02 | 3.14e-01 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | 33 | 5.33e-01 | 6.28e-02 | 7.06e-01 |
| Beta-catenin independent WNT signaling | 131 | 2.16e-01 | 6.28e-02 | 3.97e-01 |
| Defective EXT1 causes exostoses 1, TRPS2 and CHDS | 13 | 6.96e-01 | 6.25e-02 | 8.18e-01 |
| Defective EXT2 causes exostoses 2 | 13 | 6.96e-01 | 6.25e-02 | 8.18e-01 |
| Potential therapeutics for SARS | 35 | 5.24e-01 | -6.23e-02 | 7.03e-01 |
| Signaling by FGFR | 66 | 3.82e-01 | -6.22e-02 | 5.79e-01 |
| TCR signaling | 105 | 2.72e-01 | -6.22e-02 | 4.62e-01 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | 48 | 4.58e-01 | -6.19e-02 | 6.46e-01 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | 84 | 3.31e-01 | -6.15e-02 | 5.27e-01 |
| PI3K/AKT Signaling in Cancer | 84 | 3.34e-01 | -6.10e-02 | 5.31e-01 |
| p53-Dependent G1 DNA Damage Response | 58 | 4.23e-01 | 6.09e-02 | 6.16e-01 |
| p53-Dependent G1/S DNA damage checkpoint | 58 | 4.23e-01 | 6.09e-02 | 6.16e-01 |
| Signaling by VEGF | 100 | 2.94e-01 | -6.08e-02 | 4.89e-01 |
| Post-chaperonin tubulin folding pathway | 18 | 6.56e-01 | 6.07e-02 | 7.94e-01 |
| Transcriptional Regulation by VENTX | 36 | 5.31e-01 | -6.04e-02 | 7.06e-01 |
| Signalling to RAS | 18 | 6.58e-01 | -6.03e-02 | 7.95e-01 |
| Diseases associated with O-glycosylation of proteins | 50 | 4.62e-01 | 6.01e-02 | 6.48e-01 |
| Lysosome Vesicle Biogenesis | 32 | 5.57e-01 | 6.00e-02 | 7.22e-01 |
| p75 NTR receptor-mediated signalling | 88 | 3.34e-01 | 5.96e-02 | 5.31e-01 |
| p75NTR signals via NF-kB | 14 | 7.00e-01 | -5.95e-02 | 8.21e-01 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | 27 | 5.93e-01 | 5.94e-02 | 7.45e-01 |
| Nucleotide salvage | 21 | 6.39e-01 | 5.91e-02 | 7.86e-01 |
| Assembly of the pre-replicative complex | 62 | 4.23e-01 | 5.89e-02 | 6.16e-01 |
| FGFR2 alternative splicing | 23 | 6.26e-01 | -5.87e-02 | 7.76e-01 |
| Macroautophagy | 103 | 3.05e-01 | -5.86e-02 | 5.03e-01 |
| Diseases of signal transduction by growth factor receptors and second messengers | 340 | 6.46e-02 | -5.86e-02 | 1.81e-01 |
| Transport of bile salts and organic acids, metal ions and amine compounds | 63 | 4.23e-01 | -5.84e-02 | 6.16e-01 |
| RAS processing | 19 | 6.61e-01 | -5.82e-02 | 7.96e-01 |
| Nervous system development | 476 | 3.14e-02 | 5.79e-02 | 1.11e-01 |
| Regulation of RAS by GAPs | 61 | 4.35e-01 | 5.79e-02 | 6.26e-01 |
| Senescence-Associated Secretory Phenotype (SASP) | 46 | 4.97e-01 | -5.79e-02 | 6.82e-01 |
| Keratinization | 30 | 5.84e-01 | -5.78e-02 | 7.39e-01 |
| Neurexins and neuroligins | 42 | 5.19e-01 | -5.75e-02 | 7.02e-01 |
| STING mediated induction of host immune responses | 12 | 7.30e-01 | -5.75e-02 | 8.44e-01 |
| Phase 0 - rapid depolarisation | 33 | 5.70e-01 | -5.71e-02 | 7.30e-01 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | 21 | 6.51e-01 | -5.71e-02 | 7.90e-01 |
| Negative regulation of FGFR3 signaling | 20 | 6.59e-01 | -5.70e-02 | 7.95e-01 |
| Assembly of collagen fibrils and other multimeric structures | 48 | 4.96e-01 | 5.68e-02 | 6.82e-01 |
| Toll-like Receptor Cascades | 135 | 2.56e-01 | 5.68e-02 | 4.42e-01 |
| PIP3 activates AKT signaling | 238 | 1.33e-01 | -5.67e-02 | 2.97e-01 |
| KSRP (KHSRP) binds and destabilizes mRNA | 16 | 6.95e-01 | -5.66e-02 | 8.18e-01 |
| FGFR2 mutant receptor activation | 22 | 6.46e-01 | 5.65e-02 | 7.87e-01 |
| Peroxisomal lipid metabolism | 26 | 6.19e-01 | 5.63e-02 | 7.69e-01 |
| FCERI mediated MAPK activation | 31 | 5.91e-01 | -5.58e-02 | 7.44e-01 |
| Dual incision in TC-NER | 62 | 4.49e-01 | -5.56e-02 | 6.39e-01 |
| Ca2+ pathway | 54 | 4.82e-01 | -5.53e-02 | 6.68e-01 |
| Orc1 removal from chromatin | 64 | 4.45e-01 | 5.52e-02 | 6.35e-01 |
| Mitophagy | 25 | 6.34e-01 | -5.51e-02 | 7.81e-01 |
| Metabolism of lipids | 597 | 2.36e-02 | -5.47e-02 | 9.10e-02 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | 38 | 5.61e-01 | -5.45e-02 | 7.22e-01 |
| HIV Transcription Elongation | 38 | 5.61e-01 | -5.45e-02 | 7.22e-01 |
| Tat-mediated elongation of the HIV-1 transcript | 38 | 5.61e-01 | -5.45e-02 | 7.22e-01 |
| Intrinsic Pathway for Apoptosis | 46 | 5.23e-01 | 5.44e-02 | 7.03e-01 |
| Cargo trafficking to the periciliary membrane | 45 | 5.30e-01 | 5.41e-02 | 7.06e-01 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | 10 | 7.67e-01 | 5.40e-02 | 8.72e-01 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | 28 | 6.23e-01 | 5.37e-02 | 7.72e-01 |
| Downregulation of ERBB2 signaling | 24 | 6.50e-01 | 5.35e-02 | 7.90e-01 |
| PKA activation | 16 | 7.11e-01 | 5.35e-02 | 8.31e-01 |
| Peptide hormone metabolism | 58 | 4.81e-01 | 5.35e-02 | 6.68e-01 |
| Interleukin-2 family signaling | 37 | 5.76e-01 | -5.31e-02 | 7.35e-01 |
| Caspase-mediated cleavage of cytoskeletal proteins | 12 | 7.52e-01 | -5.26e-02 | 8.60e-01 |
| HCMV Late Events | 47 | 5.34e-01 | -5.25e-02 | 7.06e-01 |
| Constitutive Signaling by Aberrant PI3K in Cancer | 58 | 4.91e-01 | 5.24e-02 | 6.76e-01 |
| ABC transporters in lipid homeostasis | 14 | 7.35e-01 | -5.22e-02 | 8.48e-01 |
| Negative regulation of FGFR4 signaling | 20 | 6.87e-01 | -5.21e-02 | 8.14e-01 |
| Signaling by PDGF | 51 | 5.24e-01 | -5.16e-02 | 7.03e-01 |
| Activation of HOX genes during differentiation | 58 | 4.99e-01 | -5.14e-02 | 6.82e-01 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | 58 | 4.99e-01 | -5.14e-02 | 6.82e-01 |
| MET promotes cell motility | 29 | 6.33e-01 | 5.13e-02 | 7.80e-01 |
| Elastic fibre formation | 37 | 5.89e-01 | 5.13e-02 | 7.43e-01 |
| Acyl chain remodelling of PE | 20 | 6.94e-01 | 5.09e-02 | 8.18e-01 |
| Interconversion of nucleotide di- and triphosphates | 26 | 6.54e-01 | 5.08e-02 | 7.93e-01 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | 14 | 7.43e-01 | -5.06e-02 | 8.53e-01 |
| Metabolism of RNA | 602 | 3.55e-02 | -5.06e-02 | 1.18e-01 |
| Diseases associated with glycosaminoglycan metabolism | 35 | 6.05e-01 | 5.05e-02 | 7.56e-01 |
| Platelet sensitization by LDL | 15 | 7.40e-01 | -4.95e-02 | 8.52e-01 |
| Interleukin-37 signaling | 19 | 7.09e-01 | 4.94e-02 | 8.30e-01 |
| Negative epigenetic regulation of rRNA expression | 48 | 5.56e-01 | 4.92e-02 | 7.21e-01 |
| Keratan sulfate/keratin metabolism | 26 | 6.64e-01 | 4.92e-02 | 7.98e-01 |
| MyD88 dependent cascade initiated on endosome | 85 | 4.35e-01 | -4.90e-02 | 6.26e-01 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | 85 | 4.35e-01 | -4.90e-02 | 6.26e-01 |
| O-linked glycosylation | 80 | 4.51e-01 | 4.88e-02 | 6.41e-01 |
| RAF-independent MAPK1/3 activation | 22 | 6.95e-01 | -4.83e-02 | 8.18e-01 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | 13 | 7.64e-01 | 4.82e-02 | 8.69e-01 |
| Activation of BAD and translocation to mitochondria | 14 | 7.55e-01 | 4.81e-02 | 8.62e-01 |
| Synthesis of DNA | 113 | 3.79e-01 | -4.79e-02 | 5.78e-01 |
| Mitochondrial Fatty Acid Beta-Oxidation | 31 | 6.45e-01 | -4.78e-02 | 7.87e-01 |
| Defects in cobalamin (B12) metabolism | 12 | 7.74e-01 | -4.78e-02 | 8.77e-01 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | 32 | 6.41e-01 | 4.76e-02 | 7.86e-01 |
| ERK/MAPK targets | 22 | 7.00e-01 | -4.74e-02 | 8.21e-01 |
| Glycogen metabolism | 23 | 6.95e-01 | -4.73e-02 | 8.18e-01 |
| Association of TriC/CCT with target proteins during biosynthesis | 38 | 6.14e-01 | -4.73e-02 | 7.64e-01 |
| Signaling by GPCR | 522 | 6.78e-02 | 4.70e-02 | 1.87e-01 |
| Autophagy | 117 | 3.81e-01 | -4.69e-02 | 5.78e-01 |
| MAPK6/MAPK4 signaling | 81 | 4.68e-01 | 4.67e-02 | 6.54e-01 |
| DARPP-32 events | 21 | 7.13e-01 | -4.65e-02 | 8.32e-01 |
| G1/S DNA Damage Checkpoints | 60 | 5.36e-01 | 4.62e-02 | 7.07e-01 |
| Neuronal System | 276 | 1.88e-01 | -4.62e-02 | 3.67e-01 |
| RHO GTPases activate PAKs | 21 | 7.15e-01 | 4.60e-02 | 8.34e-01 |
| Signaling by WNT | 238 | 2.24e-01 | -4.59e-02 | 4.07e-01 |
| Signaling by NTRK1 (TRKA) | 106 | 4.16e-01 | -4.58e-02 | 6.13e-01 |
| Toll Like Receptor 9 (TLR9) Cascade | 88 | 4.59e-01 | -4.57e-02 | 6.46e-01 |
| O-linked glycosylation of mucins | 42 | 6.09e-01 | 4.57e-02 | 7.60e-01 |
| CTLA4 inhibitory signaling | 21 | 7.17e-01 | 4.56e-02 | 8.35e-01 |
| COPI-independent Golgi-to-ER retrograde traffic | 31 | 6.62e-01 | 4.53e-02 | 7.96e-01 |
| Cyclin E associated events during G1/S transition | 76 | 4.98e-01 | 4.50e-02 | 6.82e-01 |
| DAP12 signaling | 27 | 6.87e-01 | 4.48e-02 | 8.14e-01 |
| Golgi Associated Vesicle Biogenesis | 53 | 5.75e-01 | 4.45e-02 | 7.34e-01 |
| Antigen processing: Ubiquitination & Proteasome degradation | 276 | 2.07e-01 | -4.43e-02 | 3.88e-01 |
| Defective B4GALT7 causes EDS, progeroid type | 18 | 7.47e-01 | 4.38e-02 | 8.57e-01 |
| MET activates PTK2 signaling | 18 | 7.48e-01 | -4.37e-02 | 8.57e-01 |
| Cell-cell junction organization | 35 | 6.55e-01 | 4.36e-02 | 7.94e-01 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | 11 | 8.03e-01 | -4.34e-02 | 9.01e-01 |
| Fc epsilon receptor (FCERI) signaling | 124 | 4.19e-01 | -4.21e-02 | 6.14e-01 |
| Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | 14 | 7.88e-01 | 4.14e-02 | 8.90e-01 |
| Diseases of hemostasis | 14 | 7.88e-01 | 4.14e-02 | 8.90e-01 |
| PINK1-PRKN Mediated Mitophagy | 18 | 7.61e-01 | -4.13e-02 | 8.67e-01 |
| Regulation of APC/C activators between G1/S and early anaphase | 74 | 5.40e-01 | 4.13e-02 | 7.09e-01 |
| VEGFR2 mediated vascular permeability | 27 | 7.11e-01 | -4.12e-02 | 8.31e-01 |
| Metabolism of water-soluble vitamins and cofactors | 110 | 4.58e-01 | -4.10e-02 | 6.46e-01 |
| Transport of small molecules | 543 | 1.05e-01 | 4.10e-02 | 2.49e-01 |
| p38MAPK events | 13 | 7.98e-01 | -4.10e-02 | 8.98e-01 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | 11 | 8.15e-01 | -4.07e-02 | 9.05e-01 |
| DCC mediated attractive signaling | 13 | 8.00e-01 | 4.06e-02 | 8.99e-01 |
| Chaperonin-mediated protein folding | 82 | 5.27e-01 | 4.05e-02 | 7.05e-01 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | 38 | 6.70e-01 | -3.99e-02 | 8.00e-01 |
| Signaling by RAS mutants | 38 | 6.70e-01 | -3.99e-02 | 8.00e-01 |
| Signaling by moderate kinase activity BRAF mutants | 38 | 6.70e-01 | -3.99e-02 | 8.00e-01 |
| Signaling downstream of RAS mutants | 38 | 6.70e-01 | -3.99e-02 | 8.00e-01 |
| Sema4D induced cell migration and growth-cone collapse | 20 | 7.61e-01 | 3.94e-02 | 8.67e-01 |
| Negative regulation of TCF-dependent signaling by WNT ligand antagonists | 10 | 8.30e-01 | 3.92e-02 | 9.15e-01 |
| Vitamin B5 (pantothenate) metabolism | 15 | 7.93e-01 | -3.92e-02 | 8.94e-01 |
| Nucleotide Excision Repair | 105 | 4.89e-01 | -3.92e-02 | 6.75e-01 |
| Activation of BH3-only proteins | 28 | 7.23e-01 | -3.87e-02 | 8.38e-01 |
| Signaling by the B Cell Receptor (BCR) | 104 | 4.97e-01 | -3.86e-02 | 6.82e-01 |
| Metabolism of porphyrins | 23 | 7.50e-01 | -3.84e-02 | 8.58e-01 |
| Cilium Assembly | 173 | 3.86e-01 | -3.83e-02 | 5.79e-01 |
| Unfolded Protein Response (UPR) | 86 | 5.40e-01 | 3.83e-02 | 7.09e-01 |
| PI3K events in ERBB2 signaling | 14 | 8.06e-01 | 3.80e-02 | 9.01e-01 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | 88 | 5.48e-01 | -3.71e-02 | 7.13e-01 |
| Toll Like Receptor 2 (TLR2) Cascade | 88 | 5.48e-01 | -3.71e-02 | 7.13e-01 |
| Toll Like Receptor TLR1:TLR2 Cascade | 88 | 5.48e-01 | -3.71e-02 | 7.13e-01 |
| Toll Like Receptor TLR6:TLR2 Cascade | 88 | 5.48e-01 | -3.71e-02 | 7.13e-01 |
| Host Interactions of HIV factors | 114 | 4.95e-01 | -3.70e-02 | 6.82e-01 |
| Termination of O-glycan biosynthesis | 14 | 8.12e-01 | -3.68e-02 | 9.04e-01 |
| Protein localization | 145 | 4.58e-01 | 3.57e-02 | 6.46e-01 |
| G alpha (q) signalling events | 148 | 4.54e-01 | 3.57e-02 | 6.42e-01 |
| Glutathione synthesis and recycling | 11 | 8.40e-01 | -3.51e-02 | 9.22e-01 |
| Metabolism of cofactors | 18 | 7.99e-01 | 3.47e-02 | 8.98e-01 |
| Rho GTPase cycle | 133 | 4.93e-01 | -3.45e-02 | 6.79e-01 |
| GPCR downstream signalling | 479 | 2.06e-01 | 3.39e-02 | 3.87e-01 |
| BBSome-mediated cargo-targeting to cilium | 20 | 7.93e-01 | 3.39e-02 | 8.94e-01 |
| Golgi-to-ER retrograde transport | 106 | 5.53e-01 | 3.34e-02 | 7.18e-01 |
| PTEN Regulation | 131 | 5.14e-01 | -3.30e-02 | 6.97e-01 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | 16 | 8.19e-01 | 3.30e-02 | 9.08e-01 |
| Post-translational protein modification | 1159 | 6.29e-02 | -3.29e-02 | 1.77e-01 |
| Nitric oxide stimulates guanylate cyclase | 19 | 8.05e-01 | 3.27e-02 | 9.01e-01 |
| Activated NOTCH1 Transmits Signal to the Nucleus | 27 | 7.70e-01 | -3.26e-02 | 8.73e-01 |
| RAB GEFs exchange GTP for GDP on RABs | 86 | 6.02e-01 | -3.25e-02 | 7.53e-01 |
| cGMP effects | 13 | 8.40e-01 | 3.24e-02 | 9.22e-01 |
| RNA Polymerase III Abortive And Retractive Initiation | 41 | 7.24e-01 | 3.19e-02 | 8.38e-01 |
| RNA Polymerase III Transcription | 41 | 7.24e-01 | 3.19e-02 | 8.38e-01 |
| Signal Transduction | 1889 | 2.81e-02 | -3.14e-02 | 1.02e-01 |
| Downstream signaling events of B Cell Receptor (BCR) | 73 | 6.47e-01 | -3.10e-02 | 7.87e-01 |
| Adaptive Immune System | 627 | 1.90e-01 | 3.09e-02 | 3.69e-01 |
| DNA Replication Pre-Initiation | 78 | 6.41e-01 | -3.06e-02 | 7.86e-01 |
| Programmed Cell Death | 157 | 5.10e-01 | 3.05e-02 | 6.94e-01 |
| Negative regulation of FGFR2 signaling | 22 | 8.08e-01 | -3.00e-02 | 9.01e-01 |
| Signaling by BMP | 23 | 8.04e-01 | -3.00e-02 | 9.01e-01 |
| Downregulation of ERBB2:ERBB3 signaling | 11 | 8.65e-01 | -2.97e-02 | 9.31e-01 |
| RHO GTPases activate IQGAPs | 11 | 8.65e-01 | 2.95e-02 | 9.31e-01 |
| mTORC1-mediated signalling | 23 | 8.07e-01 | 2.94e-02 | 9.01e-01 |
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | 16 | 8.40e-01 | 2.92e-02 | 9.22e-01 |
| Signaling by SCF-KIT | 43 | 7.41e-01 | -2.92e-02 | 8.52e-01 |
| Adenylate cyclase inhibitory pathway | 12 | 8.62e-01 | 2.90e-02 | 9.30e-01 |
| DNA Damage Recognition in GG-NER | 35 | 7.67e-01 | 2.90e-02 | 8.72e-01 |
| Ephrin signaling | 19 | 8.27e-01 | 2.90e-02 | 9.13e-01 |
| ZBP1(DAI) mediated induction of type I IFNs | 20 | 8.25e-01 | -2.86e-02 | 9.11e-01 |
| Metabolism of proteins | 1620 | 6.22e-02 | 2.84e-02 | 1.76e-01 |
| COPI-dependent Golgi-to-ER retrograde traffic | 75 | 6.72e-01 | 2.83e-02 | 8.00e-01 |
| Cell-Cell communication | 91 | 6.42e-01 | 2.82e-02 | 7.86e-01 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | 32 | 7.84e-01 | -2.81e-02 | 8.87e-01 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | 80 | 6.67e-01 | 2.79e-02 | 7.99e-01 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | 170 | 5.34e-01 | 2.77e-02 | 7.06e-01 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | 18 | 8.40e-01 | 2.75e-02 | 9.22e-01 |
| Metabolic disorders of biological oxidation enzymes | 24 | 8.16e-01 | -2.74e-02 | 9.05e-01 |
| Neurotransmitter receptors and postsynaptic signal transmission | 136 | 5.83e-01 | -2.73e-02 | 7.38e-01 |
| Long-term potentiation | 18 | 8.43e-01 | -2.70e-02 | 9.22e-01 |
| GRB2 events in ERBB2 signaling | 14 | 8.61e-01 | -2.70e-02 | 9.30e-01 |
| Disorders of transmembrane transporters | 137 | 5.89e-01 | -2.68e-02 | 7.43e-01 |
| ATF6 (ATF6-alpha) activates chaperones | 12 | 8.76e-01 | -2.61e-02 | 9.35e-01 |
| NCAM signaling for neurite out-growth | 53 | 7.44e-01 | -2.60e-02 | 8.53e-01 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | 18 | 8.49e-01 | 2.59e-02 | 9.24e-01 |
| Defective B3GAT3 causes JDSSDHD | 18 | 8.49e-01 | 2.59e-02 | 9.24e-01 |
| SHC1 events in EGFR signaling | 11 | 8.83e-01 | -2.57e-02 | 9.36e-01 |
| Adherens junctions interactions | 20 | 8.43e-01 | 2.55e-02 | 9.22e-01 |
| Signaling by NOTCH3 | 45 | 7.68e-01 | -2.54e-02 | 8.72e-01 |
| Mitochondrial protein import | 59 | 7.39e-01 | 2.51e-02 | 8.51e-01 |
| Transcriptional regulation by RUNX1 | 164 | 5.82e-01 | -2.50e-02 | 7.38e-01 |
| Base-Excision Repair, AP Site Formation | 18 | 8.56e-01 | 2.47e-02 | 9.29e-01 |
| Purine salvage | 13 | 8.79e-01 | 2.44e-02 | 9.36e-01 |
| Basigin interactions | 22 | 8.43e-01 | -2.43e-02 | 9.22e-01 |
| MAPK family signaling cascades | 275 | 4.89e-01 | -2.43e-02 | 6.75e-01 |
| Reduction of cytosolic Ca++ levels | 10 | 8.95e-01 | -2.42e-02 | 9.44e-01 |
| Nucleobase biosynthesis | 15 | 8.73e-01 | -2.39e-02 | 9.34e-01 |
| Growth hormone receptor signaling | 22 | 8.47e-01 | 2.38e-02 | 9.24e-01 |
| Cyclin A:Cdk2-associated events at S phase entry | 78 | 7.17e-01 | 2.37e-02 | 8.35e-01 |
| Platelet Aggregation (Plug Formation) | 32 | 8.16e-01 | 2.37e-02 | 9.05e-01 |
| Regulation of TP53 Activity through Association with Co-factors | 13 | 8.82e-01 | -2.37e-02 | 9.36e-01 |
| Cell death signalling via NRAGE, NRIF and NADE | 70 | 7.35e-01 | 2.35e-02 | 8.48e-01 |
| Disease | 1197 | 1.80e-01 | 2.34e-02 | 3.59e-01 |
| LGI-ADAM interactions | 14 | 8.81e-01 | -2.32e-02 | 9.36e-01 |
| Opioid Signalling | 76 | 7.30e-01 | 2.29e-02 | 8.44e-01 |
| Activation of NF-kappaB in B cells | 61 | 7.59e-01 | 2.27e-02 | 8.66e-01 |
| Apoptosis | 154 | 6.27e-01 | 2.27e-02 | 7.76e-01 |
| Myogenesis | 24 | 8.47e-01 | -2.27e-02 | 9.24e-01 |
| Signaling by Hippo | 20 | 8.61e-01 | -2.26e-02 | 9.30e-01 |
| Nicotinate metabolism | 26 | 8.42e-01 | 2.26e-02 | 9.22e-01 |
| Resolution of Abasic Sites (AP sites) | 37 | 8.16e-01 | -2.21e-02 | 9.05e-01 |
| RNA Polymerase III Transcription Initiation | 36 | 8.20e-01 | 2.19e-02 | 9.08e-01 |
| Cargo recognition for clathrin-mediated endocytosis | 88 | 7.23e-01 | -2.19e-02 | 8.38e-01 |
| NCAM1 interactions | 33 | 8.31e-01 | 2.14e-02 | 9.16e-01 |
| Negative regulation of the PI3K/AKT network | 93 | 7.23e-01 | -2.13e-02 | 8.38e-01 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | 20 | 8.70e-01 | -2.12e-02 | 9.33e-01 |
| RNA Polymerase I Transcription Initiation | 45 | 8.06e-01 | 2.11e-02 | 9.01e-01 |
| p75NTR recruits signalling complexes | 11 | 9.03e-01 | -2.11e-02 | 9.49e-01 |
| The role of Nef in HIV-1 replication and disease pathogenesis | 27 | 8.49e-01 | 2.11e-02 | 9.24e-01 |
| mRNA Capping | 28 | 8.49e-01 | 2.08e-02 | 9.24e-01 |
| NOTCH3 Intracellular Domain Regulates Transcription | 24 | 8.60e-01 | -2.08e-02 | 9.30e-01 |
| Class I MHC mediated antigen processing & presentation | 327 | 5.27e-01 | 2.04e-02 | 7.05e-01 |
| SLBP independent Processing of Histone Pre-mRNAs | 10 | 9.12e-01 | 2.03e-02 | 9.53e-01 |
| Switching of origins to a post-replicative state | 84 | 7.51e-01 | 2.00e-02 | 8.59e-01 |
| Uptake and function of anthrax toxins | 11 | 9.09e-01 | -2.00e-02 | 9.51e-01 |
| Elevation of cytosolic Ca2+ levels | 15 | 8.96e-01 | 1.95e-02 | 9.44e-01 |
| Ion channel transport | 121 | 7.25e-01 | 1.85e-02 | 8.39e-01 |
| Zinc transporters | 14 | 9.05e-01 | -1.84e-02 | 9.49e-01 |
| Infection with Mycobacterium tuberculosis | 25 | 8.74e-01 | -1.83e-02 | 9.34e-01 |
| RIP-mediated NFkB activation via ZBP1 | 17 | 8.96e-01 | -1.83e-02 | 9.44e-01 |
| Aggrephagy | 18 | 8.93e-01 | -1.82e-02 | 9.43e-01 |
| Carboxyterminal post-translational modifications of tubulin | 28 | 8.68e-01 | 1.81e-02 | 9.32e-01 |
| FLT3 Signaling | 247 | 6.37e-01 | -1.75e-02 | 7.83e-01 |
| SUMOylation of DNA methylation proteins | 16 | 9.05e-01 | -1.72e-02 | 9.49e-01 |
| Non-integrin membrane-ECM interactions | 40 | 8.51e-01 | 1.72e-02 | 9.24e-01 |
| mRNA Splicing - Minor Pathway | 48 | 8.38e-01 | -1.70e-02 | 9.22e-01 |
| Vesicle-mediated transport | 581 | 5.05e-01 | 1.63e-02 | 6.89e-01 |
| SARS-CoV Infections | 76 | 8.07e-01 | 1.62e-02 | 9.01e-01 |
| HIV Infection | 206 | 6.92e-01 | -1.61e-02 | 8.18e-01 |
| Golgi Cisternae Pericentriolar Stack Reorganization | 14 | 9.17e-01 | 1.61e-02 | 9.57e-01 |
| Cristae formation | 11 | 9.27e-01 | -1.60e-02 | 9.62e-01 |
| NR1H2 and NR1H3-mediated signaling | 40 | 8.61e-01 | 1.60e-02 | 9.30e-01 |
| Purine ribonucleoside monophosphate biosynthesis | 12 | 9.24e-01 | -1.60e-02 | 9.61e-01 |
| Extra-nuclear estrogen signaling | 65 | 8.24e-01 | -1.59e-02 | 9.11e-01 |
| Respiratory electron transport | 97 | 7.87e-01 | 1.59e-02 | 8.90e-01 |
| MAP2K and MAPK activation | 33 | 8.77e-01 | 1.56e-02 | 9.36e-01 |
| Spry regulation of FGF signaling | 14 | 9.20e-01 | -1.55e-02 | 9.60e-01 |
| Pre-NOTCH Processing in Golgi | 16 | 9.15e-01 | 1.54e-02 | 9.56e-01 |
| Integrin signaling | 24 | 8.98e-01 | -1.51e-02 | 9.45e-01 |
| Global Genome Nucleotide Excision Repair (GG-NER) | 80 | 8.16e-01 | -1.51e-02 | 9.05e-01 |
| Transcriptional regulation by RUNX3 | 89 | 8.10e-01 | -1.47e-02 | 9.04e-01 |
| Formation of Incision Complex in GG-NER | 40 | 8.72e-01 | -1.47e-02 | 9.34e-01 |
| Signaling by RAF1 mutants | 34 | 8.83e-01 | 1.46e-02 | 9.36e-01 |
| Toll Like Receptor 4 (TLR4) Cascade | 117 | 7.88e-01 | -1.44e-02 | 8.90e-01 |
| Ion transport by P-type ATPases | 38 | 8.78e-01 | -1.44e-02 | 9.36e-01 |
| Inositol phosphate metabolism | 42 | 8.74e-01 | -1.42e-02 | 9.34e-01 |
| Developmental Biology | 737 | 5.23e-01 | 1.40e-02 | 7.03e-01 |
| Phase I - Functionalization of compounds | 66 | 8.48e-01 | 1.36e-02 | 9.24e-01 |
| Nuclear Events (kinase and transcription factor activation) | 56 | 8.61e-01 | -1.35e-02 | 9.30e-01 |
| RA biosynthesis pathway | 14 | 9.31e-01 | -1.34e-02 | 9.63e-01 |
| PKA activation in glucagon signalling | 15 | 9.29e-01 | 1.32e-02 | 9.62e-01 |
| Cellular responses to external stimuli | 435 | 6.45e-01 | -1.30e-02 | 7.87e-01 |
| Olfactory Signaling Pathway | 15 | 9.33e-01 | 1.26e-02 | 9.63e-01 |
| ECM proteoglycans | 47 | 8.87e-01 | 1.20e-02 | 9.38e-01 |
| FCERI mediated NF-kB activation | 73 | 8.60e-01 | 1.19e-02 | 9.30e-01 |
| C-type lectin receptors (CLRs) | 117 | 8.25e-01 | 1.18e-02 | 9.11e-01 |
| NGF-stimulated transcription | 34 | 9.05e-01 | -1.18e-02 | 9.49e-01 |
| Acyl chain remodelling of PG | 14 | 9.40e-01 | -1.16e-02 | 9.67e-01 |
| Interaction between L1 and Ankyrins | 23 | 9.24e-01 | 1.15e-02 | 9.61e-01 |
| Signaling by Activin | 11 | 9.47e-01 | -1.15e-02 | 9.68e-01 |
| A tetrasaccharide linker sequence is required for GAG synthesis | 22 | 9.27e-01 | 1.13e-02 | 9.62e-01 |
| UCH proteinases | 78 | 8.66e-01 | 1.10e-02 | 9.31e-01 |
| Regulation of gene expression by Hypoxia-inducible Factor | 10 | 9.52e-01 | -1.10e-02 | 9.69e-01 |
| Cytosolic sensors of pathogen-associated DNA | 57 | 8.86e-01 | 1.10e-02 | 9.38e-01 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | 22 | 9.29e-01 | 1.10e-02 | 9.62e-01 |
| Signaling by ERBB4 | 47 | 9.00e-01 | 1.06e-02 | 9.46e-01 |
| CLEC7A (Dectin-1) signaling | 90 | 8.64e-01 | 1.05e-02 | 9.31e-01 |
| Visual phototransduction | 69 | 8.84e-01 | 1.02e-02 | 9.36e-01 |
| Metabolism of folate and pterines | 15 | 9.47e-01 | -9.96e-03 | 9.68e-01 |
| Metalloprotease DUBs | 18 | 9.42e-01 | 9.90e-03 | 9.68e-01 |
| Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon | 15 | 9.47e-01 | -9.85e-03 | 9.68e-01 |
| Gamma carboxylation, hypusine formation and arylsulfatase activation | 32 | 9.24e-01 | 9.78e-03 | 9.61e-01 |
| Neddylation | 212 | 8.11e-01 | -9.56e-03 | 9.04e-01 |
| Unblocking of NMDA receptors, glutamate binding and activation | 16 | 9.48e-01 | 9.42e-03 | 9.68e-01 |
| Cellular responses to stress | 431 | 7.42e-01 | -9.30e-03 | 8.53e-01 |
| Dopamine Neurotransmitter Release Cycle | 16 | 9.49e-01 | -9.18e-03 | 9.68e-01 |
| Signaling by high-kinase activity BRAF mutants | 29 | 9.35e-01 | 8.74e-03 | 9.64e-01 |
| MicroRNA (miRNA) biogenesis | 23 | 9.43e-01 | 8.59e-03 | 9.68e-01 |
| Transcriptional regulation of granulopoiesis | 31 | 9.34e-01 | -8.56e-03 | 9.64e-01 |
| Fatty acid metabolism | 136 | 8.65e-01 | 8.45e-03 | 9.31e-01 |
| Signaling by NOTCH | 163 | 8.55e-01 | -8.32e-03 | 9.28e-01 |
| Clathrin-mediated endocytosis | 126 | 8.79e-01 | -7.87e-03 | 9.36e-01 |
| Regulation of KIT signaling | 16 | 9.57e-01 | 7.79e-03 | 9.73e-01 |
| Metabolism of vitamins and cofactors | 162 | 8.73e-01 | -7.27e-03 | 9.34e-01 |
| RNA Polymerase I Promoter Clearance | 48 | 9.32e-01 | 7.12e-03 | 9.63e-01 |
| Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. | 103 | 9.07e-01 | 6.66e-03 | 9.50e-01 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | 75 | 9.22e-01 | -6.57e-03 | 9.61e-01 |
| Degradation of beta-catenin by the destruction complex | 76 | 9.25e-01 | 6.25e-03 | 9.61e-01 |
| Metabolism | 1675 | 6.81e-01 | -6.18e-03 | 8.08e-01 |
| Assembly and cell surface presentation of NMDA receptors | 18 | 9.64e-01 | 6.11e-03 | 9.77e-01 |
| Signaling by NODAL | 16 | 9.67e-01 | 5.90e-03 | 9.80e-01 |
| Signaling by BRAF and RAF fusions | 55 | 9.40e-01 | 5.83e-03 | 9.67e-01 |
| Cellular hexose transport | 12 | 9.73e-01 | 5.72e-03 | 9.83e-01 |
| Molecules associated with elastic fibres | 27 | 9.59e-01 | 5.67e-03 | 9.73e-01 |
| RAF/MAP kinase cascade | 233 | 8.89e-01 | -5.34e-03 | 9.39e-01 |
| Stimuli-sensing channels | 66 | 9.41e-01 | -5.27e-03 | 9.67e-01 |
| Formation of the Early Elongation Complex | 32 | 9.59e-01 | 5.23e-03 | 9.73e-01 |
| Formation of the HIV-1 Early Elongation Complex | 32 | 9.59e-01 | 5.23e-03 | 9.73e-01 |
| MAPK1/MAPK3 signaling | 238 | 8.92e-01 | -5.11e-03 | 9.42e-01 |
| VxPx cargo-targeting to cilium | 18 | 9.71e-01 | -4.93e-03 | 9.83e-01 |
| NRAGE signals death through JNK | 56 | 9.50e-01 | -4.84e-03 | 9.68e-01 |
| Death Receptor Signalling | 127 | 9.28e-01 | -4.63e-03 | 9.62e-01 |
| Acyl chain remodelling of PC | 22 | 9.72e-01 | 4.33e-03 | 9.83e-01 |
| Signaling by NTRKs | 123 | 9.35e-01 | -4.26e-03 | 9.64e-01 |
| Signaling by Receptor Tyrosine Kinases | 433 | 8.83e-01 | 4.14e-03 | 9.36e-01 |
| Cell junction organization | 60 | 9.56e-01 | 4.12e-03 | 9.73e-01 |
| APC/C-mediated degradation of cell cycle proteins | 81 | 9.50e-01 | 4.05e-03 | 9.68e-01 |
| Regulation of mitotic cell cycle | 81 | 9.50e-01 | 4.05e-03 | 9.68e-01 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 86 | 9.48e-01 | 4.05e-03 | 9.68e-01 |
| PKA-mediated phosphorylation of CREB | 18 | 9.77e-01 | 3.87e-03 | 9.86e-01 |
| L1CAM interactions | 91 | 9.50e-01 | 3.80e-03 | 9.68e-01 |
| Inhibition of DNA recombination at telomere | 20 | 9.80e-01 | -3.20e-03 | 9.88e-01 |
| Peroxisomal protein import | 55 | 9.76e-01 | -2.35e-03 | 9.85e-01 |
| Platelet calcium homeostasis | 25 | 9.86e-01 | 2.04e-03 | 9.93e-01 |
| RNA Polymerase I Transcription | 49 | 9.88e-01 | 1.20e-03 | 9.93e-01 |
| Signaling by Non-Receptor Tyrosine Kinases | 50 | 9.89e-01 | 1.17e-03 | 9.93e-01 |
| Signaling by PTK6 | 50 | 9.89e-01 | 1.17e-03 | 9.93e-01 |
| Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane | 10 | 9.96e-01 | -8.29e-04 | 9.99e-01 |
| Metabolism of carbohydrates | 239 | 9.87e-01 | 5.92e-04 | 9.93e-01 |
| Membrane Trafficking | 548 | 9.89e-01 | -3.38e-04 | 9.93e-01 |
| Cleavage of the damaged pyrimidine | 16 | 9.98e-01 | -2.86e-04 | 9.99e-01 |
| Depyrimidination | 16 | 9.98e-01 | -2.86e-04 | 9.99e-01 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | 16 | 9.98e-01 | -2.86e-04 | 9.99e-01 |
| GRB2 events in EGFR signaling | 10 | 1.00e+00 | 2.86e-05 | 1.00e+00 |
Detailed Gene set reports
Classical antibody-mediated complement activation
| 187 | |
|---|---|
| set | Classical antibody-mediated complement activation |
| setSize | 11 |
| pANOVA | 6e-07 |
| s.dist | 0.869 |
| p.adjustANOVA | 2.08e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| C1R | 6214.0 |
| C1QA | 6176.0 |
| C1S | 6169.0 |
| C1QB | 6110.0 |
| C1QC | 6107.0 |
| IGHG1 | 6067.5 |
| IGHG2 | 6067.5 |
| IGHG3 | 6067.5 |
| IGHG4 | 6067.5 |
| IGKC | 6026.0 |
| CRP | 112.0 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| C1R | 6214.0 |
| C1QA | 6176.0 |
| C1S | 6169.0 |
| C1QB | 6110.0 |
| C1QC | 6107.0 |
| IGHG1 | 6067.5 |
| IGHG2 | 6067.5 |
| IGHG3 | 6067.5 |
| IGHG4 | 6067.5 |
| IGKC | 6026.0 |
| CRP | 112.0 |
Initial triggering of complement
| 524 | |
|---|---|
| set | Initial triggering of complement |
| setSize | 22 |
| pANOVA | 7.11e-08 |
| s.dist | 0.664 |
| p.adjustANOVA | 3.01e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CFB | 6455.0 |
| C1R | 6214.0 |
| C1QA | 6176.0 |
| C1S | 6169.0 |
| C2 | 6139.0 |
| C1QB | 6110.0 |
| C1QC | 6107.0 |
| IGHG1 | 6067.5 |
| IGHG2 | 6067.5 |
| IGHG3 | 6067.5 |
| IGHG4 | 6067.5 |
| FCN1 | 6057.5 |
| FCN2 | 6057.5 |
| IGKC | 6026.0 |
| C3 | 5783.0 |
| C4A | 5536.5 |
| C4B | 5536.5 |
| GZMM | 2219.0 |
| CRP | 112.0 |
| CFD | -2545.0 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CFB | 6455.0 |
| C1R | 6214.0 |
| C1QA | 6176.0 |
| C1S | 6169.0 |
| C2 | 6139.0 |
| C1QB | 6110.0 |
| C1QC | 6107.0 |
| IGHG1 | 6067.5 |
| IGHG2 | 6067.5 |
| IGHG3 | 6067.5 |
| IGHG4 | 6067.5 |
| FCN1 | 6057.5 |
| FCN2 | 6057.5 |
| IGKC | 6026.0 |
| C3 | 5783.0 |
| C4A | 5536.5 |
| C4B | 5536.5 |
| GZMM | 2219.0 |
| CRP | 112.0 |
| CFD | -2545.0 |
| COLEC11 | -5805.0 |
| MASP2 | -5951.0 |
Creation of C4 and C2 activators
| 214 | |
|---|---|
| set | Creation of C4 and C2 activators |
| setSize | 15 |
| pANOVA | 9.43e-06 |
| s.dist | 0.661 |
| p.adjustANOVA | 0.000224 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| C1R | 6214.0 |
| C1QA | 6176.0 |
| C1S | 6169.0 |
| C1QB | 6110.0 |
| C1QC | 6107.0 |
| IGHG1 | 6067.5 |
| IGHG2 | 6067.5 |
| IGHG3 | 6067.5 |
| IGHG4 | 6067.5 |
| FCN1 | 6057.5 |
| FCN2 | 6057.5 |
| IGKC | 6026.0 |
| CRP | 112.0 |
| COLEC11 | -5805.0 |
| MASP2 | -5951.0 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| C1R | 6214.0 |
| C1QA | 6176.0 |
| C1S | 6169.0 |
| C1QB | 6110.0 |
| C1QC | 6107.0 |
| IGHG1 | 6067.5 |
| IGHG2 | 6067.5 |
| IGHG3 | 6067.5 |
| IGHG4 | 6067.5 |
| FCN1 | 6057.5 |
| FCN2 | 6057.5 |
| IGKC | 6026.0 |
| CRP | 112.0 |
| COLEC11 | -5805.0 |
| MASP2 | -5951.0 |
Mucopolysaccharidoses
| 675 | |
|---|---|
| set | Mucopolysaccharidoses |
| setSize | 11 |
| pANOVA | 0.000181 |
| s.dist | 0.652 |
| p.adjustANOVA | 0.00251 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| NAGLU | 6303 |
| HGSNAT | 6193 |
| GLB1 | 5681 |
| GUSB | 5649 |
| ARSB | 5460 |
| GALNS | 5437 |
| GNS | 4358 |
| SGSH | 4186 |
| IDUA | 2747 |
| IDS | 1852 |
| HYAL1 | -3392 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| NAGLU | 6303 |
| HGSNAT | 6193 |
| GLB1 | 5681 |
| GUSB | 5649 |
| ARSB | 5460 |
| GALNS | 5437 |
| GNS | 4358 |
| SGSH | 4186 |
| IDUA | 2747 |
| IDS | 1852 |
| HYAL1 | -3392 |
Digestion
| 277 | |
|---|---|
| set | Digestion |
| setSize | 14 |
| pANOVA | 2.59e-05 |
| s.dist | -0.649 |
| p.adjustANOVA | 0.000524 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| AMY1A | -7520 |
| AMY1B | -7520 |
| AMY2A | -7520 |
| AMY2B | -7520 |
| CEL | -6620 |
| PNLIP | -5867 |
| CLPS | -5843 |
| ALPI | -5451 |
| PNLIPRP2 | -5212 |
| PNLIPRP1 | -5138 |
| GUCY2C | -4759 |
| PIR | -4084 |
| LCT | -1422 |
| MGAM | 3606 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| AMY1A | -7520 |
| AMY1B | -7520 |
| AMY2A | -7520 |
| AMY2B | -7520 |
| CEL | -6620 |
| PNLIP | -5867 |
| CLPS | -5843 |
| ALPI | -5451 |
| PNLIPRP2 | -5212 |
| PNLIPRP1 | -5138 |
| GUCY2C | -4759 |
| PIR | -4084 |
| LCT | -1422 |
| MGAM | 3606 |
Trafficking and processing of endosomal TLR
| 1237 | |
|---|---|
| set | Trafficking and processing of endosomal TLR |
| setSize | 11 |
| pANOVA | 0.000193 |
| s.dist | 0.649 |
| p.adjustANOVA | 0.00261 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| TLR7 | 6439 |
| CTSS | 6324 |
| LGMN | 6275 |
| CTSV | 6173 |
| CTSB | 6148 |
| TLR3 | 5123 |
| CTSK | 4610 |
| TLR8 | 3774 |
| HSP90B1 | 3658 |
| CNPY3 | 1169 |
| TLR9 | -5419 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| TLR7 | 6439 |
| CTSS | 6324 |
| LGMN | 6275 |
| CTSV | 6173 |
| CTSB | 6148 |
| TLR3 | 5123 |
| CTSK | 4610 |
| TLR8 | 3774 |
| HSP90B1 | 3658 |
| CNPY3 | 1169 |
| TLR9 | -5419 |
FCGR activation
| 358 | |
|---|---|
| set | FCGR activation |
| setSize | 17 |
| pANOVA | 5.39e-06 |
| s.dist | 0.637 |
| p.adjustANOVA | 0.000135 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| FGR | 6351.0 |
| FCGR1A | 6330.5 |
| FCGR2A | 6233.5 |
| HCK | 6078.0 |
| IGHG1 | 6067.5 |
| IGHG2 | 6067.5 |
| IGHG3 | 6067.5 |
| IGHG4 | 6067.5 |
| IGKC | 6026.0 |
| FCGR3A | 5563.5 |
| FYN | 4884.0 |
| LYN | 4819.0 |
| YES1 | 3375.0 |
| SRC | 1999.0 |
| CD3G | -2388.0 |
| SYK | -2668.0 |
| CD247 | -3916.0 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| FGR | 6351.0 |
| FCGR1A | 6330.5 |
| FCGR2A | 6233.5 |
| HCK | 6078.0 |
| IGHG1 | 6067.5 |
| IGHG2 | 6067.5 |
| IGHG3 | 6067.5 |
| IGHG4 | 6067.5 |
| IGKC | 6026.0 |
| FCGR3A | 5563.5 |
| FYN | 4884.0 |
| LYN | 4819.0 |
| YES1 | 3375.0 |
| SRC | 1999.0 |
| CD3G | -2388.0 |
| SYK | -2668.0 |
| CD247 | -3916.0 |
HDMs demethylate histones
| 472 | |
|---|---|
| set | HDMs demethylate histones |
| setSize | 21 |
| pANOVA | 1.18e-06 |
| s.dist | -0.613 |
| p.adjustANOVA | 3.63e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| JMJD6 | -7170 |
| KDM6A | -7145 |
| KDM3A | -6959 |
| ARID5B | -6954 |
| KDM2A | -6410 |
| KDM5D | -6281 |
| KDM5B | -6230 |
| KDM5C | -6114 |
| KDM2B | -6039 |
| KDM6B | -5986 |
| UTY | -5979 |
| KDM5A | -5414 |
| KDM3B | -4854 |
| PHF2 | -4737 |
| KDM1A | -3674 |
| KDM1B | -3383 |
| KDM4B | -2939 |
| MINA | -2841 |
| KDM4A | -1895 |
| PHF8 | -276 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| JMJD6 | -7170 |
| KDM6A | -7145 |
| KDM3A | -6959 |
| ARID5B | -6954 |
| KDM2A | -6410 |
| KDM5D | -6281 |
| KDM5B | -6230 |
| KDM5C | -6114 |
| KDM2B | -6039 |
| KDM6B | -5986 |
| UTY | -5979 |
| KDM5A | -5414 |
| KDM3B | -4854 |
| PHF2 | -4737 |
| KDM1A | -3674 |
| KDM1B | -3383 |
| KDM4B | -2939 |
| MINA | -2841 |
| KDM4A | -1895 |
| PHF8 | -276 |
| KDM4C | 418 |
Digestion and absorption
| 278 | |
|---|---|
| set | Digestion and absorption |
| setSize | 15 |
| pANOVA | 4.09e-05 |
| s.dist | -0.612 |
| p.adjustANOVA | 0.000759 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| AMY1A | -7520 |
| AMY1B | -7520 |
| AMY2A | -7520 |
| AMY2B | -7520 |
| CEL | -6620 |
| PNLIP | -5867 |
| CLPS | -5843 |
| ALPI | -5451 |
| PNLIPRP2 | -5212 |
| PNLIPRP1 | -5138 |
| GUCY2C | -4759 |
| PIR | -4084 |
| LCT | -1422 |
| RSC1A1 | -1118 |
| MGAM | 3606 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| AMY1A | -7520 |
| AMY1B | -7520 |
| AMY2A | -7520 |
| AMY2B | -7520 |
| CEL | -6620 |
| PNLIP | -5867 |
| CLPS | -5843 |
| ALPI | -5451 |
| PNLIPRP2 | -5212 |
| PNLIPRP1 | -5138 |
| GUCY2C | -4759 |
| PIR | -4084 |
| LCT | -1422 |
| RSC1A1 | -1118 |
| MGAM | 3606 |
SRP-dependent cotranslational protein targeting to membrane
| 1030 | |
|---|---|
| set | SRP-dependent cotranslational protein targeting to membrane |
| setSize | 77 |
| pANOVA | 1.67e-18 |
| s.dist | 0.578 |
| p.adjustANOVA | 1.13e-15 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL11 | 6425 |
| SRP54 | 6412 |
| SPCS3 | 6112 |
| RPL32 | 5883 |
| SSR4 | 5836 |
| SPCS2 | 5755 |
| SSR2 | 5696 |
| SSR3 | 5687 |
| RPL31 | 5659 |
| RPS27L | 5652 |
| DDOST | 5633 |
| RPL10 | 5559 |
| SSR1 | 5513 |
| RPL28 | 5479 |
| RPL3 | 5413 |
| RPS9 | 5300 |
| RPL5 | 5198 |
| SPCS1 | 5166 |
| RPL30 | 5056 |
| RPN2 | 4974 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| RPL11 | 6425 |
| SRP54 | 6412 |
| SPCS3 | 6112 |
| RPL32 | 5883 |
| SSR4 | 5836 |
| SPCS2 | 5755 |
| SSR2 | 5696 |
| SSR3 | 5687 |
| RPL31 | 5659 |
| RPS27L | 5652 |
| DDOST | 5633 |
| RPL10 | 5559 |
| SSR1 | 5513 |
| RPL28 | 5479 |
| RPL3 | 5413 |
| RPS9 | 5300 |
| RPL5 | 5198 |
| SPCS1 | 5166 |
| RPL30 | 5056 |
| RPN2 | 4974 |
| RPL26 | 4931 |
| RPN1 | 4823 |
| RPS11 | 4809 |
| RPL19 | 4745 |
| RPS27A | 4675 |
| RPL37 | 4548 |
| SRP14 | 4547 |
| RPL23 | 4522 |
| RPL14 | 4484 |
| SEC61G | 4346 |
| RPS20 | 4323 |
| RPL36A | 4311 |
| SRP9 | 4231 |
| RPS13 | 4223 |
| SRP72 | 4212 |
| RPS14 | 4209 |
| RPS6 | 4170 |
| RPL22 | 4098 |
| RPL35A | 4093 |
| RPL34 | 4070 |
| RPS8 | 4000 |
| SEC61A1 | 3998 |
| RPS3 | 3991 |
| SRP68 | 3919 |
| RPS15A | 3893 |
| RPL38 | 3816 |
| RPS4X | 3796 |
| RPS18 | 3747 |
| RPS29 | 3742 |
| RPL18A | 3672 |
| RPS16 | 3662 |
| RPL18 | 3436 |
| RPL7 | 3418 |
| FAU | 3337 |
| RPLP2 | 3271 |
| SEC11C | 3219 |
| RPS21 | 3199 |
| RPL37A | 3059 |
| SEC11A | 2919 |
| RPS26 | 2701 |
| RPS23 | 2661 |
| RPS5 | 2658 |
| SRP19 | 2357 |
| RPL4 | 1860 |
| RPS19 | 1435 |
| RPL8 | 1425 |
| RPS15 | 777 |
| RPS24 | 671 |
| RPL22L1 | 659 |
| RPS12 | 244 |
| SRPRB | -71 |
| SEC61A2 | -204 |
| RPS27 | -230 |
| RPL15 | -1821 |
| RPL23A | -2004 |
| TRAM1 | -4289 |
| RPL3L | -7431 |
Cholesterol biosynthesis
| 174 | |
|---|---|
| set | Cholesterol biosynthesis |
| setSize | 23 |
| pANOVA | 5.33e-06 |
| s.dist | -0.548 |
| p.adjustANOVA | 0.000135 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| SC5D | -7336 |
| CYP51A1 | -7147 |
| HSD17B7 | -6822 |
| LBR | -6793 |
| HMGCR | -6748 |
| HMGCS1 | -6741 |
| ACAT2 | -6707 |
| LSS | -6573 |
| IDI1 | -6507 |
| FDFT1 | -6256 |
| SQLE | -6172 |
| DHCR7 | -5325 |
| MVD | -4411 |
| ARV1 | -3944 |
| FDPS | -3923 |
| DHCR24 | -3644 |
| MSMO1 | -2913 |
| GGPS1 | -2893 |
| EBP | -1794 |
| NSDHL | -107 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| SC5D | -7336 |
| CYP51A1 | -7147 |
| HSD17B7 | -6822 |
| LBR | -6793 |
| HMGCR | -6748 |
| HMGCS1 | -6741 |
| ACAT2 | -6707 |
| LSS | -6573 |
| IDI1 | -6507 |
| FDFT1 | -6256 |
| SQLE | -6172 |
| DHCR7 | -5325 |
| MVD | -4411 |
| ARV1 | -3944 |
| FDPS | -3923 |
| DHCR24 | -3644 |
| MSMO1 | -2913 |
| GGPS1 | -2893 |
| EBP | -1794 |
| NSDHL | -107 |
| TM7SF2 | 316 |
| PMVK | 932 |
| MVK | 1395 |
Viral mRNA Translation
| 1305 | |
|---|---|
| set | Viral mRNA Translation |
| setSize | 56 |
| pANOVA | 2.1e-12 |
| s.dist | 0.543 |
| p.adjustANOVA | 3.55e-10 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL11 | 6425 |
| RPL32 | 5883 |
| RPL31 | 5659 |
| RPS27L | 5652 |
| RPL10 | 5559 |
| RPL28 | 5479 |
| RPL3 | 5413 |
| RPS9 | 5300 |
| RPL5 | 5198 |
| RPL30 | 5056 |
| RPL26 | 4931 |
| RPS11 | 4809 |
| RPL19 | 4745 |
| RPS27A | 4675 |
| RPL37 | 4548 |
| RPL23 | 4522 |
| RPL14 | 4484 |
| RPS20 | 4323 |
| RPL36A | 4311 |
| RPS13 | 4223 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| RPL11 | 6425 |
| RPL32 | 5883 |
| RPL31 | 5659 |
| RPS27L | 5652 |
| RPL10 | 5559 |
| RPL28 | 5479 |
| RPL3 | 5413 |
| RPS9 | 5300 |
| RPL5 | 5198 |
| RPL30 | 5056 |
| RPL26 | 4931 |
| RPS11 | 4809 |
| RPL19 | 4745 |
| RPS27A | 4675 |
| RPL37 | 4548 |
| RPL23 | 4522 |
| RPL14 | 4484 |
| RPS20 | 4323 |
| RPL36A | 4311 |
| RPS13 | 4223 |
| RPS14 | 4209 |
| RPS6 | 4170 |
| RPL22 | 4098 |
| RPL35A | 4093 |
| RPL34 | 4070 |
| RPS8 | 4000 |
| RPS3 | 3991 |
| RPS15A | 3893 |
| RPL38 | 3816 |
| RPS4X | 3796 |
| RPS18 | 3747 |
| RPS29 | 3742 |
| RPL18A | 3672 |
| RPS16 | 3662 |
| RPL18 | 3436 |
| RPL7 | 3418 |
| FAU | 3337 |
| RPLP2 | 3271 |
| RPS21 | 3199 |
| RPL37A | 3059 |
| RPS26 | 2701 |
| RPS23 | 2661 |
| RPS5 | 2658 |
| GRSF1 | 1892 |
| RPL4 | 1860 |
| DNAJC3 | 1649 |
| RPS19 | 1435 |
| RPL8 | 1425 |
| RPS15 | 777 |
| RPS24 | 671 |
| RPL22L1 | 659 |
| RPS12 | 244 |
| RPS27 | -230 |
| RPL15 | -1821 |
| RPL23A | -2004 |
| RPL3L | -7431 |
Peptide chain elongation
| 801 | |
|---|---|
| set | Peptide chain elongation |
| setSize | 56 |
| pANOVA | 3.56e-12 |
| s.dist | 0.537 |
| p.adjustANOVA | 4.82e-10 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL11 | 6425 |
| RPL32 | 5883 |
| RPL31 | 5659 |
| RPS27L | 5652 |
| RPL10 | 5559 |
| RPL28 | 5479 |
| RPL3 | 5413 |
| RPS9 | 5300 |
| RPL5 | 5198 |
| RPL30 | 5056 |
| RPL26 | 4931 |
| RPS11 | 4809 |
| RPL19 | 4745 |
| RPS27A | 4675 |
| RPL37 | 4548 |
| RPL23 | 4522 |
| RPL14 | 4484 |
| RPS20 | 4323 |
| RPL36A | 4311 |
| RPS13 | 4223 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| RPL11 | 6425 |
| RPL32 | 5883 |
| RPL31 | 5659 |
| RPS27L | 5652 |
| RPL10 | 5559 |
| RPL28 | 5479 |
| RPL3 | 5413 |
| RPS9 | 5300 |
| RPL5 | 5198 |
| RPL30 | 5056 |
| RPL26 | 4931 |
| RPS11 | 4809 |
| RPL19 | 4745 |
| RPS27A | 4675 |
| RPL37 | 4548 |
| RPL23 | 4522 |
| RPL14 | 4484 |
| RPS20 | 4323 |
| RPL36A | 4311 |
| RPS13 | 4223 |
| RPS14 | 4209 |
| RPS6 | 4170 |
| RPL22 | 4098 |
| RPL35A | 4093 |
| RPL34 | 4070 |
| RPS8 | 4000 |
| RPS3 | 3991 |
| RPS15A | 3893 |
| RPL38 | 3816 |
| RPS4X | 3796 |
| RPS18 | 3747 |
| RPS29 | 3742 |
| RPL18A | 3672 |
| RPS16 | 3662 |
| RPL18 | 3436 |
| RPL7 | 3418 |
| FAU | 3337 |
| RPLP2 | 3271 |
| RPS21 | 3199 |
| RPL37A | 3059 |
| RPS26 | 2701 |
| RPS23 | 2661 |
| RPS5 | 2658 |
| EEF1A1 | 2491 |
| RPL4 | 1860 |
| RPS19 | 1435 |
| RPL8 | 1425 |
| RPS15 | 777 |
| RPS24 | 671 |
| RPL22L1 | 659 |
| RPS12 | 244 |
| RPS27 | -230 |
| EEF2 | -1184 |
| RPL15 | -1821 |
| RPL23A | -2004 |
| RPL3L | -7431 |
G beta:gamma signalling through BTK
| 402 | |
|---|---|
| set | G beta:gamma signalling through BTK |
| setSize | 14 |
| pANOVA | 0.000524 |
| s.dist | 0.535 |
| p.adjustANOVA | 0.00576 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GNGT2 | 6373 |
| GNG5 | 6184 |
| GNG12 | 5768 |
| GNG11 | 5389 |
| GNG8 | 4629 |
| GNG10 | 4252 |
| GNB2 | 4125 |
| GNG2 | 3242 |
| GNG7 | 3101 |
| GNB5 | 2680 |
| BTK | 1598 |
| GNB1 | 169 |
| GNGT1 | -261 |
| GNB4 | -2066 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| GNGT2 | 6373 |
| GNG5 | 6184 |
| GNG12 | 5768 |
| GNG11 | 5389 |
| GNG8 | 4629 |
| GNG10 | 4252 |
| GNB2 | 4125 |
| GNG2 | 3242 |
| GNG7 | 3101 |
| GNB5 | 2680 |
| BTK | 1598 |
| GNB1 | 169 |
| GNGT1 | -261 |
| GNB4 | -2066 |
Selenocysteine synthesis
| 1050 | |
|---|---|
| set | Selenocysteine synthesis |
| setSize | 59 |
| pANOVA | 3.32e-12 |
| s.dist | 0.524 |
| p.adjustANOVA | 4.82e-10 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL11 | 6425 |
| RPL32 | 5883 |
| RPL31 | 5659 |
| RPS27L | 5652 |
| RPL10 | 5559 |
| RPL28 | 5479 |
| RPL3 | 5413 |
| RPS9 | 5300 |
| RPL5 | 5198 |
| RPL30 | 5056 |
| RPL26 | 4931 |
| RPS11 | 4809 |
| RPL19 | 4745 |
| RPS27A | 4675 |
| RPL37 | 4548 |
| RPL23 | 4522 |
| RPL14 | 4484 |
| RPS20 | 4323 |
| RPL36A | 4311 |
| RPS13 | 4223 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| RPL11 | 6425 |
| RPL32 | 5883 |
| RPL31 | 5659 |
| RPS27L | 5652 |
| RPL10 | 5559 |
| RPL28 | 5479 |
| RPL3 | 5413 |
| RPS9 | 5300 |
| RPL5 | 5198 |
| RPL30 | 5056 |
| RPL26 | 4931 |
| RPS11 | 4809 |
| RPL19 | 4745 |
| RPS27A | 4675 |
| RPL37 | 4548 |
| RPL23 | 4522 |
| RPL14 | 4484 |
| RPS20 | 4323 |
| RPL36A | 4311 |
| RPS13 | 4223 |
| RPS14 | 4209 |
| RPS6 | 4170 |
| RPL22 | 4098 |
| RPL35A | 4093 |
| RPL34 | 4070 |
| RPS8 | 4000 |
| RPS3 | 3991 |
| SEPHS2 | 3980 |
| RPS15A | 3893 |
| RPL38 | 3816 |
| RPS4X | 3796 |
| RPS18 | 3747 |
| RPS29 | 3742 |
| RPL18A | 3672 |
| RPS16 | 3662 |
| RPL18 | 3436 |
| RPL7 | 3418 |
| FAU | 3337 |
| RPLP2 | 3271 |
| PSTK | 3254 |
| RPS21 | 3199 |
| RPL37A | 3059 |
| RPS26 | 2701 |
| RPS23 | 2661 |
| RPS5 | 2658 |
| EEFSEC | 2543 |
| RPL4 | 1860 |
| RPS19 | 1435 |
| RPL8 | 1425 |
| RPS15 | 777 |
| RPS24 | 671 |
| RPL22L1 | 659 |
| RPS12 | 244 |
| SEPSECS | -192 |
| RPS27 | -230 |
| RPL15 | -1821 |
| RPL23A | -2004 |
| SECISBP2 | -4007 |
| RPL3L | -7431 |
Prostacyclin signalling through prostacyclin receptor
| 855 | |
|---|---|
| set | Prostacyclin signalling through prostacyclin receptor |
| setSize | 15 |
| pANOVA | 0.000596 |
| s.dist | 0.512 |
| p.adjustANOVA | 0.00631 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GNGT2 | 6373 |
| GNG5 | 6184 |
| GNG12 | 5768 |
| GNG11 | 5389 |
| GNG8 | 4629 |
| GNG10 | 4252 |
| GNB2 | 4125 |
| GNG2 | 3242 |
| GNG7 | 3101 |
| GNB5 | 2680 |
| GNAS | 1478 |
| PTGIR | 891 |
| GNB1 | 169 |
| GNGT1 | -261 |
| GNB4 | -2066 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| GNGT2 | 6373 |
| GNG5 | 6184 |
| GNG12 | 5768 |
| GNG11 | 5389 |
| GNG8 | 4629 |
| GNG10 | 4252 |
| GNB2 | 4125 |
| GNG2 | 3242 |
| GNG7 | 3101 |
| GNB5 | 2680 |
| GNAS | 1478 |
| PTGIR | 891 |
| GNB1 | 169 |
| GNGT1 | -261 |
| GNB4 | -2066 |
GABA synthesis, release, reuptake and degradation
| 421 | |
|---|---|
| set | GABA synthesis, release, reuptake and degradation |
| setSize | 15 |
| pANOVA | 0.000621 |
| s.dist | -0.51 |
| p.adjustANOVA | 0.00647 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| VAMP2 | -7236 |
| STX1A | -7228 |
| ALDH5A1 | -6712 |
| GAD1 | -5860 |
| SLC6A13 | -5107 |
| STXBP1 | -4717 |
| SYT1 | -4449 |
| DNAJC5 | -4421 |
| SLC6A1 | -4038 |
| SNAP25 | -3463 |
| SLC6A12 | -2943 |
| HSPA8 | -2807 |
| ABAT | -2296 |
| GAD2 | -369 |
| RAB3A | 295 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| VAMP2 | -7236 |
| STX1A | -7228 |
| ALDH5A1 | -6712 |
| GAD1 | -5860 |
| SLC6A13 | -5107 |
| STXBP1 | -4717 |
| SYT1 | -4449 |
| DNAJC5 | -4421 |
| SLC6A1 | -4038 |
| SNAP25 | -3463 |
| SLC6A12 | -2943 |
| HSPA8 | -2807 |
| ABAT | -2296 |
| GAD2 | -369 |
| RAB3A | 295 |
Eukaryotic Translation Termination
| 349 | |
|---|---|
| set | Eukaryotic Translation Termination |
| setSize | 59 |
| pANOVA | 1.46e-11 |
| s.dist | 0.508 |
| p.adjustANOVA | 1.65e-09 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL11 | 6425 |
| N6AMT1 | 6001 |
| RPL32 | 5883 |
| RPL31 | 5659 |
| RPS27L | 5652 |
| RPL10 | 5559 |
| RPL28 | 5479 |
| RPL3 | 5413 |
| RPS9 | 5300 |
| RPL5 | 5198 |
| RPL30 | 5056 |
| RPL26 | 4931 |
| RPS11 | 4809 |
| RPL19 | 4745 |
| RPS27A | 4675 |
| RPL37 | 4548 |
| RPL23 | 4522 |
| RPL14 | 4484 |
| RPS20 | 4323 |
| RPL36A | 4311 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| RPL11 | 6425 |
| N6AMT1 | 6001 |
| RPL32 | 5883 |
| RPL31 | 5659 |
| RPS27L | 5652 |
| RPL10 | 5559 |
| RPL28 | 5479 |
| RPL3 | 5413 |
| RPS9 | 5300 |
| RPL5 | 5198 |
| RPL30 | 5056 |
| RPL26 | 4931 |
| RPS11 | 4809 |
| RPL19 | 4745 |
| RPS27A | 4675 |
| RPL37 | 4548 |
| RPL23 | 4522 |
| RPL14 | 4484 |
| RPS20 | 4323 |
| RPL36A | 4311 |
| RPS13 | 4223 |
| RPS14 | 4209 |
| RPS6 | 4170 |
| RPL22 | 4098 |
| RPL35A | 4093 |
| RPL34 | 4070 |
| RPS8 | 4000 |
| RPS3 | 3991 |
| RPS15A | 3893 |
| RPL38 | 3816 |
| RPS4X | 3796 |
| RPS18 | 3747 |
| RPS29 | 3742 |
| RPL18A | 3672 |
| RPS16 | 3662 |
| RPL18 | 3436 |
| RPL7 | 3418 |
| FAU | 3337 |
| RPLP2 | 3271 |
| RPS21 | 3199 |
| RPL37A | 3059 |
| RPS26 | 2701 |
| RPS23 | 2661 |
| RPS5 | 2658 |
| RPL4 | 1860 |
| GSPT2 | 1561 |
| RPS19 | 1435 |
| RPL8 | 1425 |
| RPS15 | 777 |
| RPS24 | 671 |
| RPL22L1 | 659 |
| RPS12 | 244 |
| RPS27 | -230 |
| GSPT1 | -718 |
| RPL15 | -1821 |
| RPL23A | -2004 |
| ETF1 | -2776 |
| APEH | -5041 |
| RPL3L | -7431 |
Eukaryotic Translation Elongation
| 347 | |
|---|---|
| set | Eukaryotic Translation Elongation |
| setSize | 60 |
| pANOVA | 2.7e-11 |
| s.dist | 0.497 |
| p.adjustANOVA | 2.44e-09 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL11 | 6425 |
| RPL32 | 5883 |
| RPL31 | 5659 |
| RPS27L | 5652 |
| RPL10 | 5559 |
| RPL28 | 5479 |
| RPL3 | 5413 |
| RPS9 | 5300 |
| EEF1B2 | 5261 |
| RPL5 | 5198 |
| RPL30 | 5056 |
| RPL26 | 4931 |
| RPS11 | 4809 |
| RPL19 | 4745 |
| RPS27A | 4675 |
| RPL37 | 4548 |
| RPL23 | 4522 |
| RPL14 | 4484 |
| RPS20 | 4323 |
| RPL36A | 4311 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| RPL11 | 6425 |
| RPL32 | 5883 |
| RPL31 | 5659 |
| RPS27L | 5652 |
| RPL10 | 5559 |
| RPL28 | 5479 |
| RPL3 | 5413 |
| RPS9 | 5300 |
| EEF1B2 | 5261 |
| RPL5 | 5198 |
| RPL30 | 5056 |
| RPL26 | 4931 |
| RPS11 | 4809 |
| RPL19 | 4745 |
| RPS27A | 4675 |
| RPL37 | 4548 |
| RPL23 | 4522 |
| RPL14 | 4484 |
| RPS20 | 4323 |
| RPL36A | 4311 |
| RPS13 | 4223 |
| RPS14 | 4209 |
| RPS6 | 4170 |
| RPL22 | 4098 |
| RPL35A | 4093 |
| RPL34 | 4070 |
| RPS8 | 4000 |
| RPS3 | 3991 |
| RPS15A | 3893 |
| RPL38 | 3816 |
| RPS4X | 3796 |
| RPS18 | 3747 |
| RPS29 | 3742 |
| RPL18A | 3672 |
| RPS16 | 3662 |
| RPL18 | 3436 |
| RPL7 | 3418 |
| FAU | 3337 |
| RPLP2 | 3271 |
| RPS21 | 3199 |
| RPL37A | 3059 |
| RPS26 | 2701 |
| RPS23 | 2661 |
| RPS5 | 2658 |
| EEF1A1 | 2491 |
| EEF1G | 2288 |
| RPL4 | 1860 |
| RPS19 | 1435 |
| RPL8 | 1425 |
| RPS15 | 777 |
| RPS24 | 671 |
| RPL22L1 | 659 |
| RPS12 | 244 |
| RPS27 | -230 |
| EEF2 | -1184 |
| RPL15 | -1821 |
| RPL23A | -2004 |
| EEF1D | -3864 |
| RPL3L | -7431 |
| EEF1A2 | -7512 |
rRNA processing in the mitochondrion
| 1345 | |
|---|---|
| set | rRNA processing in the mitochondrion |
| setSize | 17 |
| pANOVA | 0.000406 |
| s.dist | -0.495 |
| p.adjustANOVA | 0.00475 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MT-ND4L | -6745 |
| MT-ND5 | -6686 |
| MT-ND2 | -6595 |
| MT-ATP6 | -6338 |
| MT-ND4 | -6165 |
| MT-ND1 | -5816 |
| MT-CYB | -5757 |
| NSUN4 | -5038 |
| MT-CO1 | -4661 |
| MRM1 | -4570 |
| TRMT10C | -3607 |
| MT-CO3 | -3562 |
| MT-CO2 | -2739 |
| ELAC2 | -2730 |
| MT-ND3 | -794 |
| TFB1M | -160 |
| HSD17B10 | 4217 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MT-ND4L | -6745 |
| MT-ND5 | -6686 |
| MT-ND2 | -6595 |
| MT-ATP6 | -6338 |
| MT-ND4 | -6165 |
| MT-ND1 | -5816 |
| MT-CYB | -5757 |
| NSUN4 | -5038 |
| MT-CO1 | -4661 |
| MRM1 | -4570 |
| TRMT10C | -3607 |
| MT-CO3 | -3562 |
| MT-CO2 | -2739 |
| ELAC2 | -2730 |
| MT-ND3 | -794 |
| TFB1M | -160 |
| HSD17B10 | 4217 |
Activation of gene expression by SREBF (SREBP)
| 47 | |
|---|---|
| set | Activation of gene expression by SREBF (SREBP) |
| setSize | 41 |
| pANOVA | 5.33e-08 |
| s.dist | -0.491 |
| p.adjustANOVA | 2.33e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| SC5D | -7336 |
| SREBF2 | -7273 |
| ACACA | -7269 |
| ELOVL6 | -7260 |
| CYP51A1 | -7147 |
| TBL1XR1 | -7120 |
| FASN | -6987 |
| HELZ2 | -6806 |
| HMGCR | -6748 |
| HMGCS1 | -6741 |
| LSS | -6573 |
| IDI1 | -6507 |
| PPARA | -6378 |
| SP1 | -6317 |
| FDFT1 | -6256 |
| MTF1 | -6224 |
| SQLE | -6172 |
| MED1 | -6030 |
| DHCR7 | -5325 |
| CREBBP | -5042 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| SC5D | -7336 |
| SREBF2 | -7273 |
| ACACA | -7269 |
| ELOVL6 | -7260 |
| CYP51A1 | -7147 |
| TBL1XR1 | -7120 |
| FASN | -6987 |
| HELZ2 | -6806 |
| HMGCR | -6748 |
| HMGCS1 | -6741 |
| LSS | -6573 |
| IDI1 | -6507 |
| PPARA | -6378 |
| SP1 | -6317 |
| FDFT1 | -6256 |
| MTF1 | -6224 |
| SQLE | -6172 |
| MED1 | -6030 |
| DHCR7 | -5325 |
| CREBBP | -5042 |
| CHD9 | -4654 |
| MVD | -4411 |
| NFYA | -4206 |
| CARM1 | -4173 |
| NFYC | -4048 |
| FDPS | -3923 |
| GPAM | -3891 |
| ACACB | -3648 |
| NCOA2 | -3586 |
| NCOA6 | -3424 |
| GGPS1 | -2893 |
| SMARCD3 | -2013 |
| TGS1 | -1194 |
| NCOA1 | -498 |
| TM7SF2 | 316 |
| SREBF1 | 447 |
| PMVK | 932 |
| MVK | 1395 |
| NFYB | 1492 |
| SCD | 5685 |
| RXRA | 5926 |
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain
| 1200 | |
|---|---|
| set | TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain |
| setSize | 20 |
| pANOVA | 0.000145 |
| s.dist | -0.491 |
| p.adjustANOVA | 0.00214 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PLK2 | -7453 |
| BTG2 | -6885 |
| RGCC | -6832 |
| CNOT3 | -6248 |
| CNOT6L | -6152 |
| CNOT6 | -5386 |
| CNOT1 | -5183 |
| TP53 | -4558 |
| CENPJ | -4525 |
| CDC25C | -3996 |
| CNOT10 | -3831 |
| CNOT11 | -3523 |
| TNKS1BP1 | -3429 |
| CNOT8 | -3218 |
| CNOT4 | -2929 |
| CNOT2 | -2734 |
| CNOT7 | -2361 |
| RQCD1 | -2244 |
| PLK3 | -452 |
| PLAGL1 | 2890 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PLK2 | -7453 |
| BTG2 | -6885 |
| RGCC | -6832 |
| CNOT3 | -6248 |
| CNOT6L | -6152 |
| CNOT6 | -5386 |
| CNOT1 | -5183 |
| TP53 | -4558 |
| CENPJ | -4525 |
| CDC25C | -3996 |
| CNOT10 | -3831 |
| CNOT11 | -3523 |
| TNKS1BP1 | -3429 |
| CNOT8 | -3218 |
| CNOT4 | -2929 |
| CNOT2 | -2734 |
| CNOT7 | -2361 |
| RQCD1 | -2244 |
| PLK3 | -452 |
| PLAGL1 | 2890 |
Regulation of IFNA signaling
| 944 | |
|---|---|
| set | Regulation of IFNA signaling |
| setSize | 12 |
| pANOVA | 0.00338 |
| s.dist | 0.489 |
| p.adjustANOVA | 0.0227 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| STAT1 | 6315.0 |
| USP18 | 5593.5 |
| PTPN1 | 5323.0 |
| IFNAR1 | 4473.0 |
| SOCS3 | 4435.0 |
| STAT2 | 4322.0 |
| SOCS1 | 4202.0 |
| IFNAR2 | 4090.0 |
| TYK2 | 2013.0 |
| PTPN6 | -1615.0 |
| PTPN11 | -2092.0 |
| JAK1 | -2252.0 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| STAT1 | 6315.0 |
| USP18 | 5593.5 |
| PTPN1 | 5323.0 |
| IFNAR1 | 4473.0 |
| SOCS3 | 4435.0 |
| STAT2 | 4322.0 |
| SOCS1 | 4202.0 |
| IFNAR2 | 4090.0 |
| TYK2 | 2013.0 |
| PTPN6 | -1615.0 |
| PTPN11 | -2092.0 |
| JAK1 | -2252.0 |
Signal regulatory protein family interactions
| 1062 | |
|---|---|
| set | Signal regulatory protein family interactions |
| setSize | 13 |
| pANOVA | 0.00263 |
| s.dist | 0.482 |
| p.adjustANOVA | 0.019 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| SIRPA | 6483.5 |
| SIRPB1 | 6483.5 |
| SIRPG | 6483.5 |
| SKAP2 | 6410.0 |
| TYROBP | 6386.0 |
| FYB | 4189.0 |
| PTK2 | 3889.0 |
| SRC | 1999.0 |
| CD47 | 578.0 |
| GRB2 | -609.0 |
| PTK2B | -1500.0 |
| PTPN6 | -1615.0 |
| PTPN11 | -2092.0 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| SIRPA | 6483.5 |
| SIRPB1 | 6483.5 |
| SIRPG | 6483.5 |
| SKAP2 | 6410.0 |
| TYROBP | 6386.0 |
| FYB | 4189.0 |
| PTK2 | 3889.0 |
| SRC | 1999.0 |
| CD47 | 578.0 |
| GRB2 | -609.0 |
| PTK2B | -1500.0 |
| PTPN6 | -1615.0 |
| PTPN11 | -2092.0 |
Formation of a pool of free 40S subunits
| 388 | |
|---|---|
| set | Formation of a pool of free 40S subunits |
| setSize | 66 |
| pANOVA | 1.45e-11 |
| s.dist | 0.481 |
| p.adjustANOVA | 1.65e-09 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL11 | 6425 |
| RPL32 | 5883 |
| RPL31 | 5659 |
| RPS27L | 5652 |
| RPL10 | 5559 |
| RPL28 | 5479 |
| RPL3 | 5413 |
| RPS9 | 5300 |
| RPL5 | 5198 |
| RPL30 | 5056 |
| RPL26 | 4931 |
| RPS11 | 4809 |
| RPL19 | 4745 |
| RPS27A | 4675 |
| EIF3M | 4641 |
| RPL37 | 4548 |
| RPL23 | 4522 |
| RPL14 | 4484 |
| RPS20 | 4323 |
| RPL36A | 4311 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| RPL11 | 6425.0 |
| RPL32 | 5883.0 |
| RPL31 | 5659.0 |
| RPS27L | 5652.0 |
| RPL10 | 5559.0 |
| RPL28 | 5479.0 |
| RPL3 | 5413.0 |
| RPS9 | 5300.0 |
| RPL5 | 5198.0 |
| RPL30 | 5056.0 |
| RPL26 | 4931.0 |
| RPS11 | 4809.0 |
| RPL19 | 4745.0 |
| RPS27A | 4675.0 |
| EIF3M | 4641.0 |
| RPL37 | 4548.0 |
| RPL23 | 4522.0 |
| RPL14 | 4484.0 |
| RPS20 | 4323.0 |
| RPL36A | 4311.0 |
| RPS13 | 4223.0 |
| RPS14 | 4209.0 |
| EIF3E | 4194.0 |
| RPS6 | 4170.0 |
| RPL22 | 4098.0 |
| RPL35A | 4093.0 |
| RPL34 | 4070.0 |
| EIF3K | 4045.0 |
| RPS8 | 4000.0 |
| RPS3 | 3991.0 |
| EIF3F | 3905.0 |
| RPS15A | 3893.0 |
| RPL38 | 3816.0 |
| RPS4X | 3796.0 |
| RPS18 | 3747.0 |
| RPS29 | 3742.0 |
| RPL18A | 3672.0 |
| RPS16 | 3662.0 |
| EIF3H | 3459.0 |
| RPL18 | 3436.0 |
| RPL7 | 3418.0 |
| FAU | 3337.0 |
| RPLP2 | 3271.0 |
| RPS21 | 3199.0 |
| RPL37A | 3059.0 |
| RPS26 | 2701.0 |
| RPS23 | 2661.0 |
| RPS5 | 2658.0 |
| RPL4 | 1860.0 |
| EIF3I | 1718.0 |
| RPS19 | 1435.0 |
| RPL8 | 1425.0 |
| RPS15 | 777.0 |
| RPS24 | 671.0 |
| RPL22L1 | 659.0 |
| RPS12 | 244.0 |
| EIF3L | 187.0 |
| RPS27 | -230.0 |
| EIF3G | -1094.0 |
| EIF3C | -1251.5 |
| RPL15 | -1821.0 |
| RPL23A | -2004.0 |
| EIF3B | -3141.0 |
| EIF3D | -4318.0 |
| EIF3A | -4914.0 |
| RPL3L | -7431.0 |
Mitotic Telophase/Cytokinesis
| 673 | |
|---|---|
| set | Mitotic Telophase/Cytokinesis |
| setSize | 12 |
| pANOVA | 0.00466 |
| s.dist | -0.472 |
| p.adjustANOVA | 0.0291 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MAU2 | -7133 |
| RAD21 | -5624 |
| SMC1A | -5254 |
| PDS5A | -4964 |
| SMC3 | -4484 |
| PLK1 | -3685 |
| NIPBL | -3669 |
| KIF20A | -2960 |
| KIF23 | -2366 |
| STAG2 | -2310 |
| PDS5B | -2178 |
| STAG1 | -1219 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MAU2 | -7133 |
| RAD21 | -5624 |
| SMC1A | -5254 |
| PDS5A | -4964 |
| SMC3 | -4484 |
| PLK1 | -3685 |
| NIPBL | -3669 |
| KIF20A | -2960 |
| KIF23 | -2366 |
| STAG2 | -2310 |
| PDS5B | -2178 |
| STAG1 | -1219 |
Signaling by FGFR4 in disease
| 1089 | |
|---|---|
| set | Signaling by FGFR4 in disease |
| setSize | 11 |
| pANOVA | 0.00692 |
| s.dist | -0.47 |
| p.adjustANOVA | 0.0389 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| SOS1 | -6404 |
| FRS2 | -6216 |
| PIK3CA | -5991 |
| PLCG1 | -5436 |
| KRAS | -5384 |
| PIK3R1 | -4451 |
| NRAS | -3468 |
| HRAS | -1672 |
| FGFR4 | -1460 |
| GAB1 | -824 |
| GRB2 | -609 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| SOS1 | -6404 |
| FRS2 | -6216 |
| PIK3CA | -5991 |
| PLCG1 | -5436 |
| KRAS | -5384 |
| PIK3R1 | -4451 |
| NRAS | -3468 |
| HRAS | -1672 |
| FGFR4 | -1460 |
| GAB1 | -824 |
| GRB2 | -609 |
Na+/Cl- dependent neurotransmitter transporters
| 706 | |
|---|---|
| set | Na+/Cl- dependent neurotransmitter transporters |
| setSize | 14 |
| pANOVA | 0.00234 |
| s.dist | -0.47 |
| p.adjustANOVA | 0.0175 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| SLC6A19 | -7227 |
| SLC6A20 | -7058 |
| SLC6A2 | -6537 |
| SLC6A15 | -6297 |
| SLC6A9 | -5675 |
| SLC6A5 | -5215 |
| SLC6A13 | -5107 |
| SLC18A1 | -4667 |
| SLC6A18 | -4492 |
| SLC6A1 | -4038 |
| SLC6A12 | -2943 |
| SLC6A3 | -646 |
| SLC18A2 | 2601 |
| SLC6A6 | 4008 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| SLC6A19 | -7227 |
| SLC6A20 | -7058 |
| SLC6A2 | -6537 |
| SLC6A15 | -6297 |
| SLC6A9 | -5675 |
| SLC6A5 | -5215 |
| SLC6A13 | -5107 |
| SLC18A1 | -4667 |
| SLC6A18 | -4492 |
| SLC6A1 | -4038 |
| SLC6A12 | -2943 |
| SLC6A3 | -646 |
| SLC18A2 | 2601 |
| SLC6A6 | 4008 |
Glucagon-type ligand receptors
| 445 | |
|---|---|
| set | Glucagon-type ligand receptors |
| setSize | 20 |
| pANOVA | 0.000289 |
| s.dist | 0.468 |
| p.adjustANOVA | 0.0037 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GNGT2 | 6373 |
| GNG5 | 6184 |
| GLP2R | 5948 |
| SCT | 5915 |
| GNG12 | 5768 |
| CYSLTR2 | 5543 |
| GNG11 | 5389 |
| GNG8 | 4629 |
| VIPR2 | 4377 |
| GNG10 | 4252 |
| GNB2 | 4125 |
| GNG2 | 3242 |
| GNG7 | 3101 |
| GNB5 | 2680 |
| GNAS | 1478 |
| GNB1 | 169 |
| GNGT1 | -261 |
| GNB4 | -2066 |
| ADCYAP1R1 | -4870 |
| VIPR1 | -6857 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| GNGT2 | 6373 |
| GNG5 | 6184 |
| GLP2R | 5948 |
| SCT | 5915 |
| GNG12 | 5768 |
| CYSLTR2 | 5543 |
| GNG11 | 5389 |
| GNG8 | 4629 |
| VIPR2 | 4377 |
| GNG10 | 4252 |
| GNB2 | 4125 |
| GNG2 | 3242 |
| GNG7 | 3101 |
| GNB5 | 2680 |
| GNAS | 1478 |
| GNB1 | 169 |
| GNGT1 | -261 |
| GNB4 | -2066 |
| ADCYAP1R1 | -4870 |
| VIPR1 | -6857 |
ADP signalling through P2Y purinoceptor 12
| 7 | |
|---|---|
| set | ADP signalling through P2Y purinoceptor 12 |
| setSize | 17 |
| pANOVA | 9e-04 |
| s.dist | 0.465 |
| p.adjustANOVA | 0.00861 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GNGT2 | 6373 |
| GNG5 | 6184 |
| GNG12 | 5768 |
| P2RY12 | 5501 |
| GNG11 | 5389 |
| GNG8 | 4629 |
| GNG10 | 4252 |
| GNB2 | 4125 |
| GNG2 | 3242 |
| GNG7 | 3101 |
| GNB5 | 2680 |
| GNAI2 | 1397 |
| GNB1 | 169 |
| GNGT1 | -261 |
| GNAI3 | -1320 |
| GNB4 | -2066 |
| GNAI1 | -2669 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| GNGT2 | 6373 |
| GNG5 | 6184 |
| GNG12 | 5768 |
| P2RY12 | 5501 |
| GNG11 | 5389 |
| GNG8 | 4629 |
| GNG10 | 4252 |
| GNB2 | 4125 |
| GNG2 | 3242 |
| GNG7 | 3101 |
| GNB5 | 2680 |
| GNAI2 | 1397 |
| GNB1 | 169 |
| GNGT1 | -261 |
| GNAI3 | -1320 |
| GNB4 | -2066 |
| GNAI1 | -2669 |
G beta:gamma signalling through CDC42
| 403 | |
|---|---|
| set | G beta:gamma signalling through CDC42 |
| setSize | 16 |
| pANOVA | 0.00137 |
| s.dist | 0.462 |
| p.adjustANOVA | 0.0116 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GNGT2 | 6373 |
| GNG5 | 6184 |
| GNG12 | 5768 |
| GNG11 | 5389 |
| PAK1 | 4654 |
| GNG8 | 4629 |
| GNG10 | 4252 |
| GNB2 | 4125 |
| GNG2 | 3242 |
| GNG7 | 3101 |
| GNB5 | 2680 |
| GNB1 | 169 |
| GNGT1 | -261 |
| CDC42 | -927 |
| GNB4 | -2066 |
| ARHGEF6 | -3865 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| GNGT2 | 6373 |
| GNG5 | 6184 |
| GNG12 | 5768 |
| GNG11 | 5389 |
| PAK1 | 4654 |
| GNG8 | 4629 |
| GNG10 | 4252 |
| GNB2 | 4125 |
| GNG2 | 3242 |
| GNG7 | 3101 |
| GNB5 | 2680 |
| GNB1 | 169 |
| GNGT1 | -261 |
| CDC42 | -927 |
| GNB4 | -2066 |
| ARHGEF6 | -3865 |
tRNA processing in the mitochondrion
| 1351 | |
|---|---|
| set | tRNA processing in the mitochondrion |
| setSize | 16 |
| pANOVA | 0.00139 |
| s.dist | -0.462 |
| p.adjustANOVA | 0.0117 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MT-ND4L | -6745 |
| MT-ND5 | -6686 |
| MT-ND2 | -6595 |
| MT-ATP6 | -6338 |
| MT-ND4 | -6165 |
| MT-ND1 | -5816 |
| MT-CYB | -5757 |
| MT-CO1 | -4661 |
| TRMT10C | -3607 |
| MT-CO3 | -3562 |
| MT-ND6 | -2969 |
| MT-CO2 | -2739 |
| ELAC2 | -2730 |
| MT-ND3 | -794 |
| TRNT1 | 976 |
| HSD17B10 | 4217 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MT-ND4L | -6745 |
| MT-ND5 | -6686 |
| MT-ND2 | -6595 |
| MT-ATP6 | -6338 |
| MT-ND4 | -6165 |
| MT-ND1 | -5816 |
| MT-CYB | -5757 |
| MT-CO1 | -4661 |
| TRMT10C | -3607 |
| MT-CO3 | -3562 |
| MT-ND6 | -2969 |
| MT-CO2 | -2739 |
| ELAC2 | -2730 |
| MT-ND3 | -794 |
| TRNT1 | 976 |
| HSD17B10 | 4217 |
G beta:gamma signalling through PLC beta
| 405 | |
|---|---|
| set | G beta:gamma signalling through PLC beta |
| setSize | 16 |
| pANOVA | 0.00155 |
| s.dist | 0.457 |
| p.adjustANOVA | 0.0126 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GNGT2 | 6373 |
| GNG5 | 6184 |
| GNG12 | 5768 |
| GNG11 | 5389 |
| GNG8 | 4629 |
| GNG10 | 4252 |
| GNB2 | 4125 |
| PLCB1 | 3278 |
| GNG2 | 3242 |
| GNG7 | 3101 |
| GNB5 | 2680 |
| PLCB3 | 1660 |
| GNB1 | 169 |
| GNGT1 | -261 |
| GNB4 | -2066 |
| PLCB2 | -5647 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| GNGT2 | 6373 |
| GNG5 | 6184 |
| GNG12 | 5768 |
| GNG11 | 5389 |
| GNG8 | 4629 |
| GNG10 | 4252 |
| GNB2 | 4125 |
| PLCB1 | 3278 |
| GNG2 | 3242 |
| GNG7 | 3101 |
| GNB5 | 2680 |
| PLCB3 | 1660 |
| GNB1 | 169 |
| GNGT1 | -261 |
| GNB4 | -2066 |
| PLCB2 | -5647 |
Signaling by FGFR3 fusions in cancer
| 1085 | |
|---|---|
| set | Signaling by FGFR3 fusions in cancer |
| setSize | 10 |
| pANOVA | 0.0124 |
| s.dist | -0.457 |
| p.adjustANOVA | 0.0606 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| SOS1 | -6404 |
| FRS2 | -6216 |
| PIK3CA | -5991 |
| KRAS | -5384 |
| PIK3R1 | -4451 |
| NRAS | -3468 |
| FGFR3 | -2153 |
| HRAS | -1672 |
| GAB1 | -824 |
| GRB2 | -609 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| SOS1 | -6404 |
| FRS2 | -6216 |
| PIK3CA | -5991 |
| KRAS | -5384 |
| PIK3R1 | -4451 |
| NRAS | -3468 |
| FGFR3 | -2153 |
| HRAS | -1672 |
| GAB1 | -824 |
| GRB2 | -609 |
ADP signalling through P2Y purinoceptor 1
| 6 | |
|---|---|
| set | ADP signalling through P2Y purinoceptor 1 |
| setSize | 21 |
| pANOVA | 0.000312 |
| s.dist | 0.454 |
| p.adjustANOVA | 0.00381 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GNGT2 | 6373 |
| GNG5 | 6184 |
| GNAQ | 5954 |
| PLA2G4A | 5782 |
| GNG12 | 5768 |
| GNG11 | 5389 |
| GNG8 | 4629 |
| GNG10 | 4252 |
| GNB2 | 4125 |
| GNG2 | 3242 |
| GNG7 | 3101 |
| GNA15 | 2953 |
| GNB5 | 2680 |
| GNA14 | 2649 |
| SRC | 1999 |
| GNB1 | 169 |
| GNGT1 | -261 |
| MAPK14 | -435 |
| GNB4 | -2066 |
| P2RY1 | -2171 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| GNGT2 | 6373 |
| GNG5 | 6184 |
| GNAQ | 5954 |
| PLA2G4A | 5782 |
| GNG12 | 5768 |
| GNG11 | 5389 |
| GNG8 | 4629 |
| GNG10 | 4252 |
| GNB2 | 4125 |
| GNG2 | 3242 |
| GNG7 | 3101 |
| GNA15 | 2953 |
| GNB5 | 2680 |
| GNA14 | 2649 |
| SRC | 1999 |
| GNB1 | 169 |
| GNGT1 | -261 |
| MAPK14 | -435 |
| GNB4 | -2066 |
| P2RY1 | -2171 |
| GNA11 | -4465 |
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
| 368 | |
|---|---|
| set | FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes |
| setSize | 23 |
| pANOVA | 0.000177 |
| s.dist | -0.452 |
| p.adjustANOVA | 0.00249 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PPARGC1A | -7375 |
| INS | -7321 |
| TRIM63 | -7293 |
| PCK1 | -7071 |
| RETN | -6718 |
| FOXO3 | -6696 |
| SOD2 | -6501 |
| SMAD3 | -5899 |
| FOXO1 | -5704 |
| ATXN3 | -5627 |
| NR3C1 | -5398 |
| FOXO4 | -5243 |
| CAT | -4369 |
| SMAD4 | -4040 |
| SIN3A | -4027 |
| FBXO32 | -2566 |
| HDAC2 | -1535 |
| SMAD2 | -1408 |
| PLXNA4 | 165 |
| SREBF1 | 447 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PPARGC1A | -7375 |
| INS | -7321 |
| TRIM63 | -7293 |
| PCK1 | -7071 |
| RETN | -6718 |
| FOXO3 | -6696 |
| SOD2 | -6501 |
| SMAD3 | -5899 |
| FOXO1 | -5704 |
| ATXN3 | -5627 |
| NR3C1 | -5398 |
| FOXO4 | -5243 |
| CAT | -4369 |
| SMAD4 | -4040 |
| SIN3A | -4027 |
| FBXO32 | -2566 |
| HDAC2 | -1535 |
| SMAD2 | -1408 |
| PLXNA4 | 165 |
| SREBF1 | 447 |
| SIRT3 | 2961 |
| POMC | 2977 |
| ABCA6 | 3639 |
Diseases associated with glycosylation precursor biosynthesis
| 285 | |
|---|---|
| set | Diseases associated with glycosylation precursor biosynthesis |
| setSize | 18 |
| pANOVA | 0.000968 |
| s.dist | 0.449 |
| p.adjustANOVA | 0.00901 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CTSA | 5798 |
| GLB1 | 5681 |
| SRD5A3 | 5492 |
| GALK1 | 5438 |
| GNE | 5299 |
| MPI | 5090 |
| DOLK | 4977 |
| DPM2 | 4965 |
| GALT | 4428 |
| PMM2 | 3489 |
| PGM1 | 3247 |
| GFPT1 | 2582 |
| DPM3 | 1750 |
| DPM1 | 1308 |
| NUS1 | -13 |
| DHDDS | -3497 |
| NEU1 | -4395 |
| GALE | -4408 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CTSA | 5798 |
| GLB1 | 5681 |
| SRD5A3 | 5492 |
| GALK1 | 5438 |
| GNE | 5299 |
| MPI | 5090 |
| DOLK | 4977 |
| DPM2 | 4965 |
| GALT | 4428 |
| PMM2 | 3489 |
| PGM1 | 3247 |
| GFPT1 | 2582 |
| DPM3 | 1750 |
| DPM1 | 1308 |
| NUS1 | -13 |
| DHDDS | -3497 |
| NEU1 | -4395 |
| GALE | -4408 |
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
| 737 | |
|---|---|
| set | Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) |
| setSize | 61 |
| pANOVA | 1.75e-09 |
| s.dist | 0.446 |
| p.adjustANOVA | 1.08e-07 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL11 | 6425 |
| RPL32 | 5883 |
| RPL31 | 5659 |
| RPS27L | 5652 |
| RPL10 | 5559 |
| RPL28 | 5479 |
| RPL3 | 5413 |
| RPS9 | 5300 |
| RPL5 | 5198 |
| RPL30 | 5056 |
| RPL26 | 4931 |
| RPS11 | 4809 |
| RPL19 | 4745 |
| RPS27A | 4675 |
| RPL37 | 4548 |
| RPL23 | 4522 |
| RPL14 | 4484 |
| RPS20 | 4323 |
| RPL36A | 4311 |
| RPS13 | 4223 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| RPL11 | 6425 |
| RPL32 | 5883 |
| RPL31 | 5659 |
| RPS27L | 5652 |
| RPL10 | 5559 |
| RPL28 | 5479 |
| RPL3 | 5413 |
| RPS9 | 5300 |
| RPL5 | 5198 |
| RPL30 | 5056 |
| RPL26 | 4931 |
| RPS11 | 4809 |
| RPL19 | 4745 |
| RPS27A | 4675 |
| RPL37 | 4548 |
| RPL23 | 4522 |
| RPL14 | 4484 |
| RPS20 | 4323 |
| RPL36A | 4311 |
| RPS13 | 4223 |
| RPS14 | 4209 |
| RPS6 | 4170 |
| RPL22 | 4098 |
| RPL35A | 4093 |
| RPL34 | 4070 |
| RPS8 | 4000 |
| RPS3 | 3991 |
| RPS15A | 3893 |
| RPL38 | 3816 |
| RPS4X | 3796 |
| RPS18 | 3747 |
| RPS29 | 3742 |
| RPL18A | 3672 |
| RPS16 | 3662 |
| RPL18 | 3436 |
| RPL7 | 3418 |
| FAU | 3337 |
| RPLP2 | 3271 |
| RPS21 | 3199 |
| RPL37A | 3059 |
| RPS26 | 2701 |
| RPS23 | 2661 |
| RPS5 | 2658 |
| RPL4 | 1860 |
| GSPT2 | 1561 |
| RPS19 | 1435 |
| RPL8 | 1425 |
| RPS15 | 777 |
| RPS24 | 671 |
| RPL22L1 | 659 |
| RPS12 | 244 |
| RPS27 | -230 |
| GSPT1 | -718 |
| RPL15 | -1821 |
| RPL23A | -2004 |
| ETF1 | -2776 |
| NCBP2 | -2958 |
| EIF4G1 | -3927 |
| NCBP1 | -6016 |
| UPF1 | -6701 |
| RPL3L | -7431 |
Processing of Intronless Pre-mRNAs
| 848 | |
|---|---|
| set | Processing of Intronless Pre-mRNAs |
| setSize | 17 |
| pANOVA | 0.00149 |
| s.dist | -0.445 |
| p.adjustANOVA | 0.0123 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PCF11 | -6739 |
| WDR33 | -6699 |
| NCBP1 | -6016 |
| CPSF4 | -5791 |
| CSTF1 | -5257 |
| CPSF1 | -5199 |
| CPSF7 | -4866 |
| SYMPK | -4203 |
| CPSF2 | -3101 |
| NCBP2 | -2958 |
| FIP1L1 | -2546 |
| CSTF2T | -2221 |
| CSTF2 | -1930 |
| CLP1 | -1506 |
| CSTF3 | -1407 |
| NUDT21 | -998 |
| CPSF3 | -322 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PCF11 | -6739 |
| WDR33 | -6699 |
| NCBP1 | -6016 |
| CPSF4 | -5791 |
| CSTF1 | -5257 |
| CPSF1 | -5199 |
| CPSF7 | -4866 |
| SYMPK | -4203 |
| CPSF2 | -3101 |
| NCBP2 | -2958 |
| FIP1L1 | -2546 |
| CSTF2T | -2221 |
| CSTF2 | -1930 |
| CLP1 | -1506 |
| CSTF3 | -1407 |
| NUDT21 | -998 |
| CPSF3 | -322 |
Transport of Ribonucleoproteins into the Host Nucleus
| 1275 | |
|---|---|
| set | Transport of Ribonucleoproteins into the Host Nucleus |
| setSize | 27 |
| pANOVA | 8.18e-05 |
| s.dist | -0.438 |
| p.adjustANOVA | 0.0013 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| NUP210 | -7094.0 |
| NUP160 | -6733.0 |
| NUP62 | -6659.0 |
| NUP155 | -6373.0 |
| NUP153 | -6342.0 |
| NUP43 | -6289.0 |
| NUP188 | -6155.5 |
| RAE1 | -5870.0 |
| KPNA1 | -5677.0 |
| NUP85 | -5424.0 |
| TPR | -5269.0 |
| NUP205 | -5261.0 |
| KPNB1 | -5008.0 |
| NUP133 | -4960.0 |
| RANBP2 | -4845.0 |
| AAAS | -4377.0 |
| NUP98 | -3718.0 |
| NUP214 | -3609.0 |
| NUP54 | -2250.0 |
| SEH1L | -1464.0 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| NUP210 | -7094.0 |
| NUP160 | -6733.0 |
| NUP62 | -6659.0 |
| NUP155 | -6373.0 |
| NUP153 | -6342.0 |
| NUP43 | -6289.0 |
| NUP188 | -6155.5 |
| RAE1 | -5870.0 |
| KPNA1 | -5677.0 |
| NUP85 | -5424.0 |
| TPR | -5269.0 |
| NUP205 | -5261.0 |
| KPNB1 | -5008.0 |
| NUP133 | -4960.0 |
| RANBP2 | -4845.0 |
| AAAS | -4377.0 |
| NUP98 | -3718.0 |
| NUP214 | -3609.0 |
| NUP54 | -2250.0 |
| SEH1L | -1464.0 |
| NUP93 | -406.0 |
| NDC1 | -360.0 |
| NUP35 | 170.0 |
| NUP88 | 273.0 |
| NUP107 | 497.0 |
| NUP37 | 3010.0 |
| SEC13 | 3503.0 |
IRAK4 deficiency (TLR2/4)
| 504 | |
|---|---|
| set | IRAK4 deficiency (TLR2/4) |
| setSize | 11 |
| pANOVA | 0.0126 |
| s.dist | 0.435 |
| p.adjustANOVA | 0.0614 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| TLR2 | 6129 |
| MYD88 | 5325 |
| TLR4 | 4316 |
| CD14 | 3703 |
| TLR6 | 3382 |
| IRAK4 | 2966 |
| BTK | 1598 |
| TIRAP | 1448 |
| LY96 | 592 |
| CD36 | -346 |
| TLR1 | -1356 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| TLR2 | 6129 |
| MYD88 | 5325 |
| TLR4 | 4316 |
| CD14 | 3703 |
| TLR6 | 3382 |
| IRAK4 | 2966 |
| BTK | 1598 |
| TIRAP | 1448 |
| LY96 | 592 |
| CD36 | -346 |
| TLR1 | -1356 |
Establishment of Sister Chromatid Cohesion
| 344 | |
|---|---|
| set | Establishment of Sister Chromatid Cohesion |
| setSize | 10 |
| pANOVA | 0.018 |
| s.dist | -0.432 |
| p.adjustANOVA | 0.0765 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RAD21 | -5624 |
| SMC1A | -5254 |
| PDS5A | -4964 |
| SMC3 | -4484 |
| ESCO1 | -4400 |
| ESCO2 | -2761 |
| STAG2 | -2310 |
| CDCA5 | -2238 |
| PDS5B | -2178 |
| STAG1 | -1219 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| RAD21 | -5624 |
| SMC1A | -5254 |
| PDS5A | -4964 |
| SMC3 | -4484 |
| ESCO1 | -4400 |
| ESCO2 | -2761 |
| STAG2 | -2310 |
| CDCA5 | -2238 |
| PDS5B | -2178 |
| STAG1 | -1219 |
Citric acid cycle (TCA cycle)
| 182 | |
|---|---|
| set | Citric acid cycle (TCA cycle) |
| setSize | 22 |
| pANOVA | 0.000486 |
| s.dist | -0.43 |
| p.adjustANOVA | 0.00543 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MDH2 | -7178 |
| CS | -7092 |
| IDH3B | -6892 |
| ACO2 | -6798 |
| OGDH | -6749 |
| SDHA | -5638 |
| IDH3A | -5255 |
| SUCLA2 | -5248 |
| SUCLG1 | -4846 |
| IDH2 | -4741 |
| DLST | -4733 |
| ME3 | -4390 |
| DLD | -4253 |
| FAHD1 | -3300 |
| NNT | -2531 |
| FH | -1277 |
| IDH3G | -386 |
| SDHB | -312 |
| SDHC | -136 |
| SDHD | 471 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MDH2 | -7178 |
| CS | -7092 |
| IDH3B | -6892 |
| ACO2 | -6798 |
| OGDH | -6749 |
| SDHA | -5638 |
| IDH3A | -5255 |
| SUCLA2 | -5248 |
| SUCLG1 | -4846 |
| IDH2 | -4741 |
| DLST | -4733 |
| ME3 | -4390 |
| DLD | -4253 |
| FAHD1 | -3300 |
| NNT | -2531 |
| FH | -1277 |
| IDH3G | -386 |
| SDHB | -312 |
| SDHC | -136 |
| SDHD | 471 |
| ME2 | 1871 |
| SUCLG2 | 1883 |
L13a-mediated translational silencing of Ceruloplasmin expression
| 581 | |
|---|---|
| set | L13a-mediated translational silencing of Ceruloplasmin expression |
| setSize | 74 |
| pANOVA | 1.7e-10 |
| s.dist | 0.429 |
| p.adjustANOVA | 1.35e-08 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| RPL11 | 6425 |
| RPL32 | 5883 |
| RPL31 | 5659 |
| RPS27L | 5652 |
| RPL10 | 5559 |
| RPL28 | 5479 |
| RPL3 | 5413 |
| RPS9 | 5300 |
| RPL5 | 5198 |
| RPL30 | 5056 |
| RPL26 | 4931 |
| RPS11 | 4809 |
| RPL19 | 4745 |
| RPS27A | 4675 |
| EIF3M | 4641 |
| RPL37 | 4548 |
| RPL23 | 4522 |
| RPL14 | 4484 |
| RPS20 | 4323 |
| RPL36A | 4311 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| RPL11 | 6425.0 |
| RPL32 | 5883.0 |
| RPL31 | 5659.0 |
| RPS27L | 5652.0 |
| RPL10 | 5559.0 |
| RPL28 | 5479.0 |
| RPL3 | 5413.0 |
| RPS9 | 5300.0 |
| RPL5 | 5198.0 |
| RPL30 | 5056.0 |
| RPL26 | 4931.0 |
| RPS11 | 4809.0 |
| RPL19 | 4745.0 |
| RPS27A | 4675.0 |
| EIF3M | 4641.0 |
| RPL37 | 4548.0 |
| RPL23 | 4522.0 |
| RPL14 | 4484.0 |
| RPS20 | 4323.0 |
| RPL36A | 4311.0 |
| RPS13 | 4223.0 |
| RPS14 | 4209.0 |
| EIF3E | 4194.0 |
| RPS6 | 4170.0 |
| RPL22 | 4098.0 |
| RPL35A | 4093.0 |
| RPL34 | 4070.0 |
| EIF3K | 4045.0 |
| RPS8 | 4000.0 |
| RPS3 | 3991.0 |
| EIF3F | 3905.0 |
| RPS15A | 3893.0 |
| RPL38 | 3816.0 |
| RPS4X | 3796.0 |
| RPS18 | 3747.0 |
| RPS29 | 3742.0 |
| RPL18A | 3672.0 |
| RPS16 | 3662.0 |
| EIF2S2 | 3526.0 |
| EIF3H | 3459.0 |
| RPL18 | 3436.0 |
| RPL7 | 3418.0 |
| FAU | 3337.0 |
| RPLP2 | 3271.0 |
| RPS21 | 3199.0 |
| EIF4A1 | 3166.0 |
| RPL37A | 3059.0 |
| RPS26 | 2701.0 |
| RPS23 | 2661.0 |
| RPS5 | 2658.0 |
| EIF4H | 1934.0 |
| RPL4 | 1860.0 |
| EIF3I | 1718.0 |
| RPS19 | 1435.0 |
| RPL8 | 1425.0 |
| RPS15 | 777.0 |
| RPS24 | 671.0 |
| RPL22L1 | 659.0 |
| RPS12 | 244.0 |
| EIF3L | 187.0 |
| RPS27 | -230.0 |
| EIF2S1 | -1080.0 |
| EIF3G | -1094.0 |
| EIF3C | -1251.5 |
| EIF4A2 | -1706.0 |
| RPL15 | -1821.0 |
| EIF4B | -1976.0 |
| RPL23A | -2004.0 |
| EIF3B | -3141.0 |
| EIF4E | -3818.0 |
| EIF4G1 | -3927.0 |
| EIF3D | -4318.0 |
| EIF3A | -4914.0 |
| RPL3L | -7431.0 |
MyD88 deficiency (TLR2/4)
| 678 | |
|---|---|
| set | MyD88 deficiency (TLR2/4) |
| setSize | 10 |
| pANOVA | 0.019 |
| s.dist | 0.428 |
| p.adjustANOVA | 0.079 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| TLR2 | 6129 |
| MYD88 | 5325 |
| TLR4 | 4316 |
| CD14 | 3703 |
| TLR6 | 3382 |
| BTK | 1598 |
| TIRAP | 1448 |
| LY96 | 592 |
| CD36 | -346 |
| TLR1 | -1356 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| TLR2 | 6129 |
| MYD88 | 5325 |
| TLR4 | 4316 |
| CD14 | 3703 |
| TLR6 | 3382 |
| BTK | 1598 |
| TIRAP | 1448 |
| LY96 | 592 |
| CD36 | -346 |
| TLR1 | -1356 |
Interferon alpha/beta signaling
| 541 | |
|---|---|
| set | Interferon alpha/beta signaling |
| setSize | 45 |
| pANOVA | 8.32e-07 |
| s.dist | 0.425 |
| p.adjustANOVA | 2.68e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| OAS1 | 6475.0 |
| IFITM1 | 6466.0 |
| IFITM2 | 6466.0 |
| IFITM3 | 6466.0 |
| OAS2 | 6449.0 |
| MX1 | 6444.0 |
| IFIT3 | 6430.0 |
| IRF7 | 6418.0 |
| STAT1 | 6315.0 |
| BST2 | 6264.0 |
| XAF1 | 6223.0 |
| SAMHD1 | 5831.0 |
| USP18 | 5593.5 |
| IRF8 | 5561.0 |
| PSMB8 | 5526.0 |
| PTPN1 | 5323.0 |
| IRF9 | 5309.0 |
| IFI35 | 5020.0 |
| IFNAR1 | 4473.0 |
| SOCS3 | 4435.0 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| OAS1 | 6475.0 |
| IFITM1 | 6466.0 |
| IFITM2 | 6466.0 |
| IFITM3 | 6466.0 |
| OAS2 | 6449.0 |
| MX1 | 6444.0 |
| IFIT3 | 6430.0 |
| IRF7 | 6418.0 |
| STAT1 | 6315.0 |
| BST2 | 6264.0 |
| XAF1 | 6223.0 |
| SAMHD1 | 5831.0 |
| USP18 | 5593.5 |
| IRF8 | 5561.0 |
| PSMB8 | 5526.0 |
| PTPN1 | 5323.0 |
| IRF9 | 5309.0 |
| IFI35 | 5020.0 |
| IFNAR1 | 4473.0 |
| SOCS3 | 4435.0 |
| STAT2 | 4322.0 |
| SOCS1 | 4202.0 |
| IRF1 | 4151.0 |
| IFNAR2 | 4090.0 |
| OASL | 3824.0 |
| ADAR | 3303.0 |
| IFIT2 | 3232.0 |
| EGR1 | 2346.0 |
| TYK2 | 2013.0 |
| ISG15 | -277.0 |
| RNASEL | -477.0 |
| OAS3 | -1150.0 |
| RSAD2 | -1259.0 |
| IRF3 | -1445.0 |
| PTPN6 | -1615.0 |
| IRF2 | -1713.0 |
| ABCE1 | -1885.0 |
| PTPN11 | -2092.0 |
| JAK1 | -2252.0 |
| IRF5 | -2410.0 |
| IP6K2 | -2803.0 |
| ISG20 | -3194.0 |
| IRF4 | -3797.0 |
| IFI27 | -6213.0 |
| IRF6 | -6325.0 |
Export of Viral Ribonucleoproteins from Nucleus
| 350 | |
|---|---|
| set | Export of Viral Ribonucleoproteins from Nucleus |
| setSize | 28 |
| pANOVA | 0.000104 |
| s.dist | -0.424 |
| p.adjustANOVA | 0.00161 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| HSPA1A | -7435.5 |
| NUP210 | -7094.0 |
| NUP160 | -6733.0 |
| NUP62 | -6659.0 |
| NUP155 | -6373.0 |
| NUP153 | -6342.0 |
| NUP43 | -6289.0 |
| NUP188 | -6155.5 |
| RAE1 | -5870.0 |
| NUP85 | -5424.0 |
| TPR | -5269.0 |
| NUP205 | -5261.0 |
| NUP133 | -4960.0 |
| RANBP2 | -4845.0 |
| AAAS | -4377.0 |
| NUP98 | -3718.0 |
| NUP214 | -3609.0 |
| XPO1 | -2584.0 |
| NUP54 | -2250.0 |
| SEH1L | -1464.0 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| HSPA1A | -7435.5 |
| NUP210 | -7094.0 |
| NUP160 | -6733.0 |
| NUP62 | -6659.0 |
| NUP155 | -6373.0 |
| NUP153 | -6342.0 |
| NUP43 | -6289.0 |
| NUP188 | -6155.5 |
| RAE1 | -5870.0 |
| NUP85 | -5424.0 |
| TPR | -5269.0 |
| NUP205 | -5261.0 |
| NUP133 | -4960.0 |
| RANBP2 | -4845.0 |
| AAAS | -4377.0 |
| NUP98 | -3718.0 |
| NUP214 | -3609.0 |
| XPO1 | -2584.0 |
| NUP54 | -2250.0 |
| SEH1L | -1464.0 |
| RAN | -1443.0 |
| NUP93 | -406.0 |
| NDC1 | -360.0 |
| NUP35 | 170.0 |
| NUP88 | 273.0 |
| NUP107 | 497.0 |
| NUP37 | 3010.0 |
| SEC13 | 3503.0 |
Regulation of Complement cascade
| 939 | |
|---|---|
| set | Regulation of Complement cascade |
| setSize | 36 |
| pANOVA | 1.13e-05 |
| s.dist | 0.423 |
| p.adjustANOVA | 0.000264 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CFB | 6455.0 |
| C1R | 6214.0 |
| C1QA | 6176.0 |
| C1S | 6169.0 |
| C2 | 6139.0 |
| C6 | 6137.0 |
| C1QB | 6110.0 |
| C1QC | 6107.0 |
| IGHG1 | 6067.5 |
| IGHG2 | 6067.5 |
| IGHG3 | 6067.5 |
| IGHG4 | 6067.5 |
| IGKC | 6026.0 |
| C3 | 5783.0 |
| C3AR1 | 5692.0 |
| ELANE | 5547.0 |
| C4A | 5536.5 |
| C4B | 5536.5 |
| C5AR2 | 5373.0 |
| C5AR1 | 5283.0 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CFB | 6455.0 |
| C1R | 6214.0 |
| C1QA | 6176.0 |
| C1S | 6169.0 |
| C2 | 6139.0 |
| C6 | 6137.0 |
| C1QB | 6110.0 |
| C1QC | 6107.0 |
| IGHG1 | 6067.5 |
| IGHG2 | 6067.5 |
| IGHG3 | 6067.5 |
| IGHG4 | 6067.5 |
| IGKC | 6026.0 |
| C3 | 5783.0 |
| C3AR1 | 5692.0 |
| ELANE | 5547.0 |
| C4A | 5536.5 |
| C4B | 5536.5 |
| C5AR2 | 5373.0 |
| C5AR1 | 5283.0 |
| PROS1 | 5159.0 |
| CR1 | 3475.5 |
| SERPING1 | 1856.0 |
| CFH | 1717.0 |
| CD81 | 684.0 |
| C4BPA | -48.0 |
| C8G | -60.0 |
| C7 | -782.0 |
| C8A | -1710.0 |
| CLU | -1788.0 |
| CD19 | -4443.0 |
| F2 | -6033.0 |
| CR2 | -7014.0 |
| CD59 | -7242.0 |
| CD46 | -7287.0 |
| CD55 | -7348.0 |
Thromboxane signalling through TP receptor
| 1224 | |
|---|---|
| set | Thromboxane signalling through TP receptor |
| setSize | 20 |
| pANOVA | 0.00109 |
| s.dist | 0.422 |
| p.adjustANOVA | 0.00998 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GNGT2 | 6373 |
| GNG5 | 6184 |
| GNAQ | 5954 |
| GNG12 | 5768 |
| GNG11 | 5389 |
| GNG8 | 4629 |
| GNG10 | 4252 |
| GNB2 | 4125 |
| GNG2 | 3242 |
| GNG7 | 3101 |
| GNA15 | 2953 |
| AAMP | 2782 |
| GNB5 | 2680 |
| GNA14 | 2649 |
| TBXA2R | 2292 |
| GNB1 | 169 |
| GNGT1 | -261 |
| GNB4 | -2066 |
| GNA11 | -4465 |
| GNA13 | -7109 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| GNGT2 | 6373 |
| GNG5 | 6184 |
| GNAQ | 5954 |
| GNG12 | 5768 |
| GNG11 | 5389 |
| GNG8 | 4629 |
| GNG10 | 4252 |
| GNB2 | 4125 |
| GNG2 | 3242 |
| GNG7 | 3101 |
| GNA15 | 2953 |
| AAMP | 2782 |
| GNB5 | 2680 |
| GNA14 | 2649 |
| TBXA2R | 2292 |
| GNB1 | 169 |
| GNGT1 | -261 |
| GNB4 | -2066 |
| GNA11 | -4465 |
| GNA13 | -7109 |
Presynaptic function of Kainate receptors
| 843 | |
|---|---|
| set | Presynaptic function of Kainate receptors |
| setSize | 17 |
| pANOVA | 0.00278 |
| s.dist | 0.419 |
| p.adjustANOVA | 0.0193 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GNGT2 | 6373 |
| GNG5 | 6184 |
| GNG12 | 5768 |
| GNG11 | 5389 |
| GNG8 | 4629 |
| GNG10 | 4252 |
| GNB2 | 4125 |
| PLCB1 | 3278 |
| GNG2 | 3242 |
| GNG7 | 3101 |
| GNB5 | 2680 |
| PLCB3 | 1660 |
| GNB1 | 169 |
| GNGT1 | -261 |
| GRIK3 | -1858 |
| GNB4 | -2066 |
| PLCB2 | -5647 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| GNGT2 | 6373 |
| GNG5 | 6184 |
| GNG12 | 5768 |
| GNG11 | 5389 |
| GNG8 | 4629 |
| GNG10 | 4252 |
| GNB2 | 4125 |
| PLCB1 | 3278 |
| GNG2 | 3242 |
| GNG7 | 3101 |
| GNB5 | 2680 |
| PLCB3 | 1660 |
| GNB1 | 169 |
| GNGT1 | -261 |
| GRIK3 | -1858 |
| GNB4 | -2066 |
| PLCB2 | -5647 |
Here is the session info with all the versions of packages used.
sessionInfo()## R version 4.0.2 (2020-06-22)
## Platform: x86_64-pc-linux-gnu (64-bit)
## Running under: Ubuntu 18.04.4 LTS
##
## Matrix products: default
## BLAS: /usr/lib/x86_64-linux-gnu/blas/libblas.so.3.7.1
## LAPACK: /usr/lib/x86_64-linux-gnu/lapack/liblapack.so.3.7.1
##
## locale:
## [1] LC_CTYPE=en_US.UTF-8 LC_NUMERIC=C
## [3] LC_TIME=en_US.UTF-8 LC_COLLATE=en_US.UTF-8
## [5] LC_MONETARY=en_US.UTF-8 LC_MESSAGES=en_US.UTF-8
## [7] LC_PAPER=en_US.UTF-8 LC_NAME=C
## [9] LC_ADDRESS=C LC_TELEPHONE=C
## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=C
##
## attached base packages:
## [1] stats4 parallel stats graphics grDevices utils datasets
## [8] methods base
##
## other attached packages:
## [1] pkgload_1.1.0 GGally_2.0.0
## [3] beeswarm_0.2.3 gtools_3.8.2
## [5] echarts4r_0.3.2 mitch_1.0.6
## [7] fgsea_1.14.0 gplots_3.0.3
## [9] DESeq2_1.28.1 SummarizedExperiment_1.18.1
## [11] DelayedArray_0.14.0 matrixStats_0.56.0
## [13] Biobase_2.48.0 GenomicRanges_1.40.0
## [15] GenomeInfoDb_1.24.2 IRanges_2.22.2
## [17] S4Vectors_0.26.1 BiocGenerics_0.34.0
## [19] reshape2_1.4.4 forcats_0.5.0
## [21] stringr_1.4.0 dplyr_1.0.0
## [23] purrr_0.3.4 readr_1.3.1
## [25] tidyr_1.1.0 tibble_3.0.1
## [27] ggplot2_3.3.2 tidyverse_1.3.0
## [29] locfit_1.5-9.4 statmod_1.4.34
## [31] plyr_1.8.6
##
## loaded via a namespace (and not attached):
## [1] colorspace_1.4-1 ellipsis_0.3.1 rprojroot_1.3-2
## [4] XVector_0.28.0 fs_1.4.2 rstudioapi_0.11
## [7] bit64_0.9-7 AnnotationDbi_1.50.1 fansi_0.4.1
## [10] lubridate_1.7.9 xml2_1.3.2 splines_4.0.2
## [13] geneplotter_1.66.0 knitr_1.29 jsonlite_1.7.0
## [16] broom_0.5.6 annotate_1.66.0 dbplyr_1.4.4
## [19] shiny_1.5.0 compiler_4.0.2 httr_1.4.1
## [22] backports_1.1.8 assertthat_0.2.1 Matrix_1.2-18
## [25] fastmap_1.0.1 cli_2.0.2 later_1.1.0.1
## [28] htmltools_0.5.0 tools_4.0.2 gtable_0.3.0
## [31] glue_1.4.1 GenomeInfoDbData_1.2.3 fastmatch_1.1-0
## [34] Rcpp_1.0.4.6 cellranger_1.1.0 vctrs_0.3.1
## [37] gdata_2.18.0 nlme_3.1-148 xfun_0.15
## [40] testthat_2.3.2 rvest_0.3.5 mime_0.9
## [43] lifecycle_0.2.0 XML_3.99-0.3 zlibbioc_1.34.0
## [46] MASS_7.3-51.6 scales_1.1.1 hms_0.5.3
## [49] promises_1.1.1 RColorBrewer_1.1-2 yaml_2.2.1
## [52] memoise_1.1.0 gridExtra_2.3 reshape_0.8.8
## [55] stringi_1.4.6 RSQLite_2.2.0 highr_0.8
## [58] genefilter_1.70.0 desc_1.2.0 caTools_1.18.0
## [61] BiocParallel_1.22.0 rlang_0.4.6 pkgconfig_2.0.3
## [64] bitops_1.0-6 evaluate_0.14 lattice_0.20-41
## [67] htmlwidgets_1.5.1 bit_1.1-15.2 tidyselect_1.1.0
## [70] magrittr_1.5 R6_2.4.1 generics_0.0.2
## [73] DBI_1.1.0 pillar_1.4.4 haven_2.3.1
## [76] withr_2.2.0 survival_3.2-3 RCurl_1.98-1.2
## [79] modelr_0.1.8 crayon_1.3.4 KernSmooth_2.23-17
## [82] rmarkdown_2.3 grid_4.0.2 readxl_1.3.1
## [85] data.table_1.12.8 blob_1.2.1 reprex_0.3.0
## [88] digest_0.6.25 pbmcapply_1.5.0 xtable_1.8-4
## [91] httpuv_1.5.4 munsell_0.5.0END of report